

Eric J. Lobenfeld (EL-4560)  
Dillon Kim (DK-4121)  
**HOGAN & HARTSON LLP**  
875 Third Avenue  
New York, NY 10022  
Phone: (212) 918-3000  
Fax: (212) 918-3100

*Attorneys for Defendants  
ReProtect, Inc., Dr. Richard Cone,  
and Dr. Thomas Moench*

UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF NEW YORK

-----X	
Instead Sciences, Inc.,	)
	)
Plaintiff,	)
	)
v.	)
	)
ReProtect, Inc., Ultrafem Inc., Dr. Richard Cone,	)
and Dr. Thomas Moench,	)
	)
Defendants.	)
-----X	

Civil Action No.  
08 CV 5236 (DLC)

**DECLARATION OF THOMAS MOENCH IN SUPPORT OF THE  
REPROTECT DEFENDANTS' MOTION TO DISMISS THE COMPLAINT**

I, **THOMAS MOENCH**, declare as follows:

1. I am a medical doctor and President and Chief Operating Officer of ReProtect, Inc. ("ReProtect") and submit this declaration on behalf of defendants ReProtect, Dr. Richard Cone, and myself (collectively, the "ReProtect Defendants") in support of their Motion to Dismiss the Complaint pursuant to Rule 12(b)(6) of the Federal Rules of Civil Procedure. I have personal knowledge of the facts set forth in this Declaration and, if called as a witness, could and would testify competently to such facts under oath. I reside in Baltimore, Maryland.

2. Defendant Dr. Richard Cone is the Chairman of ReProtect's Board and resides in Baltimore, Maryland. Dr. Cone is a professor in the Department of Biophysics at Johns Hopkins University.

3. Defendant ReProtect is a Delaware corporation with its principal place of business at 703 Stags Head Road, Baltimore, MD 21286. ReProtect was formed in November 1993 and is in the business of developing women's reproductive health products. ReProtect's Mission is to reduce unwanted pregnancies and sexually transmitted diseases (STDs), including HIV/AIDS.

4. ReProtect is the first company to develop a vaginal microbicide that works by maintaining the natural environment of the female reproductive tract. ReProtect's flagship product is the vaginal microbicide BufferGel<sup>®</sup>. ReProtect owns intellectual property relating to BufferGel<sup>®</sup> including two federal trademarks in the name BufferGel<sup>®</sup> and BufferGel Duet<sup>™</sup> and two U.S. Patents, U.S. Patent No. 5,592,949 ("the '949 patent") and U.S. Patent No 5,617,877 ("the '877 patent"). The '949 patent relates to a device to control pH in the vagina for contraception and disease risk reduction and the '877 patent relates to a gel-based method for contraception and disease risk reduction. Both were filed with the U.S. Patent Office on June 29, 1994 as application number 08/266,777, and subsequently divided and issued as two separate patents. Before the '949 and '877 patents issued, Drs. Moench and Cone assigned all rights in the inventions to ReProtect. BufferGel<sup>®</sup> is referred to in the License, Research and Product Development Agreement dated February 8, 1996 ("1996 Agreement") between ReProtect and Ultrafem as the "Acidic Buffer."

5. Some of this intellectual property was the subject of the 1996 Agreement between Ultrafem, Inc. ("Ultrafem") and ReProtect. The "First Payment Date" as defined under the 1996

Agreement was February 27, 1996 when ReProtect received a \$40,000 payment from Ultrafem for its R&D License to Ultrafem, a \$100,000 payment for its Cup License to Ultrafem, and a \$100,000 payment for its Gel License to Ultrafem. Ultrafem never marketed any product incorporating any ReProtect intellectual property. Ultrafem also never submitted an application to the FDA for Phase II clinical trials. Ultrafem failed to make its March 1998 monthly payment under the 1996 Agreement. On March 10, 1998, ReProtect notified Ultrafem that it was in default of the 1996 Agreement and that the 1996 Agreement would be terminated. Since Ultrafem's bankruptcy, ReProtect has not received any royalty payments under the 1996 Agreement from Ultrafem, Akcess Pacific Group, LLC ("Akcess"), or Plaintiff Instead Sciences, Inc. ("Instead").

6. Instead and its then-President, Mary Frost, have known about ReProtect's research and development efforts with BufferGel<sup>®</sup> since the Ultrafem bankruptcy. As then-President of Instead, Ms. Frost attended a conference in 2003 where ReProtect employees presented research results related to BufferGel<sup>®</sup>. I also believe that Instead knows of ReProtect's continued efforts since the Ultrafem bankruptcy to develop and market BufferGel<sup>®</sup> and products containing BufferGel<sup>®</sup>.

7. I have recently learned that Instead has continued to claim ownership over BufferGel<sup>®</sup> by running a website using the trademarked BufferGel<sup>®</sup> name and holding themselves out to the community at large as owning the BufferGel<sup>®</sup> products. These efforts by Instead have damaged ReProtect's ability to fully develop and commercialize its BufferGel<sup>®</sup> product.

8. On June 6, 2008, Plaintiff filed the Complaint in this action. The Clerk of the Court issued a Summons for the Complaint on June 9, 2008. (A true and correct copy of the

Complaint and Summons is attached hereto as **Exhibit "A"**).

9. Plaintiff attached to the Complaint a copy of the June 26, 1998 Order from the United States Bankruptcy Court Southern District of New York approving the Sales Agreement by and between Debtor, Ultrafem and Akcess (the "Order"). (For the convenience of the Court, a true and correct copy of the Order, as attached to the Complaint, is attached hereto as **Exhibit "B"**).

10. Attached to the Bankruptcy Court's June 26, 1998 Order was an Asset Purchase Agreement ("APA"), dated June 12, 1998, between Ultrafem and Akcess. (For the convenience of the Court, a true and correct copy of the APA, as attached to the Complaint, is attached hereto as **Exhibit "C"**).

11. Plaintiff also attached to the Complaint the 1996 Agreement between ReProtect and Ultrafem. (For the convenience of the Court, a true and correct copy of the 1996 Agreement, as attached to the Complaint, is attached hereto as **Exhibit "D"**).

12. Pursuant to a stipulation among the parties, so ordered by this Court on June 23, 2008, Defendants have until July 31, 2008 to move, answer, or otherwise respond to the Complaint. (A true and correct copy of the stipulation is attached hereto as **Exhibit "E"**).

13. I have attached, as **Exhibit F**, a letter from Mary B. Frost, President of Instead to Thomas Moench of ReProtect dated February 25, 2003.

14. I have attached, as **Exhibit G**, a letter from Thomas R. Moench of ReProtect to Mary B. Frost of Instead dated March 11, 2003.

15. I have attached, as **Exhibit H**, a letter from Dr. Richard A. Cone to Dori Reap of Ultrafem dated March 10, 1998 notifying Ultrafem that it was in default on its required monthly

payments and that if not remedied, the 1996 Agreement between Ultrafem and ReProtect would terminate.

16. I have attached, as **Exhibit I**, a memo from Dori Reap to the Ultrafem Board of Directors dated March 13, 1998, acknowledging receipt of Dr. Cone's notification described above in paragraph 15 hereof.

I declare under the penalty of perjury under the laws of the United States of America and the State of Maryland that the foregoing is true and correct and that this Declaration was executed in Baltimore, Maryland on July 30, 2008.

  
\_\_\_\_\_  
THOMAS MOENCH

## **EXHIBIT A**

SAO 440 (Rev. 8/01) Summons in a Civil Action

**JUDGE COTE** UNITED STATES DISTRICT COURT

Southern

District of

New York

INSTEAD SCIENCES, INC.

**SUMMONS IN A CIVIL ACTION**

V.

ReProtect, Inc., Ultrafem Inc., Dr. Richard Cone,  
Dr. Kevin Whaley and Dr. Thomas Moench

CASE NUMBER:

**08 CIV 5236**

TO: (Name and address of Defendant)

Dr. Thomas Moench  
Baltimore, MD  
Baltimore County

**YOU ARE HEREBY SUMMONED** and required to serve on PLAINTIFF'S ATTORNEY (name and address)

Robert Weisbein  
Foley & Lardner LLP  
90 Park Avenue  
New York, NY 10016-1314

an answer to the complaint which is served on you with this summons, within 20 days after service of this summons on you, exclusive of the day of service. If you fail to do so, judgment by default will be taken against you for the relief demanded in the complaint. Any answer that you serve on the parties to this action must be filed with the Clerk of this Court within a reasonable period of time after service.

**J. MICHAEL McMAHON**

CLERK

DATE

**JUN 09 2008**

(By) DEPUTY CLERK

Robert S. Weisbein (0080)  
FOLEY & LARDNER LLP  
90 Park Avenue  
New York, NY 10016-1314  
Phone: 212-338-3400  
Facsimile: 212-687-2329  
*Attorneys for Plaintiff*  
*Instead Sciences, Inc.*

**UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF NEW YORK**

---

INSTEAD SCIENCES, INC., a California  
corporation,

Plaintiff,

v.

ReProtect, Inc., a Maryland corporation, Ultrafem  
Inc., a Delaware corporation, Dr. Richard Cone  
and Dr. Thomas Moench,

Defendants.

---

**COMPLAINT**

Civil Action No.: 08 CV 5236 (DC)

Plaintiff Instead Sciences, Inc. ("Instead" or "Plaintiff"), by and through its attorneys, Foley & Lardner LLP, for its complaint against defendant ReProtect, Inc., as successor entity to ReProtect, LLC (collectively, "ReProtect"), individual defendants Dr. Richard Cone and Dr. Thomas Moench (Drs. Cone and Moench shall be collectively referred to hereinafter as "Individual Defendants"), and defendant Ultrafem, Inc. ("Debtor" or "Ultrafem") alleges as follows:



### **NATURE OF THE ACTION**

1. This is an action for declaratory judgment regarding certain patent rights owned by Plaintiff to which ReProtect now wrongfully asserts rights, and for anticipatory breach and breach of related non-competition and purchase agreements, respectively. Debtor owned these patent rights and was a party to the non-competition agreement when it commenced on August 1, 1998 a bankruptcy case under Chapter 11 of the Bankruptcy Code, *Case No. 98-72280 [PCB]*. Thus, these patent rights and the non-competition agreement became part of Debtor's bankruptcy estate. Akcess Pacific Group, LLC ("Akcess") thereafter purchased and assumed the patent rights and non-competition agreement from Debtor pursuant to a court-approved asset purchase agreement dated June 12, 1998 ("Purchase Agreement"). A true and correct copy of the Purchase Agreement is attached as Exhibit 1.

2. Akcess thereafter assigned the patent rights and non-competition agreement to Plaintiff, a wholly related entity.

3. ReProtect now wrongfully asserts that the patent rights and non-competition agreement reverted to ReProtect during Debtor's bankruptcy and that Ultrafem did not assign its patent rights and non-competition agreement to Plaintiff.

4. This complaint seeks declaratory judgment that Plaintiff owns the patent rights and that defendants must abide by the terms of the non-competition agreement, as well as seeks other relief outlined below.

### **THE PARTIES**

5. Plaintiff Instead is a California corporation with its principal place of business at 4275 Executive Square, Ste. 440, La Jolla CA 92037-1478.

6. Upon information and belief, defendant ReProtect, Inc. is a Maryland corporation with its principal place of business at 703 Stags Head Road, Baltimore, MD, 21286.

7. Upon information and belief, defendant Ultrafem, Inc. was a Delaware corporation with its last known principal place of business at 500 Fifth Avenue, Suite 3620, New York, New York 10110.

8. Upon information and belief, defendant Dr. Richard Cone is an individual residing in Baltimore, Maryland. Dr. Cone is the Chairman of ReProtect's Board.

9. Upon information and belief, Defendant Dr. Thomas Moench is an individual who resides in Baltimore, Maryland. Dr. Moench is the President and Chief Operating Officer of ReProtect.

#### **JURISDICTION AND VENUE**

10. This Court has jurisdiction over this matter pursuant to 28 U.S.C. §§ 1332 because there is diversity of citizenship between the parties and the amount in controversy exceeds \$75,000, exclusive of interest and costs. This Court also has jurisdiction over this matter pursuant to: 11 U.S.C. § 1142(b); the court-approved Purchase Agreement which states that "each party hereto...consents to the exclusive jurisdiction of the Bankruptcy Court, for the purpose of any suit, action or other proceeding arising out of any of its obligations hereunder or with respect to the transactions contemplated hereby"; and the order entered by the Bankruptcy Court pursuant to sections 1129, and sections 363 and 365 of the Bankruptcy Code confirming Debtor's Chapter 11 Plan, including the Sale Agreement between Debtor and Akcess Pacific Group, LLC ("Plan Order"). The Plan Order directs that the "Bankruptcy Court shall retain jurisdiction...to adjudicate all Claims or controversies arising out of any purchases, sales or

contracts made or undertaken by the Debtor during the pendency of the Chapter 11 Case...and to recover all assets and properties of the Debtor wherever located...”

11. In addition to the Plan Order, venue lies properly in this district pursuant to 28 U.S.C. § 1391 because a substantial part of the events and omissions giving rise to these claims occurred in this district and this proceeding arises in or relates to a Chapter 11 case filed in this Court, *Case No. 98-42280 [PCB]*.

12. Furthermore, venue is proper because defendant Ultrafem agreed in Section 22 of the Purchase Agreement that this Court was an appropriate forum and expressly waived any objection to the laying of venue in any court located in New York and any defense that any court in New York is an inconvenient forum. Similarly, defendant ReProtect agreed in section X(b) of the License, Research and Product Development Agreement dated February 8, 1996 (the “License Agreement”) that this Court was an appropriate forum and waived any right to contest jurisdiction on the grounds of forum non conveniens. A true and correct copy of the License Agreement is attached as Exhibit 2.

13. Moreover, this Court has a substantial interest in this dispute because it arises out of or relates to the License Agreement and Purchase Agreement which “shall be governed by and construed (both as to validity and performance) and enforced in accordance with the laws of the State of New York[.]” *See* Purchase Agreement at ¶ 21; *see also* License Agreement at X(h).

### **FACTUAL BACKGROUND**

#### **License Agreement**

14. Upon information and belief, ReProtect was and is in the business of developing women’s reproductive health products.

15. Upon information and belief, Debtor was in the business of designing, developing, manufacturing and selling women’s health care products.

16. On February 8, 1996, Debtor and ReProtect entered into the License Agreement to facilitate the research, development and marketing of the Feminine Cup and to grant Debtor ReProtect's rights to the Acidic Buffer, as more fully described below.

17. By the License Agreement, ReProtect conveyed to Debtor exclusive, worldwide, perpetual and unlimited rights "to develop, use, market, sell, sub-license, sub-contract, manufacture, distribute and otherwise commercially exploit **all of [ReProtect's] right, title and interest** in and to the Acidic Buffer to the extent it is applied in the manufacturing process to, or become physical components of or improvements which are applied in the manufacturing process to, the Feminine Cup, including, without limitation, the acidic buffer gel and/or absorptive acidic buffer claimed in the Acidic Buffer invention when included as a component of the Feminine Cup" ("Cup Patent Rights"). (Emphasis added.) See License Agreement at I(a)(iii).

18. In exchange for ReProtect's ownership of the Cup Patent Rights, Debtor agreed to pay ReProtect \$100,000 and grant it certain stock options.

19. On or before December 31, 1996, Debtor paid ReProtect \$100,000 and granted it the specified stock options. As a result, the Cup Patent Rights became fully vested in Debtor.

20. By the License Agreement, ReProtect conveyed to Debtor unlimited and perpetual rights "to develop, use, market, sell, sub-license, sub-contract, manufacture, distribute and otherwise commercially exploit **all of [ReProtect's] right, title and interest** in and to that portion of the Acidic Buffer which is not a vaginal device (the "Gel") (without the Feminine Cup or other vaginal device) solely for vaginal application or uses" ("Gel Patent Rights"). (The Cup Patent Rights and the Gel Patent Rights shall be collectively referred to hereinafter as the "Patent Rights"). The Gel Patent Rights conveyed are exclusive and unlimited in all countries

worldwide, including the United States, except for certain developing countries in which the rights are non-exclusive. (Emphasis added.) *See* at I(a)(iii).

21. In exchange for ReProtect's ownership of the Gel Patent Rights, Debtor agreed to pay ReProtect \$100,000 and grant it certain stock options.

22. On or before December 31, 1996, Debtor paid ReProtect \$100,000 and granted it the specified stock options. As a result, the Gel Patent Rights became fully vested in Debtor.

23. The License Agreement also set forth a separate research and development agreement ("R&D Agreement") by which ReProtect agreed to engage in certain potentially long term research and development activities for Debtor. In consideration for these activities, Debtor agreed to make monthly payments.

24. The License Agreement also set forth a separate non-competition agreement between Debtor, on the one hand, and ReProtect and the Individual Defendants, on the other hand ("Non-Compete Agreement"). The Non-Compete Agreement provides that ReProtect and the Individual Defendants cannot assist, participate or engage in the marketing of any vaginal product which is competitive with, "(i) any vaginal product which [Debtor] is then marketing or (ii) any vaginal product which [Debtor] has the right (or an option to obtain the right) to market and with respect to which an application for Phase I clinical trials has been submitted to the FDA (or an equivalent submission has been made or clinical trials have begun in any other jurisdiction), in any geographic area in which any of [Debtor's] products are then being marketed." *See* License Agreement at VI(e).

25. The License Agreement expressly provides that the Patent Rights and Non-Compete Agreement survive termination of the License Agreement.

26. The License Agreement expressly provides that the Patent Rights, R & D Agreement and Non-Compete Agreement can be assigned to third parties.

**Ultrafem's Chapter 11 Bankruptcy**

27. On April 1, 1998, Debtor commenced a case under Chapter 11 of the Bankruptcy Code in the Southern District of New York.

28. As a result, the License Agreement, Patent Rights, R & D Agreement and Non-Compete Agreement became part of Debtor's bankruptcy estate.

**Asset Purchase Agreement**

29. Debtor, as Debtor-in-Possession in Chapter 11, sold and assigned to Akcess substantially all of its assets, including all of its right, title and interest to the Patent Rights and Non-Compete Agreement, pursuant to the Purchase Agreement dated June 12, 1998.

30. Specifically, Akcess purchased "[a]ll of [Debtor's] right, title and interest in and to the patents, copyrights, trademarks, service marks, and trade names, and all applications therefore, whether U.S. or foreign, and franchises, goodwill and other intangible property (collectively, the 'Intangibles')..." pursuant to the Purchase Agreement. See Purchase Agreement at section 1.1(a).

31. Akcess also acquired all of Debtor's rights "under all non-compete agreements (other than agreements with employees)" pursuant to the Purchase Agreement. See Purchase Agreement at section 1.1(h).

32. Akcess did not assume the R & D Agreement, nor did the Debtor assign the R&D Agreement to Akcess under the Purchase Agreement.

33. On June 26, 1998, the Court entered an Order approving the Purchase Agreement ("Sale Order").

**Debtor's Chapter 11 Plan of Liquidation**

34. Debtor's Plan of Liquidation ("Plan") was dated May 15, 2000.

35. Pursuant to the Plan, the Bankruptcy Court retains jurisdiction "to adjudicate all Claims or controversies arising out of any purchases, sales or contracts made or undertaken by the Debtor during the pendency of the Chapter 11 Case...and to recover all assets and properties of the Debtor wherever located..."

36. The Bankruptcy Court issued the Plan Order confirming the Plan pursuant to section 1129(b) of the Bankruptcy Code on August 1, 2000.

**Assignment**

37. Akcess thereafter assigned its rights to the Patent Rights and Non-Compete Agreement to Instead, a wholly related entity.

**ReProtect's Interference with Plaintiff's Patent Rights**

38. Instead desires to exercise its Patent Rights and enforce the Non-Compete Agreement.

39. ReProtect refuses to recognize Instead's ownership of the Patent Rights.

40. As a result, ReProtect is withholding information from Instead that is necessary for Instead to fully exercise its Patent Rights.

41. Furthermore, ReProtect is holding itself out to the public as the owner of the Patent Rights. This is preventing Instead from entering into business arrangements pertaining to the Patent Rights.

42. Moreover, ReProtect and the Individual Defendants have indicated that they will not abide by the terms of the Non-Compete Agreement on several occasions.

**FIRST CLAIM FOR RELIEF**

**(Declaratory Judgment that Instead Owns the Cup Patent Rights)**

43. Plaintiff repeats and realleges each and every allegation contained in paragraphs 1 through 43 of this Complaint as if fully set forth herein.

44. This cause of action arises under the Federal Declaratory Judgment Act, 28 U.S.C. § 2201.

45. An actual controversy now exists as to the rights and other legal relations of Plaintiff and ReProtect with respect to the Cup Patent Rights. Plaintiff asserts that it owns the Cup Patent Rights conveyed by the License Agreement. ReProtect disputes Plaintiff's assertion, and contends that Plaintiff has no interest in the Cup Patent Rights.

46. Plaintiff desires a declaration from this Court as to its rights and ReProtect's obligations vis a vis the Cup Patent Rights: Instead owns all the rights to the Cup Patent Rights conveyed under the License Agreement.

47. A judicial declaration is necessary and appropriate at this time so that the parties may ascertain their rights in the Cup Patent Rights conveyed under the License Agreement, and Plaintiff may obtain the relief to which it is entitled.

**SECOND CLAIM FOR RELIEF**

**(Declaratory Judgment that Instead Owns the Gel Patent Rights)**

48. Plaintiff repeats and realleges each and every allegation contained in paragraphs 1 through 48 of this Complaint as if fully set forth herein.

49. This cause of action arises under the Federal Declaratory Judgment Act, 28 U.S.C. § 2201.

50. An actual controversy now exists as to the rights and other legal relations of Plaintiff and ReProtect with respect to the Gel Patent Rights. Plaintiff asserts that it owns the



Gel Patent Rights conveyed by the License Agreement. ReProtect disputes Plaintiff's assertion, and contends that Plaintiff has no interest in the Gel Patent Rights.

51. Plaintiff desires a declaration from this Court as to its rights and ReProtect's obligations vis a vis the Gel Patent Rights: Instead owns all the rights to the Gel Patent Rights conveyed under the License Agreement.

52. A judicial declaration is necessary and appropriate at this time so that the parties may ascertain their rights in the Gel Patent Rights conveyed under the License Agreement, and Plaintiff may obtain the relief to which it is entitled.

**THIRD CLAIM FOR RELIEF**

**(Declaratory Judgment that ReProtect and Individual Defendants Must Abide by the Non-Compete Agreement)**

53. Plaintiff repeats and realleges each and every allegation contained in paragraphs 1 through 53 of this Complaint as if fully set forth herein.

54. This cause of action arises under the Federal Declaratory Judgment Act, 28 U.S.C. § 2201.

55. An actual controversy now exists as to the rights and other legal relations of Plaintiff and defendant ReProtect with respect to the Non-Compete Agreement. Plaintiff asserts that defendant ReProtect and the Individual Defendants must abide by the Non-Compete Agreement. ReProtect and Individual Defendants dispute Plaintiff's assertion, and contend that Plaintiff has no right to enforce the Non-Compete Agreement.

56. Plaintiff desires a declaration from this Court as to its rights and other legal relations concerning ReProtect and the Individual Defendants under the Non-Compete Agreement: ReProtect and the Individual Defendants must abide by the terms of the Non-Compete Agreement.

57. A judicial declaration is necessary and appropriate at this time so that Plaintiff may ascertain its rights under the Non-Compete Agreement and obtain the relief to which it is entitled.

**FOURTH CLAIM FOR RELIEF**  
**(Anticipatory Breach of Non-Compete Agreement by ReProtect and Individual Defendants)**

58. Instead repeats and realleges each and every allegation set forth in paragraphs 1 through 57 above as if fully set forth herein.

59. The Non-Compete Agreement is a valid and binding agreement between Plaintiff, on the one hand, and ReProtect and the Individual Defendants, on the other hand.

60. Plaintiff has complied fully with its obligations under the Non-Compete Agreement.

61. Pursuant to the Non-Compete Agreement, ReProtect and the Individual Defendants agreed to refrain from assisting, participating or engaging in the marketing of any vaginal product which is competitive with, "(i) any vaginal product which [Debtor] is then marketing or (ii) any vaginal product which [Debtor] has the right (or an option to obtain the right) to market and with respect to which an application for Phase I clinical trials has been submitted to the FDA (or an equivalent submission has been made or clinical trials have begun in any other jurisdiction), in any geographic area in which any of [Debtor's] products are then being marketed." See License Agreement at VI(e).

62. On several occasions, ReProtect and Individual Defendants have informed Plaintiff that they will not abide by the terms of the Non-Compete Agreement.

63. ReProtect and Individual Defendants are therefore in anticipatory breach of their obligations under the Non-Compete Agreement by clearly and unequivocally expressing their intention not to abide by the terms of the Non-Compete Agreement.

64. As a direct and proximate result of ReProtect's and Individual Defendants' anticipatory breaches of the Non-Compete Agreement, Plaintiff has suffered damages in an amount to be determined at trial.

**FIFTH CLAIM FOR RELIEF**  
**(Breach of Asset Purchase Agreement by Debtor)**

65. Instead repeats and realleges each and every allegation set forth in paragraphs 1 through 64 above as if fully set forth herein.

66. The APA between the Debtor and Instead is a valid and binding contract between the Debtor and Instead.

67. Upon information and belief, Instead alleges that Debtor has failed to perform and is in material breach of the APA to the extent Debtor did not transfer, assign and convey to Instead the Patent Rights and Non-Compete Agreement described in the foregoing paragraphs of this Complaint.

68. As a direct and proximate result of the breach, Instead has been damaged in an amount according to proof at trial.

69. Plaintiff Instead has fully performed all of its obligations and otherwise complied with all the terms and conditions of the APA.

70. Instead is entitled to recover damages from Debtor for Debtor's material breach of the APA alleged in this Complaint in an amount to be proven at trial.

**SIXTH CLAIM FOR RELIEF**

**(Tortious Interference with Asset Purchase Agreement by ReProtect)**

71. Instead repeats and realleges each and every allegation set forth in paragraphs 1 through 70 above as if fully set forth herein.

72. The Purchase Agreement is a valid and binding agreement between Ultrafem and Plaintiff.

73. Plaintiff has complied fully with its obligations under the Purchase Agreement.

74. As a party noticed regarding Ultrafem's bankruptcy, defendant ReProtect knew of the existence of the Purchase Agreement. In fact, ReProtect had the ability to object to the Court's Sale Order approving the Purchase Agreement.

75. ReProtect intentionally and wrongfully interfered with the Purchase Agreement by procuring and inducing a breach of the Purchase Agreement by Ultrafem without justification.

76. Ultrafem has in fact committed a material breach of the Purchase Agreement if Ultrafem did not assign Plaintiff the Patent Rights and/or assign Plaintiff the Non-Compete Agreement. Plaintiff has been directly and proximately damaged as a result of this breach.

77. As a direct and proximate result of ReProtect's tortious interference with the Purchase Agreement, Plaintiff has incurred damages in an amount to be proven at trial.

**PRAYER FOR RELIEF**

WHEREFORE, Plaintiff prays for an entry of judgment and for relief against Defendants as follows:

1. Damages according to proof at trial, including interest;
2. Any other consequential or other damages to which Instead may be legally entitled;
3. All costs, attorneys' fees and expenses incurred by Instead in connection with this

lawsuit;

4. A Court Declaration confirming that:

a. Instead owns all the rights to the Gel Patent Rights conveyed under the License Agreement.

b. Instead owns all the rights to the Gel Patent Rights conveyed under the License Agreement.

c. ReProtect and the Individual Defendants must abide by the terms of the Non-Compete Agreement; and

5. Such other relief as the Court deems just and proper.

FOLEY & LARDNER LLP

Dated: New York, New York  
June 6, 2008

By: 

Robert S. Weisbein (0080)  
FOLEY & LARDNER LLP  
90 Park Avenue  
New York, NY 10016-1314  
Phone: 212-682-7474  
Facsimile: 212-687-2329  
Email: [rweisbein@foley.com](mailto:rweisbein@foley.com)  
*Attorneys for Plaintiff*  
*Instead Sciences, Inc.*

Of Counsel:

Victor A. Vilaplana, Esq.  
Foley & Lardner LLP  
402 West Broadway  
Suite 2100  
San Diego, CA 92101-3542  
Phone: 619-234-6655  
Facsimile: 619-234-3510

## **EXHIBIT B**

Togut, Segal & Segal  
Attorneys for Debtor  
and Debtor-in-Possession  
One Penn Plaza  
New York, New York 10119  
Albert Togut (AT-9759)  
Neil Berger (NB-3599)

UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK

-----X  
In re: : Chapter 11 Case No.  
: 98 B 42280 [PCB]  
ULTRAFEM, INC., :  
: Debtor. :  
Employer Tax Identification No. 33-0435037 :  
-----X

**ORDER (i) APPROVING SALE AGREEMENT BY AND  
BETWEEN THE DEBTOR AND AKCESS PACIFIC GROUP LLC; (ii)  
AUTHORIZING, PURSUANT TO §363 OF THE  
BANKRUPTCY CODE, THE SALE OF SUBSTANTIALLY  
ALL OF THE DEBTOR'S ASSETS FREE AND CLEAR OF LIENS,  
CLAIMS AND ENCUMBRANCES; AND (iii) AUTHORIZING,  
PURSUANT TO §365 OF THE BANKRUPTCY CODE, THE  
ASSUMPTION AND ASSIGNMENT BY THE DEBTOR OF  
CERTAIN UNEXPIRED LEASES AND EXECUTORY CONTRACTS**

UPON the application (the "Application") of Ultrafem, Inc. (the "Debtor"), dated June 15, 1998, for the entry of an Order pursuant to §§363(b), (f) and (m), and 365(a) and (f) of the Bankruptcy Code, authorizing the Sale Agreement among the Debtor and Akcess Pacific Group LLC (the "Buyer"), dated June 12, 1998 (the "Sale Agreement"), a copy of which is annexed hereto as Exhibit "1", pursuant to which the Debtor has agreed to sell, subject to approval by this Court, its patent known as "Vaginal Discharge Collection Device and Intravaginal Drug Delivery System", U.S. Patent No. 5,295,984 (the "Patent") and all of the Debtor's other patents,

copyrights, trademarks, service marks, tradenames and all applications therefore, and all of the assets identified in the Schedule annexed hereto as Exhibit "2" and identified in the Sale Agreement (the "Assets"); and pursuant to the June 16, 1998 (the "Scheduling Order") Order (a) fixing the date, time and place of the hearing to approve the Sale Agreement (the "Approval Hearing"), (b) approving form and manner of notice thereof, and (c) setting the procedures for the submission of competing offers; and good and sufficient notice of the Application, the Bidding Hearing, the Approval Hearing, and the Sale Agreement (all as defined in the Scheduling Order); and upon the affidavit of Michael Stewart of Houlihan Lokey Howard & Zukin ("HLHZ"); and the opportunity to file and serve objections and higher and better offers, having been given, as evidenced by Affidavits of Service and Affidavits of Publication filed with the Clerk of this Court, and no further notice being necessary; and upon the record of the Approval Hearing; and all parties in interest having been heard or having had the opportunity to be heard regarding the Application and approval of the Sale Agreement; and the Court having considered any and all competing offers, and having determined that such competing offers are not higher and better offers for the Assets; and the Court having considered any responses and objections to the Application, and having overruled or approved the resolution of any such objections; and upon the consent of the Committee; and good and sufficient cause being shown therefor; it is

**HEREBY FOUND** that:

- i. This Court has jurisdiction over this proceeding pursuant to 28 U.S.C. §§1334 and 157(a). The Application is a core proceeding pursuant to 28 U.S.C. §157(b).
- ii. Good and sufficient notice of the Application, the Sale Agreement, the Bidding Hearing, and the Approval Hearing has been given by



the Debtor pursuant to the Scheduling Order.

- iii. All objections to the Application and the entry of this Order are overruled and the Application is granted.

4. The Debtor is the owner of the Assets and the interests subject to the Sale Agreement including, without limitation, the Patent, known as: "Vaginal Discharge Collection Device and Intravaginal Drug Delivery System", U.S. Patent No. 5,295,984, and all of the Debtor's other patents, trademarks and other intellectual properties to be conveyed pursuant to the Sale Agreement ("Patents") and the Debtor is able to convey title to the Assets and the Patents to the Buyer pursuant to the terms of the Sale Agreement.

5. The Debtor is authorized to sell the Assets and the Patents to Akcess Pacific Group, LLC (the "Buyer") pursuant to the Sale Agreement.

6. The purchase of the Assets and the Patents by the Buyer and the Sale thereof by the Debtor, pursuant to this Order and the Sale Agreement, was negotiated in good faith and represent an arms' length transaction.

7. The sale of the Assets and the Patents pursuant to the Sale Agreement is in the best interests of this estate and its creditors.

8. The terms of the Sale Agreement reflect the Debtor's prudent business judgment under the relevant circumstances.

9. The claims asserted against the Patents by Audrey Contente are the subject of a *bona fide* dispute.

10. The Debtor has satisfied the requirements of §§363(f) and 365(a) and (b) of the Bankruptcy Code.

**IT IS HEREBY ORDERED** that:

A. Pursuant to §§363(b), (f) and 365 of the Bankruptcy Code, the Debtor is authorized to consummate the transactions contemplated under the Sale Agreement, and transfer the Assets and the Patents to the Buyer free and clear of all mortgages, security interests, charges, encumbrances, liens, assessments, covenants, claims, interests, title defects, pledges, and burdens of every kind whatsoever including, without limitation, any and all claims with respect to the Patents and any royalties therefrom asserted by Audrey Contente in the action pending in the United States District Court for the Southern District of New York, Case No. 98 Civ. 0912 or otherwise (collectively, "Liens").

B. Any Liens that encumber or purport to encumber the Assets and the Patents shall be transferred to and attach to the proceeds of the Assets and the Patents with the same force, validity, priority and effect, if any, as they had against the Assets and the Patents and subject to the further order of this Court.

C. In the event that any Person or Entity (as those terms are defined in the Bankruptcy Code) which has filed statements or other documents or agreements evidencing Liens on or interests in the Assets and the Patents has not delivered to the Debtor prior to the Closing, in proper form for filing and executed by the appropriate parties, assignment statements, termination statements, instruments of satisfaction, releases of liens, and other documents for the purpose of documenting the release of all Liens, or other interests which such person or entity has with respect to the Assets and the Patents, the Debtor is authorized and directed to execute and file such statements, instruments, releases, and other documents on behalf of the person or entity with respect to the Assets and the Patents.

D. At the Closing, the Buyer is authorized and directed to assume and

pay, or otherwise satisfy in full in accordance with their terms or such other terms agreed to by and between the Buyer and such other parties, the Assumed Liabilities (as defined in the Sale Agreement), if any, and the Debtor is permanently relieved of any and all obligations on account of the Assumed Liabilities and all persons or entities who have asserted or may assert a claim on account of any of the Assumed Liabilities are permanently barred from asserting such claim against the Debtor.

E. Upon the Closing, the Buyer shall not be deemed to (i) be the successor of the Debtor, (ii) have, de facto or otherwise merged with or into the Debtor, or (iii) be a continuation or substantial continuation of the Debtor or the enterprise of the Debtor.

F. Except to the extent otherwise expressly provided in the Sale Agreement and this Order, at the Closing, the Buyer shall not assume any liability or obligation of the Debtor of any kind, character or description whether known or unknown, absolute or contingent, accrued or unaccrued, liquidated or unliquidated, secured or unsecured, joint or several, due or to become due, vested or unvested, executory, determined, determinable or otherwise, and whether or not the same is required to be accrued on the financing statements of the holder of the liability or obligation.

G. Upon the Closing, the Buyer will pay to the Debtor the Purchase Price in full (as defined in the Sale Agreement).

H. The Debtor is hereby granted a valid and perfected first priority lien and security interest in and against all of the Patents (the "Debtor Lien") in the amount of \$2,500,000, and the Debtor Lien be, and it hereby is, perfected and effective as of the date hereof, without the necessity of the filing or recordation of any document or other notice. Notwithstanding the foregoing, the Debtor may record a copy of this Order with any recording

officer that it may deem necessary or appropriate to evidence, perfect or give notice of the Debtor Lien, and the Buyer shall execute any and all documents which the Debtor reasonably requests with respect to the Debtor Lien, including, but not limited to, evidencing and/or recording the Debtor Lien.

I. This Court shall retain jurisdiction over the Debtor and the Buyer, including, without limitation, jurisdiction to resolve any disputes, claims, or actions which may arise in connection with the Sale Agreement and any other agreements or instruments executed in connection therewith, the transactions contemplated under the Sale Agreement and such other agreements and instruments and for the purpose of enforcing the terms and provisions of this Order.

J. The Debtor is authorized and directed to execute, acknowledge, and deliver such corporate name change certificates, deeds, assignments, conveyances, and other assurances, documents, and instruments of transfer and take such other action that may be reasonably necessary to perform the terms and provisions of the Sale Agreement and related agreements, and shall take any other action that may reasonably be requested by the Buyer for purposes of assigning, transferring, granting, conveying, and confirming to the Buyer, or reducing to possession, any or all of the Assets and the Patents and to execute such nonmaterial amendments to the Sale Agreement and related agreements as may be required to effectuate the Sale Agreement and the consummation of the purchase and sale.

K. For each of the Assets consisting of or related to leasehold interests in property owned by others, the conveyance, assignment, transfer, and delivery thereof to the Buyer shall be subject to all of the rights and interests of the owner of the leased property other than rights not enforceable under §365 of the Bankruptcy Code.

L. From and after entry of this Order, the Debtor shall not take or cause to be taken any action which would interfere with the transfer of the Assets to the Buyer or its assignees or designees in accordance with the terms of this Order.

M. All persons or entities who are presently, or at the Closing (as defined in the Sale Agreement), in possession of any of the Assets are hereby directed to surrender possession of such Assets to the Buyer or its assignees or designees at the Closing.

N. From and after the Closing, the Buyer shall have the right and authority, subject to the terms of the Sale Agreement, to collect for the account of the Buyer any sums which shall be due and payable on account of any of the Assets transferred or intended to be transferred to the Buyer at the Closing and to endorse with the name of the Debtor any checks or drafts relating to the Assets which may be payable to the order of the Debtor; provided, however, that the disposition of any such sums and any such checks shall be in accordance with the terms of the Sale Agreement.

O. At or prior to the Closing, the Debtor shall pay or cause to be paid any and all transfer, stamp or other similar taxes and any filing or recording fees payable as a result of the sale or transfer of the Assets and the assumption and assignment of the Assumed Liabilities (as defined in the Sale Agreement).

P. The Debtor may, at a time and in a manner satisfactory to the Buyer, in its sole discretion, execute and deliver whatever lawful agreements that are reasonably necessary and make whatever lawful arrangements that are reasonably required to assure the transfer of the Assets free and clear of any claims by any governmental unit for taxes incurred as a consequence of the sale of any of the Assets under the terms of the Sale Agreement or to relieve the Buyer from any claim for transferee liability with respect to such taxes.

Q. At the Closing, the Debtor shall be authorized pursuant to Section 328 of the Bankruptcy Code to pay all fees due and payable to HLHZ pursuant to the engagement letter between the Committee and HLHZ dated May 14, 1998, as modified and approved by this Court by Order dated June 9, 1998. Reimbursement of HLHZ's expenses shall be subject to further Order of this Court, upon due application therefor by HLHZ pursuant to Section 330 of the Bankruptcy Code.

R. Pursuant to §365(f) of the Bankruptcy Code, conditioned upon the closing of the transactions contemplated by the Sale Agreement, all obligations under executory contracts and unexpired leases listed in Schedule 1.3 of the Sale Agreement shall be assumed by the Debtor and assigned to the Buyer, without the execution of any further documents or instruments. Unless the other parties to such unexpired leases or executory contracts shall have waived their rights to receive a cure of any pre-petition defaults, the Debtor shall cure all defaults under such executory contracts or unexpired leases within thirty (30) days after the Closing, and this Court shall retain jurisdiction to hear and determine any and all disputes in connection therewith. Upon the Closing, the Debtor shall have no further obligations under such executory contracts or expired leases pursuant to §365(k) of the Bankruptcy Code.

S. Consistent with paragraph 13 of the Sale Agreement, the Debtor and Buyer shall maintain all documents, data compilations and tangible objects of the Debtor which are in their possession or which may come into their possession for a period of fourteen months from the date hereof, and neither the Debtor nor Buyer will destroy or abandon those documents, data compilations or tangible objects without prior written notice to, among others, (i) Schoengold & Sporn, P.C., 233 Broadway, New York, New York 10279, Attn: Christopher Lometti, Esq.; (ii) Abbey, Gardy & Squiteri, LLP, 212 East 39th Street, New York, New York 10016; Attn: Jill S.

Abrams, Esq.; and to such other parties as the Court may direct. Inspection of the documents, data compilations and tangible objects may be had upon reasonable request, with the cost and expense of such inspection to be borne by the party making the request.

T. The provisions of this Order authorizing the Debtor to enter into the Sale Agreement and authorizing and directing the transactions contemplated by the Sale Agreement shall be self-executing and neither the Debtor nor the Buyer shall be required to execute or file any releases, termination statements, assignments, consents, or other instruments to effectuate consummation to implement the foregoing provisions hereof except as provided in the Sale Agreement and this Order. Notwithstanding the foregoing, the Debtor, Buyer and all other parties are authorized and directed to take any and all actions necessary and appropriate to effectuate, consummate, and implement fully the Sale Agreement.

U. The Buyer is a purchaser in good faith of the Assets and is entitled to the protection afforded by §363(m) of the Bankruptcy Code.

V. This Order is binding upon and inures to the benefit of any successors or assigns of the Debtor or the Buyer, including any trustee appointed in this case or any subsequent case of the Debtor under Chapter 7 of the Bankruptcy Code.

W. This Order is a final, appealable order.

DATED: New York, New York  
June 26, 1998

/s/ Prudence Carter Beatty

---

HONORABLE PRUDENCE CARTER BEATTY  
UNITED STATES BANKRUPTCY JUDGE

## **EXHIBIT C**



June 12, 1998 (12:09pm)

**ASSET PURCHASE AGREEMENT**

This Asset Purchase Agreement ("Agreement") is made and entered into as of the 12th day of June 1998 by and between Ultrafem, Inc., a Delaware corporation with offices at 130 West 42nd Street, Suite 1103, New York, New York 10036, as a Debtor-in-Possession in Chapter 11, Case No. 98-42280 (PCB) ("Seller"), and Akcess Pacific Group, LLC, a California limited liability company, with an address at P.O. Box 7166, Rancho Santa Fe, California 92067 ("Buyer").

**RECITALS**

This Agreement is made with reference to the following facts:

A. Seller is the owner of certain Assets (as defined below) relating to the development, manufacture, distribution, marketing and sale of INSTEAD®, a proprietary vaginal discharge collection device (the "Product") based on its patented SoftCup® technology, and other assets and property relating thereto as more particularly hereinafter described and desires to sell substantially all of its assets (except as otherwise explicitly provided herein) and business relating to the Product (the "Business").

B. Seller desires to sell and Buyer desires to purchase the Assets, and to assume certain liabilities related thereto.

C. Seller and Buyer have reached an agreement with respect to the sale of the Assets of Seller on the terms and conditions hereinafter set forth.

NOW THEREFORE, in consideration of the premises and mutual covenants and agreements herein contained, and for other good and valuable consideration, the parties hereto agree as follows:

**1. Purchase and Sale of Assets.**

**1.1. Assets to be Transferred at Closing.** Subject to and upon the terms and conditions of this Agreement, at the Closing of the transactions contemplated by this Agreement to be held on the Closing Date (as such terms are hereinafter defined in Section 8), Seller will sell, transfer, assign and convey to Buyer by appropriate bills of sale, assignments and other instruments of transfer, for the consideration hereinafter provided, and the Buyer shall purchase from the Seller, the following properties, and assets of Seller (collectively the "Assets"):

(a) All of Seller's right, title and interest in and to the patents, copyrights, trademarks, service marks, and trade names, and all applications therefor, whether U.S. or foreign, and franchises, goodwill and other intangible property (collectively, the

"Intangibles"), the material items of which are listed on Schedule 1.1(a), including but not limited to, product formulas, research and development, trade secrets and know how.

(b) All of Seller's right, title and interest in and to all of the machinery, equipment, furniture, office equipment, other fixed assets, and molds and material tangible personal property owned by Seller and useful or used in the operation of its Business ("Machinery and Equipment"), the material items of which are listed on Schedule 1.1(b), at the locations listed on such Schedule.

(c) All of Seller's right, title and interest in and to all existing inventory of the Product, finished goods and work-in-process, and related raw materials, boxes, packaging and other materials and supplies ("Inventory") at the locations listed on Schedule 1.1(c).

(d) All fixtures and improvements, including work-in-progress, if any, owned by Seller and located in and on the real property leased by Seller and used or useful in the operation of its Business described on Schedule 1.1 (d) hereto ("Improvements").

(e) All of the other fixed and other tangible property owned by Seller and used or useful in the operation of its Business, and replacements thereof and improvements thereto, the principal items of which are identified on Schedule 1.1(e) hereto.

(f) All trade accounts receivable, unbilled orders, and contract rights relating to the sale of the Product, as listed on Schedule 1.1(f).

(g) All records relating to regulatory filings, inspection reports and correspondence relating thereto, including but not limited to 510(k) application(s), sales, distribution, advertising and marketing, including all market research, artwork, advertising, marketing concepts, marketing materials and market measurement data associated with the Product, and Seller's files, logs and other records, including accounting records specifically relating to the operation of its Business, as Buyer may reasonably require, but not including any corporate or accounting books or records of Seller.

(h) To the extent assignable without any payment by Seller, the rights of Seller under (i) all non-compete agreements (other than agreements with employees), confidentiality agreements, and non-disclosure agreements, and (ii) the contracts, licenses, leases and agreements in effect on the Closing Date relating to the operation of its Business and the Assets (other than agreements with employees) identified (i) in Schedule 1.3 and (ii) by Buyer in writing between the date hereof and the Closing Date, which Buyer in its sole discretion elects to assume as of the Closing Date, including but not limited to and any renewals or extensions thereof.

(i) All of Seller's right, title and interest in and to the name "Ultrafem" and the Business now known as Ultrafem, Inc., which principally engaged in the manufacture, distribution and sale of the Product; provided, however, that nothing herein shall prevent the Company from continuing to use the name "Ultrafem" in connection with its Chapter 11 case

and/or disclosing in connection with its use of its new name that it was formerly known as "Ultrafem, Inc."

(j) Any security deposit, prepaid expense or other prepaid item specifically relating to an Assumed Liability assumed by Buyer at the Closing.

**1.2. Conveyance Free of Liens.** On the Closing Date, (i) Seller will have good and marketable title to the Assets free and clear of all security interests, liens, mortgages, pledges, charges, deeds of trust, claims or other encumbrances of any nature whatsoever ("Claims"), and/or (ii) as the result of a Final Approval Order of the Bankruptcy Court, all the Assets will be transferred to Buyer at the Closing free and clear of any such Claims, except for the Assumed Liabilities identified in Section 1.3 below. As used herein, "Bankruptcy Court" shall mean the United States Bankruptcy Court for the Southern District of New York; "Approval Order" shall mean an order of the Bankruptcy Court approving this Agreement and the consummation of the transactions contemplated herein and providing, among other matters, that (i) the Assets shall be transferred to the Buyer free and clear of any and all Claims, (ii) any and all Claims against the Assets shall attach to the proceeds of the sale of the Assets; (iii) the Buyer shall assume the Assumed Liabilities, and (iv) the Buyer is a good faith Buyer entitled to protection pursuant to Section 363(m) of the Bankruptcy Code; and "Final" as applied to the Approval Order or any other governmental order or action, shall mean that such order or action has not been stayed, vacated or otherwise rendered ineffective.

**1.3. Assumed Liabilities and Retained Liabilities.**

(a) At the Closing, Buyer assumes and agrees to perform, pay as they become due and discharge the liabilities, obligations and commitments of the Seller relating to and under the contracts, licenses, leases, and agreements specifically identified (i) in Schedule 1.3, and (ii) by Buyer in writing between the date hereof and the Closing Date (collectively, "Assumed Contracts"), which Buyer in its sole discretion elects to assume as of the Closing Date, to the extent that such liabilities, obligations and commitments arise after the Closing (collectively, the "Assumed Liabilities").

(b) Buyer shall not assume or agree to perform, pay or discharge, and the Seller shall remain unconditionally liable for:

(i) any and all federal, state and local income, franchise, sales, gross receipts, excise and other taxes, assessments and governmental charges, as well as withholding and social security taxes required to have been paid or accrued prior to the Closing, and interest and penalties thereon ("Taxes") relating to Seller's Business or employees of Seller attributable to (and including the last day of) and required to be paid or accrued for any period ending on or before the Closing Date, except that Buyer shall be responsible for Taxes relating to the Accounts Receivable transferred to Buyer, or

(ii) all obligations, liabilities and commitments, fixed or contingent, of the Seller other than as set forth in Section 1.3(a),

(collectively, the "Retained Liabilities").

**1.4. Excluded Assets.** The Assets shall not include: (i) cash on hand or in bank accounts, cash equivalents, reserves, prepaid interest, securities, prepaid insurance, or, except as provided in 1.1(j) above, prepaid expenses, deposits and other prepaid items (including, but not limited to, those bank accounts, security deposits and insurance policies listed on Schedule 1.4, which are excluded Assets hereunder); (ii) tangible personal property disposed of or consumed between the date hereof and the Closing Date as specifically authorized by this Agreement; (iii) claims of Seller to the extent they pertain to the operation of its Business prior to the Closing Date; (iv) any tax credits and/or refunds with respect to operations of the Seller or insurance policy credits or refunds of insurance premiums; (v) insurance policies; (vi) any corporate or accounting books or records of Seller, including but not limited to, checkbooks and canceled checks, minute books, stock books and similar corporate books and records of the Company; or (vii) any claims in favor of Seller or its bankruptcy estate under Chapter 5 of the Bankruptcy Code.

**2. Purchase Price and Payment.**

**2.1. Purchase Price.** In full consideration of the sale of the Assets to Buyer, on the Closing Date Buyer shall:

(a) pay Seller at the Closing, by certified or bank check or by wire transfer of federal funds to an account or accounts designated by Seller, the aggregate sum of Two Million Five Hundred Thousand Dollars (\$2,500,000) (which amount includes the Deposit described in Section 2.2 herein); and

(b) deliver to Seller Buyer's Promissory Note (the "Note") in the principal amount of Two Million Five Hundred Thousand Dollars (\$2,500,000), bearing simple interest at the rate of eight (8%) percent per annum with all principal and accrued and unpaid interest thereon being due and payable twenty-four (24) months following the Closing Date. Buyer shall have the obligation (i) to make quarterly payments on the Note in an amount equal to five (5%) of gross revenues (as adjusted for returns, discounts and bad debt, and less any applicable sales or other taxes) resulting from the sale of the Product or any other product derived from or arising out of the Assets acquired under this Agreement; and (ii) on the first anniversary of the Closing Date a principal amount equal to \$833,333.33 less the amounts paid pursuant to clause (i), plus accrued interest thereon; and (iii) all remaining principal and accrued interest on the second anniversary of the Closing Date. The Note shall be secured by a perfected first lien and security interest in the Intangibles, and may be prepaid without any premium, or discount; and

(c) assume the Assumed Liabilities specified in Section 1.3;

(collectively, hereinafter the "Purchase Price")

## 2.2. Deposit.

(a) Concurrently with the execution of this Agreement, the Buyer or an affiliate shall deposit into escrow with the Escrow Agent, cash, or a certified or bank check, or by wire transfer to the account specified in Schedule 2.2, in the amount of Two Hundred Fifty Thousand Dollars (\$250,000.00) (the "Deposit").

(b) At the Closing, the Deposit shall be paid to the Seller as a credit against the Purchase Price in addition to the amount payable at the Closing in accordance with Section 2.1, and the earnings thereon shall be paid to the Seller.

(c) The parties agree that in the event that this Agreement is terminated by Buyer prior to the Closing pursuant to Section 10(b), Seller shall suffer damages resulting from such termination, the amount and extent of which will be difficult to calculate or establish, and Buyer desires to limit its potential liability thereunder; accordingly, in the event of a termination of this Agreement by Buyer pursuant to Section 10(b), the parties agree that the amount of the Deposit constitutes reasonable compensation to Seller for such termination and shall be paid to Seller (including all earnings thereon) within twenty-four (24) hours of the date of such termination pursuant to Section 10(b), as liquidated damages, which shall constitute Seller's sole and exclusive remedy. In the event this Agreement is terminated prior to the Closing for any reason other than pursuant to Section 10(b), the Deposit and all earnings thereon shall within twenty-four (24) hours be repaid to the Buyer and the Buyer shall not be entitled to any other remedy or relief, except as provided in Section 6.3 below.

2.3. Assumed Liabilities. As of the Closing Date, the Seller shall assign to Buyer and Buyer shall assume the Assumed Liabilities, without recourse to the Seller, to the extent permitted under Section 365 of Chapter 11, Title 11 of the United States Code, 11 U.S.C. §§ 101, *et seq.* ("Bankruptcy Code"). From and after the Closing, the Buyer shall indemnify and hold the Seller harmless from and against all claims, losses, liabilities, demands, actions, suits, obligations and expenses, including reasonable legal fees and expenses, relating to or arising out of Buyer's failure to pay, discharge or perform any of the Assumed Liabilities.

3. Representations and Warranties of Seller. Seller represents and warrants to Buyer as follows:

3.1. Organization and Qualification of Seller. Seller is a corporation duly incorporated and validly existing under the laws of the jurisdiction of its incorporation with the corporate power and authority to carry on its Business, to own the Assets and operate its properties and to execute and deliver this Agreement and any other agreements to be entered into by it in connection with this Agreement on or prior to the Closing Date and to perform its obligations hereunder and thereunder. Seller is duly qualified to transact Business as a foreign corporation in each jurisdiction, where the ownership or use of the Assets and the conduct of its Business necessitates such qualification.

3.2. Authorization of Agreement; No Breach; Consents. Upon approval by the Bankruptcy Court, (a) the execution and delivery of this Agreement and any other agreements to be

entered into by Seller in connection with this Agreement on or prior to the Closing Date by Seller and the consummation by Seller of all transactions contemplated hereby and thereby will have been duly authorized and approved by all requisite corporate and stockholder action, or in the absence thereof, by appropriate Bankruptcy Court order, and (b) this Agreement is and such other agreements will be the valid and binding obligations of Seller enforceable against Seller in accordance with their respective terms. All persons who have executed or will execute this Agreement and such other agreements on behalf of Seller have been or will be duly authorized to do so by all necessary corporate action of Seller, or in the absence thereof, by appropriate Bankruptcy Court order. Except for the Final Approval Order of the Bankruptcy Court, Seller may enter into this Agreement and such other agreements and perform its obligations hereunder and thereunder without the necessity of obtaining any consent or approval from anyone, including any governmental authority except as otherwise indicated in this Agreement.

**3.3. Litigation.** Except as set forth in Schedule 3.3, there are no governmental inquiries, or actions, suits, investigations or proceedings pending or, to the best knowledge of Seller, threatened, by or before any court, agency or other governmental body (including but not limited to the U.S. Food and Drug Administration) against or affecting Seller (or any corporation or entity affiliated with Seller) which seeks to enjoin or prohibit or otherwise challenge the transactions contemplated hereby, or which could prevent, delay, materially impair the carrying out of this Agreement and the transactions contemplated hereby.

**3.4. Governmental Action.** Except for an Approval Order of the Bankruptcy Court, no governmental action, consent, order, or authorization is required in connection with the execution, delivery and performance by the Seller of this Agreement or any of the instruments or agreements herein referred to, or the taking of any action herein contemplated. Seller has operated its Business in conformity in all material respects with applicable laws and regulations.

**3.5. Compliance with Environmental Laws.** Except as set forth in the three Phase I environmental audits relating to the real property leased by the Company in connection with its Missoula, Montana operations, copies of which have been delivered to Buyer, to the best of Seller's knowledge (i) Seller and its operations have been in compliance with, and Seller is not in violation of, any material requirement of any applicable environmental law as currently in effect; (ii) neither Seller nor any of its predecessors used, released or disposed of any hazardous substance in any manner that could reasonably be expected to result in material liability to Seller; (iii) the property leased or operated by Seller is not contaminated by any hazardous substance in a manner that requires investigation or corrective action under applicable environmental laws; and (iv) the property leased or operated by Seller is not affected by any condition that could reasonably be expected to result in material liability of Seller under any environmental law as currently in effect. For the purposes of this Agreement, the term "hazardous substance" means (i) any gasoline, fuel oil or any other petroleum product, explosives, alcohols or chemical solvents or polychlorinated biphenyls, (ii) any substance, waste, material or product defined as hazardous, radioactive, extremely hazardous or toxic under any environmental law and (iii) asbestos or asbestos-containing substances.

**3.6. Intellectual Property.** Schedule 3.6 sets forth all intellectual property of Seller. Seller owns, or is licensed to, or otherwise has, the right to use such intellectual property. Seller has

not received any notice that it is in violation of, or infringing upon, any patent, trademark, service mark, trade name, copyright or franchise of any third-party, and, except as set forth on Schedule 3.6, no claims have been asserted, nor is there any litigation pending or threatened claiming such infringement. Except as set forth on Schedule 3.6, Seller has not licensed or encumbered any of its intellectual property to any third-party, nor have any other distribution rights been granted by Seller to a third-party. Except as set forth on Schedule 3.6, Seller has not entered into any other agreements whereby Seller has been appointed as a distributor or licensee of any products, patents or trademarks owned by a third-party. Except as set forth on Schedule 3.6, Seller has not entered into any agreement which restricts or affects the use of any of the intellectual property. Seller owns or has licensed from third-parties, and has the right to use, all necessary intellectual property in order to conduct its Business in all material respects as currently conducted.

**3.7. Insurance.** All of the Assets, properties, Business and operations of Seller are insured by policies of insurance in type and amount believed to be adequate for Seller as a debtor-in-possession, which policies of insurance are listed in Schedule 3.7. All of such policies listed in Schedule 3.7 have been and will be until the Closing Date in full force and effect with no premium arrearages.

**3.8. Subsidiaries and Other Affiliates.** Seller does not have any subsidiaries and does not own, either directly or indirectly, any interest or investment, whether debt or equity (other than an interest as a creditor holding a trade account receivable), or any obligation, joint venture, option or right to acquire any interest, direct or indirect, in any other corporation or other entity.

**3.9. Inventory and Accounts Receivable.** Schedule 3.9 sets forth an unaudited statement of Inventory and accounts receivable of Seller as of May 31, 1998, and the Seller's sales for the period subsequent to May 31, 1998. Schedule 3.9 also sets forth a description of Seller's policy and terms applicable to its collection of accounts receivable.

**3.10. Contracts and Leases.** Seller has provided and/or made available to Buyer copies of all material executory contracts and unexpired leases of real and personal property, which are listed on Schedule 3.10.

**3.11. No Other Representations or Warranties.** THE SALE OF THE ASSETS HEREUNDER IS MADE "AS IS" AND "WHERE IS" WITHOUT ANY REPRESENTATION OR WARRANTY AS TO THE CONDITION OR QUALITY OF ANY OF THE ASSETS OR AS TO TITLE TO ANY OF THE ASSETS OR SPECIFICALLY AS TO ANY OTHER MATTER RELATING TO ANY OR ALL OF THE ASSETS, EXCEPT AS SET FORTH IN THIS SECTION. EXCEPT AS SET FORTH IN THIS SECTION 3, ALL WARRANTIES, WHETHER EXPRESS OR IMPLIED, ARE HEREBY EXCLUDED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

**4. Representations and Warranties of Buyer.** Buyer hereby represents and warrants to Seller as follows:



**4.1. Organization; Good Standing; Power.** Buyer is a limited liability company duly organized, validly existing and in good standing under the laws of the State of California and has the corporate power and authority to execute, deliver and perform this Agreement and consummate the transactions contemplated hereby.

**4.2. Authorization.** Buyer has taken all corporate or other action necessary to authorize the execution, delivery and performance of this Agreement and any other agreements and instruments to be entered into by Buyer in connection with this Agreement on or prior to the Closing Date by Buyer and the consummation by Buyer of all transactions contemplated hereby and thereby; such execution, delivery and performance do not and will not violate, result in any default or acceleration under or conflict with any terms of, any law, charter, by-law, lien, order, award, judgment, decree or contract to which Buyer is a party or is subject or by which Buyer is bound; this Agreement is and such other agreements and instruments will be legal, valid and binding obligations of Buyer enforceable against Buyer in accordance with their respective terms.

**4.3. No Restrictions.** Buyer is not a party to, subject to or bound by any contract, commitment or agreement, any charter, by-law or other corporate restriction, or any order, judgment, decree, injunction, law, statute, ordinance, rule, regulation or other restriction of any kind or character, which could (a) prevent Buyer from entering into this Agreement or from consummating the transactions contemplated hereby, or (b) materially impair the carrying out of this Agreement and the transactions contemplated hereby.

**4.4. Litigation.** There are no actions, suits, investigations or proceedings pending or, to the best knowledge of Buyer, threatened, before any court, agency or other governmental body against or affecting Buyer (or any corporation or entity affiliated with Buyer) which seeks to enjoin or prohibit or otherwise challenge the transactions contemplated hereby, or which could prevent, delay, or materially impair the carrying out of this Agreement and the transactions contemplated hereby.

**4.5. Governmental Action.** Except for an Approval Order of the Bankruptcy Court, no governmental action, consent, order, or authorization is required in connection with the execution, delivery and performance by the Buyer of this Agreement or any of the instruments or agreements herein referred to, or the taking of any action herein contemplated.

**4.6. Financial Capability.** Buyer and its affiliates have sufficient funds and/or have obtained or will have obtained prior to the Closing binding commitments from responsible financial institutions or partners of Buyer or its affiliates to enable them to borrow such funds and/or Buyer and its affiliates will have made on or before the Closing Date binding arrangements between themselves, as are needed to enable Buyer and/or such affiliates, as the case may be, to pay the Purchase Price and to consummate the transactions contemplated by this Agreement, and will maintain such funds and/or commitments and/or arrangements until the Closing Date. If necessary, Buyer will provide such further information and assurances as reasonably requested by the Bankruptcy Court, to demonstrate its ability to consummate the transactions contemplated by this Agreement. Seller may provide copies of such commitments and any other information provided by Buyer to Seller to the Official Committee of Unsecured Creditors of Seller.



5. Access to Information. Throughout the period between the date hereof and the Closing Date, Seller shall afford to Buyer, its counsel, accountants, and other representatives, at all reasonable times during normal business hours and upon reasonable notice, reasonable access to all of the properties, books, contracts, commitments and records of Seller relating to the Assets and its Business and furnish to Buyer during such period all such information concerning the Assets and Seller's Business as Buyer may reasonably request.

6. Covenants.

6.1. Interim Operations. Subject to the Bankruptcy Code, until the Closing the Seller shall (a) not sell, transfer or otherwise encumber any of the Assets (other than the sale of Inventory and collection of receivables in the ordinary course of business by Seller as a debtor-in-possession), (b) maintain such insurance policies as provided in Section 3.7 or as shall be required by the Bankruptcy Court, (c) not enter into any contract or commitment requiring Seller to pay in excess of \$10,000 in the aggregate without the prior written notice to the Buyer, (d) not make any material capital expenditure or improvement without prior written notice to Buyer, and (e) will use reasonable efforts to preserve, protect and maintain the Assets. Between the date hereof and the Closing Date Seller shall not take any action to collect accounts receivable except in the ordinary course of business by Seller as debtor-in-possession and in accordance with the policy and terms set forth on Schedule 3.9.

6.2. Bankruptcy Court Scheduling Order and Approval Order. As soon as possible, but in no event later than June 16, 1998, Seller, at its sole cost and expense, shall file with the Bankruptcy Court a proposed scheduling order ("Scheduling Order") substantially in the form attached hereto as Exhibit 6.2 and supporting application which, among other things, requests that the Bankruptcy Court (i) approve the form of the notice of sale of the Assets, (ii) approve the terms and conditions of the sale of the Assets (substantially as set forth in Schedule 6.2), (iii) approve the proposed Break-up Fee (as defined in Section 6.3), (iv) fix the date of an auction to take place at the offices of Houlihan Lokey Howard & Zukin, 31 West 52<sup>nd</sup> Street, New York, New York 10019 ("Auction Date"), (v) specify the terms and conditions of the auction to be conducted on the Auction Date (substantially as set forth in Exhibit 6.2), and (vi) schedule the date and time of the hearing at which the Bankruptcy Court shall enter the Approval Order approving the sale of the Assets to the successful bidder.

6.3. Break-up Fee.

(a) Except if this Agreement has been terminated under Section 10(b), in the event the Bankruptcy Court issues an order approving the Seller's acceptance of an offer for all or any portion of the Assets from a party other than the Buyer ("Overbid Order"), the Deposit and any earnings thereon shall be paid to the Buyer as provided for in Section 2.2 herein, and the Seller shall pay or cause to be paid to the Buyer a so-called break-up fee of One Hundred Fifty Thousand dollars (\$150,000.00) (the "Break-up Fee") either (i) promptly from the proceeds received in connection with the closing of such other sale, or (ii) if the closing of such other sale does not occur within forty-five (45) days of the Overbid Order, the Break-up Fee shall be paid from any non-refundable deposit which is or becomes available to Seller, whichever shall first occur.

(b) The Seller agrees to recommend to the Bankruptcy Court the approval of the Break-up Fee as appropriate compensation to the Buyer should it not be the successful bidder for the Assets, given the costs and expenses incurred by Buyer including legal, accounting and other professional fees incurred by the Buyer, the loss of executive time and effort and the loss of other business opportunities, each of which cannot reasonably be calculated. The Break-up Fee is in lieu of and not in addition to direct reimbursement of any and all costs, expenses and losses incurred by Buyer. Notwithstanding any other provision of this Agreement to the contrary, the Buyer shall be entitled to terminate this Agreement immediately and receive a full refund of the Deposit in the event that the Bankruptcy Court does not approve the terms and conditions of the Break-up Fee.

6.4. Actions of Seller. Seller will use its reasonable best efforts to assist Buyer to obtain product liability insurance and/or property insurance from the insurance companies listed on Schedule 1.4 which have issued insurance policies to Seller, provided that Buyer shall pay the premiums for resulting the policies, if any, obtained by Buyer. Seller shall take all such actions as may be reasonably necessary to consummate the transactions contemplated hereby, including without limitation, such actions (i) as may be necessary to obtain prompt Bankruptcy Court approval of the transactions contemplated hereby, and (ii) at Buyer's election, that qualify Buyer as a successor in interest under any Assumed Contracts, provided that Seller shall not be required to make any payment in connection therewith. While the Seller will cooperate with parties identifying themselves as potential bidders and Seller will assist such parties in conducting due diligence, by virtue of executing this Agreement, Seller has committed to use its best efforts to consummate the sale of its Assets to Buyer.

6.5. Satisfaction of Conditions. The Seller shall use reasonable efforts to cause to be satisfied the conditions to its obligations set forth in Section 7.

#### 7. Conditions Precedent to Closing.

7.1. Conditions to the Obligations of Buyer. The performance of the obligations of Buyer hereunder is subject to the fulfillment or waiver by Buyer on or before the Closing Date of the following conditions:

- (a) the Approval Order shall have been entered and not stayed;
- (b) the Seller shall be authorized by the Approval Order or otherwise (i) to assume and assign to the Buyer the Assumed Liabilities and (ii) to sell and transfer to the Buyer the Assets, and, as the result of a Final Approval Order of the Bankruptcy Court, all of the Assets (including, but not limited to, the Intangibles) will be transferred to Buyer at the Closing free and clear of any Claims (except for the Assumed Liabilities identified in Section 1.3 above), including but not limited to litigation claims, whether set forth on Schedule 3.3 or otherwise.
- (c) the representations and warranties of the Seller contained herein shall be true and correct in all material respects on the date made and on the Closing Date as if made again on the Closing Date except for changes expressly contemplated by this Agreement (including, but not limited to those contemplated under Section 8 and Section 20);

(d) the Seller shall have complied with all covenants of the Seller contained in this Agreement in all material respects;

(e) Buyer shall have received the Closing Documents set forth in Section 9.1; and

(f) all action necessary for the assignment or transfer of the intellectual property, including but not limited to patent assignments, will have been taken by Seller.

**7.2. Conditions to the Obligations of Seller.** The performance of the obligations of Seller hereunder is subject to the fulfillment on or before the Closing Date of the following conditions:

(a) the Approval Order shall have been entered and not stayed;

(b) the Buyer shall have assumed the Assumed Liabilities and paid to the Seller the Purchase Price in accordance with the terms hereof;

(c) the representations and warranties of the Buyer contained herein shall be true and correct in all material respects on the date made, on the date of the Approval Order and on the Closing Date as if made again on the Closing Date except for changes expressly contemplated in this Agreement;

(d) the Buyer shall have complied with all covenants of the Buyer contained in this Agreement in all material respects; and

(e) Seller shall have received the Closing Documents set forth in Section 9.2 hereof.

**8. Closing Date.** The closing ("Closing") shall occur at the offices of Togut Segal & Segal, One Penn Plaza, Suite 3335, New York, New York 10119 at 10:00 A.M. on the later of (i) the third (3rd) business day following the date of the entry of an order of the Bankruptcy Court approving the sale of the Assets to the Buyer ("Sale Order"), or (ii) if the Sale Order has been stayed pending appeal, the date the stay has been lifted or the date the Sale Order becomes Final (the "Closing Date"). The Closing shall constitute the acts which take place on the Closing Date by which the transactions contemplated by this Agreement are consummated. Buyer acknowledges that Seller has substantially ceased its operations, it is not able to continue operations and retain current employees beyond June 28, 1998 and there can no assurance that this will not adversely affect the Business and the Assets. Buyer acknowledges that time is of the essence.

**9. The Closing.** On the Closing Date, the parties shall exchange documents as follows:

**9.1. Deliveries by Seller.** Seller shall deliver to Buyer:

(a) One or more bills of sale covering all of the tangible assets, described in Section 1.1(b), (c), (d), (e), (g) and (j).

(b) Assignments of the leases, licenses, contracts, and agreements described in Section 1.1(b).

(c) Assignments of the Intangible assets described in Section 1.1(a), including but not limited to assignments of patents, trademarks and copyrights and the accounts receivable and other Assets described in Section 1.1(f).

(d) Statement of accounts receivable, current as of the Closing Date, identifying each account and the amount owed.

(e) A copy of the resolutions duly adopted by the Board of Directors of Seller authorizing and approving the execution, delivery and performance of this Agreement and the sale and transfer of the Assets to the Buyer pursuant to the terms of this Agreement, and the execution and delivery of any other documents and agreements contemplated hereunder, certified by an officer of Seller.

(f) An incumbency certificate or certificates dated the Closing Date certifying the incumbency of all officers and directors of Seller who have executed this Agreement or documents in connection with this Agreement or the transactions contemplated hereby, containing specimens of the signatures of each of the officers and directors whose incumbency is certified and shall be executed by an officer or director of Seller other than an officer or director whose incumbency is certified.

(g) An executed certificate of amendment to the Company's certificate of incorporation in a form suitable for filing with the Secretary of State of Delaware to change the Company's name from Ultrafem, Inc. to a different name which does not use the name "Ultrafem".

(h) Such further instruments of assignment, conveyance or transfer or other documents covering the Assets as Buyer or its counsel may reasonably request to assure the full and effective assignment and transfer to it of the Assets and all the right, title and interest therein and to assure the effective carrying out of the transactions contemplated hereby.

**9.2. Deliveries by Buyer.** Buyer shall deliver to Seller:

(a) The Purchase Price as specified in Section 2, including the cash portion thereof and the Note.

(b) A document executed by the Buyer whereby Buyer agrees to assume the Assumed Liabilities described in Section 1.3.

(c) Such security agreement(s) and instruments as may be necessary to give Seller a valid perfected first lien and security interest in the Intangibles.

(d) A copy of the resolutions duly adopted by the Board of Directors of Buyer authorizing and approving the execution, delivery and performance of this Agreement, the delivery of the Purchase Price and the execution and delivery of any and all other documents and agreements contemplated hereunder, certified by the Secretary or an Assistant Secretary of Buyer.

(e) An incumbency certificate or certificates dated the Closing Date certifying the incumbency of all officers of Buyer who have executed this Agreement or documents in connection with this Agreement or the transactions contemplated hereby; containing specimens of the signatures of each of the officers whose incumbency is certified and shall be executed by officers of Buyer other than an officer whose incumbency is certified.

(f) Such further instruments or other documents as Seller or their counsel may reasonably request to assure the effective carrying out of the transactions contemplated hereby.

9.3. Transfer Taxes and Recording Fees. At or prior to the Closing, the Seller shall pay or cause to be paid any and all transfer, stamp or other similar Taxes or and any filing or recording fees ("Fees") payable as a result of and in connection with the sale or transfer of the Assets to be purchased hereunder and the assumption and assignment of the Assumed Liabilities or shall have obtained an exception thereof under the Bankruptcy Code and/or the Approval Order, and Seller shall indemnify and hold harmless the Buyer from and against payment of any such Taxes and Fees.

9.4. Expenses. Except for the Breakup Fee as provided in Section 6.3 herein, Seller and Buyer shall bear their respective expenses incurred in the negotiation and consummation of this Agreement.

10. Termination. This Agreement may be terminated only in accordance with this Section, as follows:

(a) Except as is set forth in subsections (b), (c), (d) and (f) below, this Agreement may not be terminated without an order of the Bankruptcy Court.

(b) If the Buyer defaults in any of the obligations imposed upon the Buyer pursuant to this Agreement, or if any representations or warranties made by the Buyer are not true or correct in any material respect, the Seller may, in its sole and absolute discretion, provide notice (the "Default Notice") to the Buyer of such default in writing. If said default is not cured in full within three (3) business days from the date the Default Notice is sent by overnight mail, facsimile or personal delivery, then on the third (3rd) business day following the day the Default Notice is so delivered, the Agreement shall terminate; provided, however, that if such default is Buyer's failure to timely close in accordance with Section 8, Buyer shall have twenty-seven (27) days to cure such default.

(c) If the Seller defaults in any of the obligations imposed upon the Seller pursuant to this Agreement, or if any representations or warranties made by the Seller are not true or

correct in any material respect, the Buyer may, in its sole and absolute discretion, provide notice (the "Default Notice") to the Seller of such default in writing. If said default is not cured in full within three (3) business days from the date the Default Notice is sent by overnight mail, facsimile or personal delivery, then on the third (3rd) business day following the day the Default Notice is so delivered, this Agreement shall terminate.

(d) This Agreement may be terminated by the joint written consent of the Seller and the Buyer, and in such event, the parties shall have no further obligation or liability to each other under this Agreement.

(e) In the event the Bankruptcy Court, pursuant to a procedure established by the Bankruptcy Court in the Scheduling Order, approves a competing bid for the Assets, this Agreement shall terminate, and the Breakup Fee shall be paid to Buyer as provided in Section 6.3.

(f) At the sole option of Buyer, in the event the Bankruptcy Court fails to enter the Approval Order by September 30, 1998.

**11. Attorney-In-Fact for the Seller.** The Seller agrees that, effective as of the Closing Date, it hereby constitutes and appoints the Buyer, its successors and permitted assigns, the true and lawful attorney of the Seller, in the name of the Buyer or in their respective names, but for the benefit and at the expense of the Buyer: (i) to institute and prosecute all proceedings which the Buyer may deem proper in order to collect, assert or enforce any claim, right or title of any kind in or to the Assets; (ii) to defend or compromise any and all actions, suits or proceedings in respect of any of the Assets, and to do all such acts and things in relation thereto as the Buyer shall deem advisable; and (iii) to take all action which the Buyer, its successors or assigns, may reasonably deem proper in order to provide for the Buyer, its successors or assigns, the benefits under any of the Assets where any required consent of another party to the sale or assignment thereof to the Buyer pursuant to this Agreement shall not have been obtained; provided, however, that the foregoing shall not apply to any any claims in favor of Seller or its bankruptcy estate under Chapter 5 of the Bankruptcy Code. If the Buyer, in the name of the Seller, desires to institute and prosecute any action, suit or proceeding, or take any other action pursuant to this Section 11, the Buyer shall give the Seller ten (10) days' written notice prior to taking any such action in the name of the Seller. The Seller acknowledges that the foregoing powers are coupled with an interest and shall be irrevocable by the Seller. The Buyer shall be entitled to retain for its own account any amounts collected pursuant to the foregoing powers, including any amounts payable as interest in respect thereof. Buyer shall defend, indemnify and hold harmless the Seller for any damages, costs and expenses, including reasonable attorneys' fees, the Seller may incur on account of the acts of Buyer taken pursuant to the authority granted to it under this Section.

**12. Brokerage Fees.** Except for Houlihan Lokey Howard & Zukin, which has been engaged as an investment advisor by the Official Committee of Unsecured Creditors and is to be compensated out of the proceeds of the sale of the Assets pursuant to an order of the Bankruptcy Court, the Seller and the Buyer represent and warrant that they have not employed any broker, finder or investment banker who might be entitled to any brokerage, finder's fee, underwriting discount or

other fee or commission from the Buyer or the Seller in connection with the purchase or sale of the Assets, the assumption and assignment of the Assumed Liabilities and the Seller and Buyer each hereby indemnify and holds harmless the other from and against any loss, cost, damage or expense (including reasonable attorney's fees) arising out of any claim of any broker retained by the indemnitor for any fee or commission in connection with this transaction.

13. **Preservation of and Access to Books and Records.** Following the Closing Date, except in the event that Buyer subsequently sells all or substantially all of the Assets, Buyer shall preserve for at least three years after the Closing Date all books and records included in the Assets and thereafter shall not dispose of any such books and records without first offering them to Seller (without cost to Seller) upon 60 days written notice. Buyer shall also afford Seller, its accountants and agents access to such books and records during regular business hours and upon reasonable notice to Buyer and Seller shall be permitted to make extracts from or copies of such books and records. Further, following the Closing Date, Seller shall preserve until closing of Seller's Chapter 11 case all corporate or accounting books or records of Seller, including but not limited to, checkbooks and canceled checks, minute books, stock books and similar corporate books and records of the Company, which are not included in the Assets being sold hereunder, and thereafter shall not dispose of any such books and records without first offering them to Buyer (without cost to Buyer) upon 60 days written notice. Seller shall also afford Buyer, its accountants and agents access to such books and records during regular business hours and upon reasonable notice to Seller and Buyer shall be permitted to make extracts from or copies of such books and records.

14. **Additional Documents.** The parties agree that they will execute or furnish such documents and further assurances to each other or to proper authorities as may be necessary for the full implementation and consummation of this Agreement.

15. **Notices.** Any notices or other communications required or permitted under this Agreement shall be in writing and shall be sufficiently given if hand delivered, if telecopied (with a confirmation copy by mail), or if sent by a nationally recognized overnight delivery service addressed as follows:

if to Seller:

Ultrafem, Inc.  
130 West 42nd Street, Suite 1103  
New York, New York 10036  
Fax: (212) 921-2067  
Attn: Ms. Dori M. Reap and Ms. Tonya G. Hinch

with copies to:

Togut, Segal & Segal  
One Penn Plaza, Suite 3335  
New York, New York 10119  
Fax No.: (212) 967-4258

Kensington & Ressler L.L.C.  
400 Madison Avenue  
New York, NY 10017  
Fax No.: (212) 838-7060



Attn: Albert Togut, Esq.  
Neil Berger, Esq.

Attn: Howard D. Ressler, Esq.  
Helen J. Williamson, Esq.

if to Buyer:

with copies to:

Akcess Pacific Group, LLC  
P.O. Box 7166  
Rancho Santa Fe, CA 92067  
Fax No.: (619) 756-7896  
Attn: Leslie Sebastian

Zevnik Horton Guibord McGovern  
Palmer & Fognani, L.L.P.  
101 West Broadway  
San Diego, CA 92101  
Fax No.: (619) 515-9628  
Attn: Kenneth D. Polin, Esq.

or to such other address as the parties may designate in writing.

**16. Survival of Representations and Warranties; Indemnification.** The representations, warranties, covenants and agreements of the parties herein contained (i) shall survive the Closing for a period of one hundred eighty (180) days (the "Survival Period"), regardless of any investigation made by the parties hereto, and (ii) shall be effective with respect to any breach thereof, notice of which shall have been duly given in accordance with Section 15 hereof prior to the expiration of the aforesaid period. Further, from the Closing Date through the Survival Period, Buyer may file a claim in accordance with applicable bankruptcy law against Seller's Chapter 11 estate for any alleged claims, costs, damages, fines, judgments, losses, liabilities or expenses allegedly suffered or incurred by Buyer, its affiliates, successors in interest, transferees, assigns, beneficiaries, shareholders, officers, members, directors, attorneys, accountants and agents, and each of them, in all capacities including individually (collectively, the "Indemnitees"), arising out of (i) any breach by Seller of any of the representations, warranties, covenants and agreements contained in this Agreement, or (ii) any claims asserted against Buyer after the Closing Date arising from Seller's operation of the Business and/or ownership of the Assets prior to the Closing Date.

**17. Successors and Assigns; Benefits.** Except (i) for an assignment by Buyer of its rights hereunder to an affiliate (including the assignment to and assumption by such affiliate of all Assumed Liabilities), or (ii) in connection with the transfer after the Closing Date of all or certain of the Assets being purchased herein (and any corresponding Assumed Liabilities) to an affiliate of Buyer, no party shall have the right to assign its rights or delegate its obligations under this Agreement; provided, however, that any such affiliate must, at the date of such assignment, be in compliance with all representations and warranties made herein by Buyer as if such affiliate made such representations and warranties as to itself, and provided, further however, that Buyer shall be and shall remain liable for and shall guarantee, all of the obligations of such affiliate, including, but not limited to, such affiliate's obligations under the Note and the Assumed Liabilities assumed by such affiliate. Nothing expressed or referred to in this Agreement is intended or will be construed to give any person other than the parties to this Agreement any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein, it being the intention of the parties to this Agreement that the Agreement be for the sole and exclusive benefit of such parties and not for the benefit of any other person. For the purposes of this Agreement, the term "affiliate" means, with



respect to a particular party, persons or entities controlling, controlled by or under common control with such party.

18. **Severability.** The invalidity or illegality of any provision, term, or agreement contained in or made a part of this Agreement shall not affect the validity of the remainder of this Agreement.

19. **Entire Agreement.** This Agreement, together with the Schedules and Exhibits, contains all of the terms agreed upon by the parties with respect to the subject matter hereof, supersedes all prior agreements, understandings, negotiations and discussions, whether written or oral, of the parties, and there are no representations or understandings between the parties except as provided herein. This Agreement may not be amended or modified in any way except by a written amendment to this Agreement duly executed by the parties.

20. **Waiver.** No waiver of a breach of, or default under, any provision of this Agreement shall be deemed a waiver of such provision or of any subsequent breach or default of the same or similar nature or of any other provision or condition of this Agreement. Performance of or compliance with any covenant given herein or satisfaction of any condition to the obligations of either party hereunder may be waived by the party to whom such covenant is given or whom such condition is intended to benefit, except to the extent any such condition is required by law; provided that any such waiver must be in writing. No delay or omission on the part of any party hereto in exercising any right hereunder will operate as a waiver of such right or any other right under this Agreement. In the event that Buyer is default for failure to timely close as provided in Section 8 and seeks to cure such default, the condition set forth in Section 7.1 (c) shall be deemed to have been satisfied as of the third (3rd) business day following the date of the Sale Order.

21. **Applicable Law.** Except where superseded by federal law, this Agreement shall be governed by and construed (both as to validity and performance) and enforced in accordance with the laws of the State of New York applicable to agreements made and to be performed wholly within such jurisdiction.

22. **Consent to Jurisdiction; Setoff.** Each party hereto, to the extent that it may lawfully do so, hereby consents to the exclusive jurisdiction of the Bankruptcy Court, as well as to the jurisdiction of all courts to which an appeal may be taken from the Bankruptcy Court, for the purpose of any suit, action or other proceeding arising out of any of its obligations hereunder or with respect to the transactions contemplated hereby, and expressly waives any and all objections it may have as to venue, including, without limitation, the inconvenience of such forum, in any of such courts. In addition, to the extent that it may lawfully do so, each party hereto consents to the service of process by personal service or U.S. certified or registered mail, return receipt requested, addressed to it at the address provided herein. To the extent a party hereto has or hereafter may acquire any immunity from jurisdiction of any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution or otherwise) with respect to itself or its property, it hereby irrevocably waives such immunity in respect of its obligations under this Agreement.

23. Waiver of Jury Trial. EACH PARTY HEREBY VOLUNTARILY AND IRREVOCABLY WAIVES TRIAL BY JURY IN ANY ACTION BROUGHT ON OR WITH RESPECT TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY.

24. Section Headings. The section headings are for reference only and will not limit or control the meaning of any provision of this Agreement.

25. Counterparts. This Agreement may be executed in any number of counterparts, each of which may be deemed to be an original and all of which together shall be deemed to be one and the same instrument.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the day, month and year hereinabove set forth.

SELLER:

ULTRAFEM, INC.

By: \_\_\_\_\_  
Dori M. Reap, Office of the Chief Executive  
and Senior Vice President

By: \_\_\_\_\_  
Tonya G. Hinch, Office of the Chief Executive  
and Senior Vice President

BUYER:

AKCESS PACIFIC GROUP, LLC

By: \_\_\_\_\_  
Leslie Sebastian  
Joseph Pike  
Title: \_\_\_\_\_

23. Waiver of Jury Trial. EACH PARTY HEREBY VOLUNTARILY AND IRREVOCABLY WAIVES TRIAL BY JURY IN ANY ACTION BROUGHT ON OR WITH RESPECT TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY.

24. Section Headings. The section headings are for reference only and will not limit or control the meaning of any provision of this Agreement.

25. Counterparts. This Agreement may be executed in any number of counterparts, each of which may be deemed to be an original and all of which together shall be deemed to be one and the same instrument.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the day, month and year hereinabove set forth.

SELLER:

ULTRAFEM, INC.

By:

Dori M. Resp, Office of the Chief Executive  
and Senior Vice President

By:

Tonya G. Hinch, Office of the Chief Executive  
and Senior Vice President

BUYER:

ACCESS PACIFIC GROUP, LLC

By:

Leslie Sebastian

Joseph Pike

Title: CEO

06.12.08 07:30 PM \*KENSINGTON T MESSER FOR

23. Waiver of Jury Trial. EACH PARTY HEREBY VOLUNTARILY AND IRREVOCABLY WAIVES TRIAL BY JURY IN ANY ACTION BROUGHT ON OR WITH RESPECT TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY.

24. Section Headings. The section headings are for reference only and will not limit or control the meaning of any provision of this Agreement.

25. Counterparts. This Agreement may be executed in any number of counterparts, each of which may be deemed to be an original and all of which together shall be deemed to be one and the same instrument.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the day, month and year hereinabove set forth.

SELLER:

ULTRAFEM, INC.

By: Dori M. Reap 6/12/98  
Dori M. Reap, Office of the Chief Executive  
and Senior Vice President

By: \_\_\_\_\_  
Tonya G. Hinch, Office of the Chief Executive  
and Senior Vice President

BUYER:

AKCESS PACIFIC GROUP, LLC

By: \_\_\_\_\_  
Leslie Sebastian  
Joseph Pike  
Title: \_\_\_\_\_

6-12-1998 7:40PM FROM KENSINGTON \* RESSLER 212 633 7060

P. 2

23. Waiver of Jury Trial. EACH PARTY HEREBY VOLUNTARILY AND IRREVOCABLY WAIVES TRIAL BY JURY IN ANY ACTION BROUGHT ON OR WITH RESPECT TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY.

24. Section Headings. The section headings are for reference only and will not limit or control the meaning of any provision of this Agreement.

25. Counterparts. This Agreement may be executed in any number of counterparts, each of which may be deemed to be an original and all of which together shall be deemed to be one and the same instrument.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the day, month and year hereinabove set forth.

SELLER:

ULTRAFEM, INC.

By:

Dori M. Reap, Office of the Chief Executive  
and Senior Vice President

By:

*[Signature]* 6/12/98  
Polya G. Hinch, Office of the Chief Executive  
and Senior Vice President

BUYER:

ACCESS PACIFIC GROUP, LLC

By:

Leslie Sebastian  
Joseph Pike  
Title \_\_\_\_\_

- 18 -

10 30PM

MONTH 5 2001

7981676717

60190 5557/07 01

June 15, 1998 (4:52pm)

**SCHEDULES AND EXHIBITS**

Schedule 1.1(a)	-	Intangible Assets
Schedule 1.1(b)	-	Machinery and Equipment
Schedule 1.1(c)	-	Inventory Locations
Schedule 1.1(d)	-	Fixtures and Improvements
Schedule 1.1(e)	-	Other Tangible Assets
Schedule 1.1(f)	-	Accounts Receivable, Deposits and Contract Rights
Schedule 1.3	-	Assumed Liabilities
Schedule 1.4	-	Excluded Assets
Schedule 2.2	-	Wire Transfer Instructions
Schedule 3.3	-	Litigation
Schedule 3.6	-	Intellectual Property
Schedule 3.7	-	Insurance
Schedule 3.9	-	Inventory and Accounts Receivable
Schedule 3.10	-	Contracts and Leases
Exhibit 6.2	-	Form of Scheduling Order and Approval Order

**Jasek, Terry L.**

---

**From:** Mona, Margaret M.  
**Sent:** Monday, February 09, 2004 2:28 PM  
**To:** Jasek, Terry L.  
**Subject:** Purchase Agreement As Requested (98B-

Hello Terry:

Attached are some document downloaded from the docket as you requested. I printed from the documents listed in Item 44 the **Exhibit asset purchase agreement** and Item 66 on the docket **Order approving sale ....** I am giving to you a document containing the docket in the case also in case I did not select the "Sale Order."

Best regards,

Margaret

2/9/2004

June 15, 1998 (4:52pm)

**SCHEDULE 1.1(a)**  
**INTANGIBLE ASSETS**

the name Ultrafem

**Trademarks**

The Company obtained the following registrations for its trademarks with the United States Patent and Trademark Office for "INSTEAD®," "INSTEAD® and its logo," "SoftCup," and "Ultrafem" in 1996, 1997, 1992 and 1993, respectively:

<u>Mark</u>	<u>Registration Number</u>	<u>Issue Date</u>
INSTEAD	2,026,125	December 24, 1996
INSTEAD and logo	2,056,353	April 22, 1997
SoftCup	1,740,545	December 15, 1992
Ultrafem	1,788,031	August 17, 1993

As of May 2, 1998, the INSTEAD® mark has been registered in Argentina, Australia, Canada, Korea, Mexico, New Zealand, Paraguay, Switzerland, Taiwan and Turkey. The Company has also filed an application to register the trademark "INSTEAD®" in Brazil, Chile, India, Pakistan, Panama, Philippines, Russia, South Africa, Uruguay, Venezuela, and the European Community.

**Patents**

**PATENTS PENDING**

- Australian Patent Application No. 684,717 (formerly 46547/93)  
Filing Date: June 28, 1993  
Title: Vaginal Discharge Collection and Drug Delivery Device
- Brazilian Patent Application No. P19306596  
Filing Date: December 22, 1994  
Title: Vaginal Discharge Collection and Drug Delivery Device
- Canadian Divisional Patent Application 2,201,791  
Filing Date: April 4, 1997  
Title: Feminine Hygiene Device
- European Patent Application No. 91901923.2  
Filing Date: December 7, 1990  
Title: Feminine Hygiene Device



June 15, 1998 (4:52pm)

Designated European Countries: Belgium, Denmark, France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland/Lichtenstein, and United Kingdom.

- European Patent Application No. 93916826  
Filing Date: June 28, 1993  
Title: Vaginal Discharge Collection and Drug Delivery Device  
  
Designated European Countries: Belgium, Denmark, France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland/Lichtenstein, and United Kingdom.
- Canadian Patent Application No. 2,138,668  
Filing Date: June 28, 1993  
Title: Vaginal Discharge Collection and Drug Delivery Device
- International (PCT) Application No. US98/06014  
Filing Date: March 26, 1998  
Title: Intravaginal Drug Delivery System and Discharge Collection Device
- International (PCT) Application No. US97/11464  
Filing Date: July 3, 1997  
Title: Method and System for Manufacturing Elastomeric Articles
- International (PCT) Application US98/06015  
Filing Date: March 26, 1998  
Title: Discharge Collection Device and Intravaginal Drug Delivery System
- U.S. Patent Application S.N. 08/828,961  
Filing Date: March 28, 1997  
Title: Discharge Collection Device and Intravaginal Drug Delivery System
- U.S. Patent Application S.N. 08/828,962  
Filing Date: March 28, 1997  
Title: Intravaginal Drug Delivery System and Discharge Collection Device
- U.S. Patent Application S.N. 08/215,062  
Filing Date: March 21, 1994  
Title: Vaginal Discharge Collection Device and Intravaginal Drug Delivery System
- U.S. Patent Application S.N. 08/886,010  
Filing Date: July 3, 1997  
Title: Method and System for Manufacturing Elastomeric Articles

June 15, 1998 (4:52pm)

**PATENTS ISSUED/ALLOWED**

- U.S. Patent No. 5,295,984  
Issue Date: March 22, 1994  
Title: Vaginal Discharge Collection Device and Intravaginal Drug Delivery System
- Canadian Patent Application No. 2,070,426  
Issue Date: November 11, 1997  
Title: Feminine Hygiene Device

June 15, 1998 (4:52pm)

**SCHEDULE 1.1(b)**  
**MACHINERY AND EQUIPMENT**

Molds wherever located

Located at Ultraform's Plant/Warehouse at 1600 North Avenue, Missoula, Montana 59801:

- two semi-automatic manufacturing lines consisting of a thermoforming line and related attachments, replacements, parts and supplies
- five (5) flow wrapper machines
- four (4) cartoning machines
- computers, monitors, printers and software used in the conduct of Seller's business and manufacturing operations
- security system
- various plant improvements and upgrades
- inventory and work-in-progress, see Schedule 1.1(c)
- office equipment and furniture

Located at Ultraform's Offices at 130 West 42nd Street, Suite 1103, New York, NY 10036:

- office equipment, furniture, computers, printers, software and monitors, including: file cabinets, chairs, bookcases, credenzas, prep closet, and table, TV, supply cabinet

June 12, 1998 (9:47am)

Located at Johns Hopkins University

Certain laboratory equipment

25/21/58

12:34

ULTRA-FEM + NEW YORK

NO. 244 515

JUN 1, 1968  
3 11 AM

Ultraform MT Fixed Assets  
FIXED ASSET SUMMARY REPORT  
as of 6/30/98 04/98

located <sup>also</sup> at John's Hopkins University

as of 06/06/98									
Fixed Asset Cost									
Accumulated Depreciation									
Total Asset									
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
SYN No.	Asset Description	Original Cost	Current Cost	Original Accum. Depreciation	Current Accum. Depreciation	Original Asset	Current Asset	Original Asset	Current Asset
000001	Balance A-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000002	Balance B-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000003	Balance C-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000004	Balance D-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000005	Balance E-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000006	Balance F-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000007	Balance G-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000008	Balance H-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000009	Balance I-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000010	Balance J-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000011	Balance K-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000012	Balance L-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000013	Balance M-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000014	Balance N-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000015	Balance O-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000016	Balance P-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000017	Balance Q-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000018	Balance R-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000019	Balance S-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000020	Balance T-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000021	Balance U-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000022	Balance V-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000023	Balance W-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000024	Balance X-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000025	Balance Y-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000026	Balance Z-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000027	Balance AA-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000028	Balance AB-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000029	Balance AC-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000030	Balance AD-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000031	Balance AE-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000032	Balance AF-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000033	Balance AG-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000034	Balance AH-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000035	Balance AI-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000036	Balance AJ-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000037	Balance AK-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000038	Balance AL-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000039	Balance AM-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000040	Balance AN-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000041	Balance AO-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000042	Balance AP-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000043	Balance AQ-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000044	Balance AR-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000045	Balance AS-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000046	Balance AT-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000047	Balance AU-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000048	Balance AV-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000049	Balance AW-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000050	Balance AX-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000051	Balance AY-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000052	Balance AZ-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000053	Balance BA-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000054	Balance BB-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000055	Balance BC-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000056	Balance BD-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000057	Balance BE-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000058	Balance BF-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000059	Balance BG-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000060	Balance BH-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000061	Balance BI-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000062	Balance BJ-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000063	Balance BK-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000064	Balance BL-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000065	Balance BM-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000066	Balance BN-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000067	Balance BO-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000068	Balance BP-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000069	Balance BQ-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000070	Balance BR-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000071	Balance BS-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000072	Balance BT-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000073	Balance BU-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000074	Balance BV-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000075	Balance BW-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000076	Balance BX-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000077	Balance BY-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000078	Balance BZ-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000079	Balance CA-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000080	Balance CB-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000081	Balance CC-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000082	Balance CD-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000083	Balance CE-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000084	Balance CF-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000085	Balance CG-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000086	Balance CH-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000087	Balance CI-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000088	Balance CJ-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000089	Balance CK-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000090	Balance CL-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000091	Balance CM-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000092	Balance CN-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000093	Balance CO-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000094	Balance CP-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000095	Balance CQ-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000096	Balance CR-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000097	Balance CS-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000098	Balance CT-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000099	Balance CU-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00
000100	Balance CV-115 Book	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00

June 12, 1998 (9:47am)

Located at JK Molds, 2048 West 11th Street, Upland, California 91786

- Certain molds

05/01/98

12:34

ULTRAFEM + NEW YORK

NO.844 019

June 1, 1998

10:11 AM

Page 17

# Ultrafem MT Fixed Assets FIXED ASSET SUMMARY REPORT as of 05/01/98

Asset No	Beginning Cost	Fixed Asset Cost			Ending Cost	Prior Accum Deprec/178	Accumulated Depreciation			Total Accum Deprec	Net Book Value
		Current Year Acquisition	Current Year Depreciation	Current Year Salvage			Current Year	Current Year	Current Year		
00000000	177955.00	0.00	0.00	0.00	177955.00	1897.75	26693.25	0.00	0.00	28491.00	
Total											
00000000	177955.00	0.00	0.00	0.00	177955.00	1897.75	26693.25	0.00	0.00	28491.00	
Total											

JK

JK

June 12, 1998 (9:47am)

Located at Liberty Tool at 4201 Sellice Way, Coeur d'Alene, Idaho 83814.

### Certain molds

25/01/99 12:34 ULTRAFEM + NEW YORK

~~17,844~~ 716

June 1, 1968  
10:11 AM

Ultrafem MT Fixed Assets  
FIXED ASSET SUMMARY REPORT

AS of 04/98

[illegible]

June 12, 1998 (9:47am)

Located at Liberty Tool at 4201 Seltice Way, Coeur d'Alene, Idaho 83814:

Certain molds

000305 000	1133.00	0.00	0.00	0.00	1133.00	1133.00	0.00	0.00	0.00	1133.00
Mold Insert										
000306 000	1140.00	0.00	0.00	0.00	1140.00	1140.00	0.00	0.00	0.00	1140.00
2nd Cavity Rim Mold										
000307 000	14000.00	0.00	0.00	0.00	14000.00	14000.00	0.00	0.00	0.00	14000.00
Cavity Mold #1 Puc										
000308 000	14351.33	0.00	0.00	0.00	14351.33	14351.33	0.00	0.00	0.00	14351.33
Cavity Mold #1 Puc										
000309 000	100.00	0.00	0.00	0.00	100.00	100.00	0.00	0.00	0.00	100.00
Cavity Mold #1 Puc										
000310 000	14351.33	0.00	0.00	0.00	14351.33	14351.33	0.00	0.00	0.00	14351.33
Cavity Mold #1 Puc										
000311 000	4591.00	0.00	0.00	0.00	4591.00	4591.00	0.00	0.00	0.00	4591.00
Temp Core Inserting Mold #1										
000312 000	160.00	0.00	0.00	0.00	160.00	160.00	0.00	0.00	0.00	160.00
Cavity Mold #1 Puc										
000313 000	16250.34	0.00	0.00	0.00	16250.34	16250.34	0.00	0.00	0.00	16250.34
Cavity Mold #1 Puc										
000314 000	110.00	0.00	0.00	0.00	110.00	110.00	0.00	0.00	0.00	110.00
Cavity Mold #1 Puc										
000315 000	100.00	0.00	0.00	0.00	100.00	100.00	0.00	0.00	0.00	100.00

Located At Liberty Tool

12/16/21 P. 16:21

LIBERTY TOOL 5:03PM 6/11/98

000361 000	11576.00	0.00	0.00	0.00	11576.00	11576.00	0.00	0.00	0.00	11576.00
Mold #1										
000362 000	21066.00	0.00	0.00	0.00	21066.00	21066.00	0.00	0.00	0.00	21066.00
Temp Control Mold #1										
000393 000	1600.15	0.00	0.00	0.00	1600.15	1600.15	0.00	0.00	0.00	1600.15
Food Service Pot Metal Detection Of Molds										
000399 000	10100.00	0.00	0.00	0.00	10100.00	10100.00	0.00	0.00	0.00	10100.00
Cavity Mold #6										
000400 000	10100.00	0.00	0.00	0.00	10100.00	10100.00	0.00	0.00	0.00	10100.00
Cavity Mold #6										
000405 000	27700.00	0.00	0.00	0.00	27700.00	27700.00	0.00	0.00	0.00	27700.00
Summerless Mold Controller Mold #1										
000416 000	13250.00	0.00	0.00	0.00	13250.00	13250.00	0.00	0.00	0.00	13250.00
Cavity Mold #1										

Liberty Tool

Liberty Tool

Liberty Tool

Liberty Tool

Liberty Tool

June 17, 1998 (9:43am)

**SCHEDULE 1.1(c)**  
**INVENTORY LOCATIONS**

<u>Raw Materials</u>	<u>Finished Goods</u>
Ultrafem Plant/Warehouse 1600 North Avenue Missoula, Montana 59801	Ultrafem Plant/Warehouse 1600 North Avenue Missoula, Montana 59801
Liberty Tool 4201 Seltice Way Coeur d'Alene, Idaho 83814	Morgan & Sampson 1651 S. Carlos Avenue Ontario, CA 91761
Clopay Plastics 312 Walnut Street, Suite 1600 Cincinnati, Ohio 45202-4036	Morgan & Sampson 429C Waiakamilo Road Honolulu, Hawaii 96817
Bloomer Plastics 1710 N. Industrial Drive P.O. Box 5 Bloomer, Wisconsin 54724	Rudie Wilhelm Warehouse Co. 2400 South East Mailwell Drive Milwaukee Oregon 97222
JK Molds 2048 West 11th Street Upland, California 91786	John Jeffrey Corporation 50 Heller Road Belmar New Jersey 21227



- |

June 12, 1998 (9:47am)

**SCHEDULE 1.1(d)**  
**FIXTURES AND IMPROVEMENTS**

Ultrafem's manufacturing facility located at 1600 North Avenue, Missoula, Montana 59801

Ultrafem's offices located at 130 West 42nd Street, Suite 1103, New York, NY 10036

June 12, 1998 (9:47am)

**SCHEDULE 1.1(e)**  
**OTHER TANGIBLE ASSETS**

Marketing materials at Missoula, Montana and CMR (see attached)

## Memorandum

DATE: April 10, 1998  
 TO: Wendy Greeson  
 FROM: Deb Fienberg *Deb*  
 RE: Fulfillment inventory at CMR  
 CC: Tanya Hinch, Dori Reap, Wendell Guthrie, Lynn Caperus

*CMR*  
*Consolidated Market Response*  
*700 W. Lincoln, Suite 200*  
*Charleston, IL 61920*

We would like to do the following with the inventory currently in stock at CMR:

<i>Approximate</i>		
<u>Item</u>	<u>Quantity</u>	<u>Action</u>
Starter Kits	8,064	Store for 6 months
Deluxe Kits	24,780	Store for 6 months
Remaining	See Attached	Destroy

Again, thank you for all your support. We really appreciate CMR holding the starter kits and deluxe kits free of charge. As we have discussed, please feel free to offer a starter kit to each CSR. Just send me a note reflecting the new inventory.

*\*will be finalized at closing. (quantity approx at 4/10/98)*  
*Deb*

03/18/98

17:38

ULTRAFEM + NEW YORK

NO. 367

022

**FULFILLMENT QUANTITIES AT  
MISSOULA, MT WAREHOUSE**

<i>APPROXIMATE</i>	
DESCRIPTION	QUANTITY*
Deluxe Starter Kits	52,305
Professional Starter Kits	1,873
Consumer Starter Kits	2,013
In Market Starter Videos	116,931
Out of Market Starter Videos	129
Educational Videos	23,886
Travel Case	13,600
Coupon Mailer	2,000
\$2.00 Coupon - 3/31/98 Expiration	12,000
Professional Brochure	2,500

\*As of 3/18/98; will be finalized at closing

June 15, 1998 (4:52pm)

**SCHEDULE 1.1(f)**

**ACCOUNTS RECEIVABLE, DEPOSITS AND CONTRACT RIGHTS**

Statement of accounts receivable, current as of the Closing Date, identifying each account and the amount owed, will be provided to Buyer at the Closing

Unbilled Orders

Buyer to specify any deposits or prepaid expenses to be assigned in connection with any Assumed Liabilities or contract rights relating to the sale of the Product

Seller's rights to the telephone number 1-800-Instead, to the extent transferable

June 12, 1998 (4:17pm)

**SCHEDULE 1.3**  
**ASSUMED LIABILITIES**

Clopay Plastics  
312 Walnut Street, Suite 1600  
Cincinnati, Ohio 45202-4036

(Reservoir Film Manufacturer)

GE Capital Modular Space  
PO Box 641595  
Missoula, Montana 59806

(Plant/Warehouse located at 1600  
North Avenue, Missoula, MT 59801)

Shell Company  
PO Box 2463  
Houston, Texas 77252-2463

(Sale Contract for raw materials)

Western Trade Center  
PO Box 8182  
Missoula, MT 59807

(Plant/Warehouse located at 1600 North Avenue  
Missoula, MT 59801)

Unless otherwise indicated, Seller is in default under the Assumed Contracts

June 12, 1998 (9:47am)

**SCHEDULE 1.4  
EXCLUDED ASSETS**

1997 Chevrolet Corvette

IBM Thinkpad Laptop Computer

Agreement dated as of February 8, 1996 between Seller and ReProtect, LLC. Seller has not made payments required thereunder for the months of March, April, May, and June 1998, and Seller is in default thereunder.

Bank Accounts

<u>Name of Bank</u>	<u>Account No.</u>	<u>Description</u>
The Chase Manhattan Bank 60 East 42 <sup>nd</sup> Street New York, NY 10165	6216028943-65 (High View Security Deposit)	Savings
	128-6192870-19	Charge card CD
	904-901262 (Business Checking)	DIP Operating Acct.
	904-901270 (Business Checking)	DIP Payroll Acct.
	904-901297 (Business Checking)	DIP Tax Acct.
Bank of America P.O. Box 3700 San Francisco, CA 94137	0033-1-30804 P.O. Box 37000 Parent No. 98898 Lockbox No. 73088	Lockbox
First Interstate Bank 101 E. Front Missoula, MT 5980	1400945380	Veriphone

Security Deposits

<u>Description</u>	<u>Date of Deposit</u>	<u>Security Deposit Amount</u>
Tokai Financial - postage meter	6/25/96	149.39
Bell Atlantic - deposit on upgrade	10/21/97	500.00
America Properties - Security deposit 130 W. 42 <sup>nd</sup>	2/19/98	12,133.34
GE Capital		7,740.00

June 12, 1998 (9.47am)

Insurance

DIRECTORS AND OFFICERS' INSURANCE:	Genesis Insurance Company 25550 Chagrin Boulevard, Suite 300 Beachwood, OH 44122-5676  Admiral 1255 Caldwell Road Cherry Hill, NJ 08034
LIABILITY COVERAGE:	General Star Indemnity Co. 550 South Hope Street, Suite 700 Los Angeles, CA 90071-2648
PROPERTY INSURANCE:	Chubb Insurance Co. 15 Mountain View Road Warren, NJ 07059
WORKERS COMPENSATION:	Chubb Insurance Co. 15 Mountain View Road Warren, NJ 07059
E&O COMMUNICATIONS LIABILITY INS.:	Employers Reinsurance Company
EMPLOYMENT PRACTICES INSURANCE:	Granite State Insurance Company Morefar Marketing Inc. 501 Carr Road Wilmington, DE 19809
COMMERCIAL AUTOMOBILE COVERAGE:	Chubb Insurance 15 Mountain View Road Warren, NJ 07059

See attached list of assets which Seller has not paid for, and may not have title and/or possession



25/29/98

**15:14**

ULTRAFEM - NEW YORK

NO. 262 519

Assets in our possession and in use (when MFG. product bills arrived after 4/1/88); therefore, not paid Ultraform MT Fixed Assets

## Ultraform MT Fixed Assets

## FIXED ASSET SUMMARY REPORT

as of 04/98									
Filed Asset Cost					Accumulated Depreciation				
	(4)	(5)	(6)		(6)	(7)	(8)		
Engineering Cost	Current Year Acquisition	Current Year Trans-In	Current Year/Stop Trans-Out	Ending Cost	Princ Accum Deprec/1998 Expense	Cost Accum Deprec/1998 Expense	Cost Accum Deprec/1998 Trans-In	Cost Accum Deprec/1998 Trans-Out	Total Accum Deprec
000000 000	0.00	3500.00	0.00	0.00	3500.00	0.00	292.66	0.00	0.00
Engineering Changes JX Main #1									\$1,000 pd 2500 NOT
000002 000	0.00	7240.00	0.00	0.00	7240.00	0.00	482.66	0.00	0.00
Engineering Modifications to JX Main #1									NOT paid
000003 000	0.00	2250.00	0.00	0.00	2250.00	0.00	197.00	0.00	0.00
Wiring to the Engineering Modular									NOT paid
000004 000	0.00	5750.00	0.00	0.00	5750.00	0.00	501.31	0.00	0.00
200 Amp Power to Engineering Modular									NOT paid
000005 000	0.00	3550.00	0.00	0.00	3550.00	0.00	347.00	0.00	0.00
1000 Dealers for Machine Shop									NOT paid
000006 000	0.00	8884.51	0.00	0.00	8884.51	0.00	772.32	0.00	0.00
Wiring to Machine Shop									1500 pd 7384 NOT
000007 000	0.00	23572.00	0.00	0.00	23572.00	0.00	2067.72	0.00	0.00
Stretchable Type Add On Warehouse									2100 pd 21472 NOT

NO. 847 528

## CRP DETAIL ED (2)

Construction In Progress  
As Of April 30, 1988

Location: M514	Date	PO#	Line#	Vendor	Description	Total Price	Payments	Balance Due	Accrued
12/30/87	11213	3		Gordon, Phil, Engineering Services For Clean Room & HVAC		\$ 3,082.50			
12/30/87	11213	3		Gordon, Phil, Engineering Services For Clean Room & HVAC		\$ 4,825.00		4,825.00	
11/1/87	11372	3		Gordon, Phil, Engineering Services For Clean Room & HVAC		\$ 145.00			
12/1/87	11437	3		Gordon, Phil, Engineering Services For Clean Room & HVAC		\$ 540.00			
11/3/87	10976	3		Art & Archie Architectural Drawings for new Classroom		\$ 4,300.00		4,300.00	
12/1/87	11374	3		Palmer Electr Palmer Electric, Wiring for new Classroom		\$ 25,287.00		25,287.00	
12/2/87	11453	3		Palmer Electr Cable Tray for Wiring Super Audio		\$ 2,488.00		2,488.00	
11/3/87	11376	3		Palmer Electr Wiring room and Machine shop		\$ 1,222.00		1,222.00	
12/2/87	11276			Interstate Abs Alarm Extensions To Warehouse		\$ 7,244.80		7,244.80	
11/5/87	10974			Art & Archie Architectural Drawings for Employee Overhead		\$ 4,072.00		4,072.00	
11/5/87	10975			Art & Archie Architectural Modification To Air Filtration System		\$ 17,210.00		17,210.00	

ULTRAFEM + NEW YORK

17:13

26/01/98

NO. 847 222

ULTRAFEM + NEW YORK

Location: Remmle  
payments due

Date	PO #	Line #	Vendor	Description	Total Price	Payments	Balance Due	Account
<b>HERKONCEMENT</b>								
5/10/06	7765	3	Remmle	Fully Auto Line #3	\$2,007,800.00	\$ 600,788.00		
5/11/06						\$ 600,788.00		
11/22/06						\$ 300,389.00	\$ 600,668.00	\$ 300,350.00
7/31/07	10380	3	Remmle	Installation Fully Auto Line #3	\$ 24,901.00	\$ 8,715.35	\$ 16,185.65	
5/10/06	2632	4	Remmle	Fully Auto Line #4	\$1,586,000.00	\$ 448,000.00		
5/12/06						\$ 448,000.00		
11/22/06						\$ 224,000.00	\$ 320,000.00	
5/24/06	3027	3&4	Remmle	Lock Test Station	\$ 560,000.00	\$ 186,000.00	\$ 364,000.00	\$ 17,964.00
6/27/07	10422	3	Remmle	Rem Inspection & Sorting Upgrade Line #	\$ 280,000.00	\$ 80,300.00	\$ 199,700.00	
6/27/07	10622	4	Remmle	Rem Inspection & Sorting Upgrade Line #	\$ 170,000.00	\$ 60,200.00	\$ 109,800.00	
7/28/06	2673	3&4	Remmle	Open Station Line #3 & 4 Fully Auto	\$ 56,000.00		\$ 56,000.00	\$ 2,000.00
10/20/07	11242	3&4	Remmle	Amendments to Reduced Throughput & R	\$ 33,800.00		\$ 33,800.00	\$ 15,255.00
7/10/06	2672	3	Remmle	Engineering Study Of Lock Test	\$ 16,500.00		\$ 16,500.00	\$ 14,550.00
3/19/07	10424	3	Remmle	Prototype Rem Cleaning Apparatus	\$ 8,000.00		\$ 8,000.00	\$ 100.00

NO. 247

CIP DETAILED (2)

Construction In Progress  
As Of April 30, 1998

Date	PO #	Line #	Vendor	Description	Total Price	Payments	Balance Due	Accrued
4/28/97				Freight C/Inchweyer AL-1 & AL-2				
						209.44		
<b>Location: Liberty Tool</b>								
8/18/98	2800	2	Liberty Tool	Model P9	\$ 98,440.00	\$ 48,770.00		
10/28/97						\$ 47,500.00		
10/28/97	10144	2	Liberty Tool	Model #10	\$ 102,147.00	\$ 51,073.50		
8/11/97						\$ 29,504.84		
10/28/97	10144	3	Liberty Tool	Model #11	\$ 102,147.00	\$ 51,073.50		
8/11/97						\$ 29,504.84		
10/28/97	10145	3	Liberty Tool	Model #12	\$ 102,147.00	\$ 51,073.50		
8/11/97						\$ 29,504.84		
10/28/97	10145	3	Liberty Tool	Model #13	\$ 102,147.00	\$ 51,073.50		
8/11/97						\$ 29,504.84		
<b>Location: Precision</b>								
10/28/97	10216	3	Precision	Material Probe For Accumulator Dya.	\$ 69,821.00	\$ 13,824.20		
3/7/97						\$ 29,888.30		
4/21/97						\$ 24,367.35		
10/28/97						\$ 10,443.15		
10/28/97						\$ 12,923.50		
<b>Location: Mid States C Shingler Package- RAID</b>								
10/28/97	10445	3	Mid States C Shingler Package- RAID		\$ 9,500.00	\$ 3,167.00		
8/11/97						\$ 6,333.00		
10/28/97	10423	3	Mid States C Shingling Conveyor- Line #3		\$ 47,568.00	\$ 15,852.00		
4/28/98						\$ 31,716.00		
10/28/97	10830	3	Mid States Installation Of Shingling Project		\$ 17,547.00	\$ 5,000.70		
12/12/97						\$ 2,723.95		
12/12/97						\$ 11,608.30		

NO. 247

23  
42.247

CIP DETAINED (2)

Construction in Progress  
As of April 30, 1998

Date	PO#	Line #	Vendor	Description	Total Price	Payments	Refund Due	Accrual
10/18/97	11133	3	Korcor	Setup To Test Shuntworth	6,800.00			
<b>Location: M/Lg</b>								
<b>payments due</b>								
4/19/97	10407	3	Mis States C	Air Table & Conveyer For Accumulator Sy	40,446.00			
7/31/97		3						
10/27/97				Misc Add Ons to Air Table		12,482.00		
				Freight-Air Table & Conveyer		28,864.00		
						-7,098.00		
						150.00		7070.00
<b>Location: T.J. White</b>								
6/27/97	10824	3	U White Corp	Accumulator System- Line BG	189,780.00			
7/25/97						69,872.00		
8/5/97						89,904.00		
10/1/97	11307	3	U White Corp	Conveyer High Mt. Accumulator Spt.		49,934.00		8,998.00
						-458.00		859.40
<b>Location: M/Lg</b>								
7/21/97	10945	3	Med States C	48"x17" Air Table RAD Testing & Video	13,308.00			
						6,344.00		
						4,158.00		8156.00
<b>payments due</b>								
7/24/97	10831	3	Med States C	Chain Conveyer From Remanite To Aocce	11,205.00			
11/14/97						3,735.80		7470.00
				Freight - Chain Conveyer		-7,708.00		2,333.00
						-2,333.00		
<b>Location: M/Lg</b>								
9/15/97	11010	3	Bj Hestel Wor Duct Work for HVAC Duct PART		2,000.00			
12/18/97	11276	3	Palmer Electr Electrical Panel - Cleanroom Super Auto		18,318.00			
						28,728.00		2,335.20
						-2,400.00		420.00
						1,800.00		7,570.00
						-2,333.00		1,837.00
<b>Location: M/Lg</b>								
7/24/97	10838	3	Nelson & Associates Drafting for New Cleanroom Super A		1,770.00			
10/29/97						300.00		
						1,037.50		432.50
7/15/97	10831	3	Gordon, Phil, Engineering Services for Clean Room & HVAC					
8/20/97	11007	3	Gordon, Phil, Engineering Services for Clean Room & HVAC			3,090.00		
						582.50		

June 12, 1998 (9:47am)

**SCHEDULE 2.2**  
**WIRE TRANSFER INSTRUCTIONS**

The deposit shall be wired to the following account:

**Togut, Segal & Segal Special**  
**Account #: 026046849**

**Chase Manhattan Bank**  
**ABA # 021000021**

**2 Penn Plaza**  
**New York, NY 10124**

**Attn: Shawnette Richardson**

Please indicate in the wire transfer (1) the name of the sender, (2) the name of the person or company from whose account the funds are being transferred, (3) a telephone number which can be called in case a question arises with respect to the wire and (4) the tax identification number of the person or company transferring the funds.

June 12, 1998 (9:47am)

**SCHEDULE 3.3  
LITIGATION**

- Audrey Contente v. Ultrafem, Inc., John Andersen, Charles D. Peebler, Jr., Martin Nussbaum, Richard A. Cone, Joy V. Jones, and Barrie Zesiger, Case No. 98-CIV-0912, pending in United States District Court for the Southern District of New York, alleging wrongful, unlawful and discriminatory conduct.
- Lynn E. McNeill-Avele and Geachew Avele v. Ultrafem, Inc., a Delaware Corporation, Longs Drug Stores, Inc., a California corporation, and DOES 1 through 100 inclusive, Case No. 97AS05702, pending in the Superior Court of the State of California in and for the County of Sacramento, alleging personal injury.
- Earl Pruyn, M.D. v. Ultrafem, Inc., a Delaware Corporation, John W. Andersen, Charles D. Peebler, Jr., Audrey Contente, Joy Vida Jones, martin Nussbaum, Richard A. Cone, Barrie Zesiger, Case No. CV 97-149-M-LBE, pending in the United States District Court for the Southern District of Montana, Missoula Division, relating to 10% Subordinated Convertible Debentures. Dismissed without prejudice as to counts; with prejudice as to two counts.
- Philip Berliner, Gerson Sontag and Robert M. Sayre, on behalf of themselves and all others similarly situated v. Ultrafem, Inc., John W. Andersen, Audrey Contente, Dori M. Reap, Tonya G. Hinch, Gary Nordmann, Wendell Guthrie, Richard A. Cone, Joy Vida Jones, Martin Nussbaum, Charles D. Peebler, Jr., Barrie Zesiger, Jeffries & Company and Hampshire Securities Corporation, Case No. 98-CIV-1977 pending in United States District Court for the Southern District of New York, relating to \$40 million public offering of 2 million shares of common stock
- John Magnan, on behalf of himself and all others similarly situated v. Ultrafem, Inc., John W. Andersen, Audrey Contente, Charles D. Peebler, Joy Vida Jones, Barrie R. Zesiger and Dori M. Reap, Case No. 98 CIV 1900, pending in United States District Court for the Southern District of New York.
- Tiffany Lewin, on behalf of herself and all others similarly situated v. John W. Andersen, Audrey Contente, Charles D. Peebler, Jr., Joy Vida Jones, Barrie R. Zesiger, and Dori M. Reap, Case No. 98-CIV-2609 pending in United States District Court for the Southern District of New York, relating to \$40 million public offering of 2 million shares of common stock
- Marcel Renny, on behalf of himself and all others similarly situated v. John W. Andersen, Audrey Contente, Dori M. Reap, Tonya G. Hinch, Gary Nordmann, Wendell Guthrie, Richard A. Cone, Joy Vida Jones, Martin Nussbaum, Charles D. Peebler, Jr., Barrie Zesiger, Jeffries & Company and Hampshire Securities

June 12, 1998 (9:47am)

Corporation, Case No. 98-CIV-3043 pending in United States District Court for the Southern District of New York, relating to \$40 million public offering of 2 million shares of common stock

- Jacquelin Shere and Rose Shere, on behalf of themselves and all others similarly situated v. John W. Andersen, Audrey Contente, Charles D. Peebler, Jr., Joy Vida Jones, Barrie R. Zesiger, and Dori M. Reap, Case No. 98-CIV-35392609 pending in United States District Court for the Southern District of New York, relating to \$40 million public offering of 2 million shares of common stock

- Nachum Barnetsky, on behalf of himself and all others similarly situated v. John W. Andersen, Audrey Contente, Dori M. Reap, Tonya G. Hinch, Gary Nordmann, Wendell Guthrie, Richard A. Cone, Joy Vida Jones, Martin Nussbaum, Charles D. Peebler, Jr., Barrie Zesiger, Jeffries & Company and Hampshire Securities Corporation, Case No. 98-CIV-3488 pending in United States District Court for the Southern District of New York, relating to \$40 million public offering of 2 million shares of common stock



June 12, 1998 (9:47am)

**SCHEDULE 3.6**  
**INTELLECTUAL PROPERTY**

See Schedule 1.1(a)

Audrey Contente litigation (see Schedule 3.3)

Agreement dated as of February 8, 1996 between Seller and ReProtect, LLC. Seller has not made payments required thereunder for the months of March, April, May, and June 1998, and Seller is in default thereunder.

June 12, 1998 (9:47am)

**SCHEDULE 3.7**  
**INSURANCE**

See insurance listed on Schedule 1.4

## **EXHIBIT C**

June 12, 1998 (9:47am)

**SCHEDULE 3.9**  
**INVENTORY AND ACCOUNTS RECEIVABLE**

**Inventory**

Inventory on Seller's books as at 5/31/98 (unaudited)  
(stated at lower of weighted average cost or market basis) - \$4,018,483

Raw Materials	\$409,338
Offsite raw Materials	\$176,048
Nonconforming inventory	\$23,335
WIP	\$0
Finished Goods	\$3,539,580
Reserve for Inventory writedown	<del>(\$129,818)</del>
Total Inventory	\$4,018,483

Does not reflect a physical inventory count

See attached for Finished Goods Inventory details. The finished goods breakout does not reflect the reserve for obsolete inventory.

**Receivables**

Accounts Receivable as of 5/31/98 (unaudited) - \$503,093

See attached for current receivable listing (Seller makes no guarantees of collection of accounts receivable)

**Customer Orders**

During the period from June 1, 1998 through June 11, 1998 Seller has received orders totaling \$75,399 (See attached)

05-31-98

CUSTOMER		SALES PROMO						
NAME	NUMBER	ACCRUAL	TOTAL	CURRENT	1 - 30 DAYS	31 - 60 DAYS	61 - 90 DAYS	91 & OVER
ACHIE Markets, Inc	ACH0001		\$ 1,473.07	\$ 1,440.00	\$ -	\$ -	\$ -	\$ 33.07
ACHIE Markets, Inc Total			\$ 1,473.07	\$ 1,440.00	\$ -	\$ -	\$ -	\$ 33.07
American Drug Stores	ADS0001		\$ 24,346.43	\$ 22,880.60	\$ -	\$ 784.00	\$ 512.15	\$ 149.68
American Drug Stores	ADS0002		\$ 78.80	\$ -	\$ -	\$ -	\$ -	\$ 78.80
American Drug Stores	ADS0003		\$ 5,680.51	\$ 1,080.00	\$ -	\$ 4,396.61	\$ -	\$ 244.80
American Drug Stores	ADS0004		\$ 273.40	\$ -	\$ -	\$ 273.40	\$ -	\$ -
American Drug Stores	ADS0005		\$ 303.16	\$ -	\$ -	\$ 383.16	\$ -	\$ -
American Drug Stores Total		\$ 6,187.70	\$ 30,768.30	\$ 23,960.60	\$ -	\$ 5,880.17	\$ 502.95	\$ 473.38
Associated Food SLC	AFS0001		\$ (38.16)	\$ (38.16)	\$ -	\$ -	\$ -	\$ -
Associated Food SLC Total			\$ (38.16)	\$ (38.16)	\$ -	\$ -	\$ -	\$ -
Albertsons	ALB0001		\$ 59,917.02	\$ 30,082.86	\$ -	\$ 6,959.84	\$ 1,117.44	\$ 22,776.88
Albertsons	ALB0002		\$ 22,780.01	\$ 8,197.29	\$ -	\$ -	\$ -	\$ 14,582.72
Albertsons Total		\$ 78,528.75	\$ 82,697.03	\$ 38,280.15	\$ -	\$ 5,859.84	\$ 1,117.44	\$ 37,359.60
Associated Grocers	ASG0001		\$ 4,371.68	\$ 3,524.36	\$ -	\$ -	\$ -	\$ 847.32
Associated Grocers Total		\$ 847.32	\$ 4,371.68	\$ 3,524.36	\$ -	\$ -	\$ -	\$ 847.32
Bargain Wholesale	BAR0001		\$ 29,082.82	\$ -	\$ -	\$ -	\$ -	\$ 29,082.82
Bargain Wholesale Total			\$ 29,082.82	\$ -	\$ -	\$ -	\$ -	\$ 29,082.82
Bergan Brunswig	BER0004		\$ 5,149.54	\$ -	\$ -	\$ 5,149.54	\$ -	\$ -
Bergan Brunswig	BER0005		\$ 1,599.95	\$ (29.66)	\$ -	\$ 1,628.60	\$ -	\$ -
Bergan Brunswig	BER0006		\$ 708.98	\$ (22.00)	\$ -	\$ 730.98	\$ -	\$ -
Bergan Brunswig	BER0007		\$ (0.01)	\$ (0.01)	\$ -	\$ -	\$ -	\$ -
Bergan Brunswig Total			\$ 7,458.46	\$ (51.66)	\$ -	\$ 7,510.12	\$ -	\$ -
J.R. Gottlieb & Co.	CAR0001		\$ 936.00	\$ 838.00	\$ -	\$ -	\$ -	\$ 98.00
J.R. Gottlieb & Co. Total			\$ 936.00	\$ 838.00	\$ -	\$ -	\$ -	\$ 98.00
Certified Grocers	CEG0001		\$ 6,840.78	\$ (88.76)	\$ -	\$ -	\$ -	\$ 6,929.54

05-31-98

CUSTOMER		SALES PROMO		TOTAL		CURRENT		1-30 DAYS		31-60 DAYS		61-90 DAYS		91 & OVER	
NAME	NUMBER	ACCRUAL													
Certified Grocers Total		\$ 190.00	\$ 6,840.76	\$ (98.76)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 6,939.54	
City Market	CIM0001		\$ 112.44	\$ (67.82)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 0.26	\$ -	\$ 180.00	
City Market Total			\$ 112.44	\$ (67.82)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 0.26	\$ -	\$ 180.00	
The Corps Corporation	CCP0001		\$ 648.00	\$ 648.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	
The Corps Corporation Total			\$ 648.00	\$ 648.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	
Costco	COS0001		\$ 606.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	
Costco	COS0002		\$ 606.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	
Costco	COS0003		\$ 606.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	
Costco	COS0004		\$ 606.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	
Costco	COS0005		\$ 606.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	
Costco	COS0006		\$ 606.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	
Costco Total			\$ 3,636.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	
Cub Foods	CUB0010		\$ 94.14	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 94.14	
Cub Foods Total			\$ 94.14	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 94.14	
CVS Distribution	CVS0001		\$ 5,696.91	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 5,696.91	
CVS Distribution	CVS0002		\$ 17,798.18	\$ (451.85)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 17,346.33	
CVS Distribution	CVS0003		\$ 5,338.46	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 5,338.46	
CVS Distribution	CVS0004		\$ 5,014.32	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 5,014.32	
CVS Distribution	CVS0005		\$ 141.12	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 141.12	
CVS Distribution	CVS0008		\$ 3,924.86	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 3,924.86	
CVS Distribution	CVS0009		\$ 377.10	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 377.10	
CVS Distribution Total			\$ 38,490.95	\$ (451.85)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 37,939.10	
Domestic	DOM0001		\$ 3,273.60	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 3,273.60	
Domestic Total			\$ 3,273.60	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 3,273.60	
Drug Emporium	DRE0003		\$ 292.80	\$ 292.80	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 292.80	
Drug Emporium	DRE0005		\$ 67.11	\$ (0.89)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 66.22	

05-31-08

CUSTOMER		SALES PROMO		CURRENT		1-30 DAYS		31-60 DAYS		61-90 DAYS		91 & OVER	
NAME	NUMBER	ACCRUAL	TOTAL										
Drug Emporium	DRE0006		\$ (4.77)	\$ (4.77)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Drug Emporium	DRE0016		\$ 284.02	\$ -	\$ -	\$ -	\$ -	\$ 284.02	\$ -	\$ -	\$ -	\$ -	\$ -
Drug Emporium	DRE0017		\$ 270.04	\$ -	\$ -	\$ -	\$ -	\$ 270.04	\$ -	\$ -	\$ -	\$ -	\$ -
Drug Emporium	DRE0020		\$ 292.80	\$ 292.80	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Drug Emporium	DRE0021		\$ (8.00)	\$ (8.00)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Drug Emporium	DRE0022		\$ 15.12	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Drug Emporium	DRE0031		\$ 90.62	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 15.12	\$ -
Drug Emporium	DRE0032		\$ 19.44	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 19.44	\$ -
Drug Emporium	DRE0033		\$ 64.80	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 19.44	\$ -
Drug Emporium	DRE0034		\$ 194.40	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 64.80	\$ -
Drug Emporium	DRE0037		\$ 19.44	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 194.40	\$ -
Drug Emporium	DRE0041		\$ 19.44	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 19.44	\$ -
Drug Emporium	DRE0043		\$ 392.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 19.44	\$ -
Drug Emporium Total		\$ 392.00	\$ 2,009.26	\$ 572.76	\$ -	\$ -	\$ -	\$ 554.08	\$ -	\$ -	\$ -	\$ 382.00	\$ -
Jack Eckerd Drug	ECK0001		\$ 4,666.75	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 4,666.75	\$ -
Jack Eckerd Drug	ECK0003		\$ 2,093.60	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 2,093.60	\$ -
Jack Eckerd Drug	ECK0005		\$ 1,813.60	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 1,813.60	\$ -
Jack Eckerd Drug	ECK0006		\$ 2,386.80	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 2,386.80	\$ -
Jack Eckerd Drug	ECK0007		\$ 139.68	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 139.68	\$ -
Jack Eckerd Drug	ECK0008		\$ 1,757.28	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 1,757.28	\$ -
Jack Eckerd Drug Total			\$ 12,857.71	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 12,857.71	\$ -
Genco Distributors	END0001		\$ 259.20	\$ 259.20	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Genco Distributors Total			\$ 259.20	\$ 259.20	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Fairway Foods	FAU0001		\$ 1,252.80	\$ 432.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Fairway Foods Total		\$ 820.80	\$ 1,252.80	\$ 432.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Fleming Companies	FLE0001		\$ 9,261.58	\$ 8,918.40	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Fleming Companies	FLE0002		\$ 4,944.00	\$ 4,944.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Fleming Companies	FLE0003		\$ 216.00	\$ 216.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Fleming Companies Total		\$ 363.18	\$ 14,461.58	\$ 14,078.40	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -

05-31-99

CUSTOMER		SALES PROMO		TOTAL	CURRENT	1-30 DAYS	31-60 DAYS	61-90 DAYS	91 & OVER
NAME	NUMBER	ACCRUAL							
Fred Meyer	FRM0001		\$ 799.02	\$ (164.69)	\$ -	\$ -	\$ 863.70	\$ -	\$ -
Fred Meyer	FRM0002		\$ (0.21)	\$ (0.21)	\$ -	\$ -	\$ -	\$ -	\$ -
Fred Meyer Total			\$ 798.81	\$ (164.89)	\$ -	\$ -	\$ 863.70	\$ -	\$ -
GHC Merchandise	GHC0001		\$ 7,686.97	\$ 7,686.97	\$ -	\$ -	\$ -	\$ -	\$ -
GHC Merchandise Total			\$ 7,686.97	\$ 7,686.97	\$ -	\$ -	\$ -	\$ -	\$ -
Hughes Family Markets	HUG0001		\$ 550.02	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 550.02
Hughes Family Markets Total			\$ 550.02	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 550.02
Lochin Industries	LOC0001		\$ 136,036.77	\$ -	\$ -	\$ -	\$ -	\$ 67,633.32	\$ 68,403.45
Lochin Industries Total			\$ 136,036.77	\$ -	\$ -	\$ -	\$ -	\$ 67,633.32	\$ 68,403.45
Longs Drugs	LOD00012		\$ 162.32	\$ 161.60	\$ -	\$ -	\$ 0.72	\$ -	\$ -
Longs Drugs	LOD00014		\$ 161.60	\$ 161.60	\$ -	\$ -	\$ -	\$ -	\$ -
Longs Drugs	LOD00015		\$ 143.37	\$ 142.40	\$ -	\$ -	\$ 0.97	\$ -	\$ -
Longs Drugs	LOD00019		\$ 143.08	\$ 142.40	\$ -	\$ -	\$ 0.68	\$ -	\$ -
Longs Drugs	LOD00020		\$ 158.40	\$ 158.40	\$ -	\$ -	\$ -	\$ -	\$ -
Longs Drugs	LOD00027		\$ 177.60	\$ 177.60	\$ -	\$ -	\$ -	\$ -	\$ -
Longs Drugs	LOD00029		\$ 9.30	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Longs Drugs	LOD00058		\$ (280.80)	\$ (280.80)	\$ -	\$ -	\$ -	\$ -	\$ 9.30
Longs Drugs	LOD00063		\$ 86.24	\$ -	\$ -	\$ -	\$ 86.24	\$ -	\$ -
Longs Drugs Total			\$ 761.11	\$ 683.20	\$ -	\$ -	\$ 86.91	\$ -	\$ 9.30
Lucky Stores	LUC00001		\$ (36.85)	\$ (50.95)	\$ -	\$ -	\$ 10.08	\$ 4.03	\$ -
Lucky Stores Total			\$ (36.85)	\$ (50.95)	\$ -	\$ -	\$ 10.08	\$ 4.03	\$ -
May Drug Stores	MAY0001		\$ 259.20	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 259.20
May Drug Stores Total			\$ 259.20	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 259.20
McKesson	MCCK0001		\$ (1,369.00)	\$ (1,369.00)	\$ -	\$ -	\$ -	\$ -	\$ -
McKesson	MCCK0003		\$ 219.46	\$ -	\$ -	\$ -	\$ -	\$ 219.46	\$ -



25/09/2008 11:15:15 12124461483

100 500 NCP.12/20 006

05-31-98

CUSTOMER		SALES PROMO		CURRENT		1 - 30 DAYS	31 - 60 DAYS	61 - 90 DAYS	91 & OVER
NAME	NUMBER	ACCRUAL	TOTAL	CURRENT					
McKesson	MCX0006		\$ 240.00	\$ 240.00	\$ -	\$ -	\$ -	\$ -	\$ -
McKesson	MCX0010		\$ 19.16	\$ 19.16	\$ -	\$ -	\$ -	\$ -	\$ -
McKesson	MCX0012		\$ 283.20	\$ 283.20	\$ -	\$ -	\$ -	\$ -	\$ -
McKesson	MCX0026		\$ 285.45	\$ -	\$ -	\$ 285.45	\$ -	\$ -	\$ -
McKesson	MCX0038		\$ 101.33	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 101.33
McKesson Total		\$ 686.24	\$ 686.24	\$ 518.40	\$ -	\$ 285.45	\$ -	\$ 219.48	\$ 101.33
Nash Finch Dist.	NAS0001		\$ 1,425.60	\$ 518.40	\$ -	\$ -	\$ -	\$ -	\$ 907.20
Nash Finch Dist. Total		\$ 907.20	\$ 1,425.60	\$ 518.40	\$ -	\$ -	\$ -	\$ -	\$ 907.20
Price Less Drug	PRU0001		\$ 2.08	\$ 2.08	\$ -	\$ -	\$ -	\$ -	\$ -
Price Less Drug	PRU0007		\$ 5.81	\$ 5.81	\$ -	\$ -	\$ -	\$ -	\$ -
Price Less Drug Total			\$ 7.89	\$ 7.89	\$ -	\$ -	\$ -	\$ -	\$ -
Price Mart	PRM0001		\$ 292.80	\$ 292.80	\$ -	\$ -	\$ -	\$ -	\$ -
Price Mart Total			\$ 292.80	\$ 292.80	\$ -	\$ -	\$ -	\$ -	\$ -
Promotions Unlimited	PRO0001		\$ 8,139.44	\$ 9,139.44	\$ -	\$ -	\$ -	\$ -	\$ -
Promotions Unlimited			\$ 8,139.44	\$ 9,139.44	\$ -	\$ -	\$ -	\$ -	\$ -
Promotions Unlimited Total			\$ 8,139.44	\$ 9,139.44	\$ -	\$ -	\$ -	\$ -	\$ -
Rite Aid Corp	RAC0001		\$ 22,963.20	\$ -	\$ -	\$ -	\$ -	\$ 1,574.40	\$ 21,388.80
Rite Aid Corp	RAC0002		\$ 11,788.60	\$ -	\$ -	\$ -	\$ -	\$ 1,604.80	\$ 8,740.80
Rite Aid Corp	RAC0003		\$ 21,134.40	\$ -	\$ -	\$ -	\$ 3,786.80	\$ 1,190.40	\$ 16,147.20
Rite Aid Corp	RAC0004		\$ 17,539.20	\$ -	\$ -	\$ -	\$ 1,080.00	\$ -	\$ 16,459.20
Rite Aid Corp	RAC0005		\$ 31,248.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 31,248.00
Rite Aid Corp	RAC0006		\$ 40,732.80	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 40,732.80
Rite Aid Corp	RAC0007		\$ 17,537.80	\$ -	\$ -	\$ -	\$ -	\$ 489.20	\$ 17,048.60
Rite Aid Corp	RAC0008		\$ 6,030.40	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 6,030.40
Rite Aid Corp Total		\$ 133,859.88	\$ 187,950.40	\$ -	\$ -	\$ -	\$ 5,532.80	\$ 5,068.80	\$ 158,358.80
Ralph's Grocery	RAG0001		\$ 1,055.80	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 1,055.80
Ralph's Grocery	RAG0002		\$ 35,187.20	\$ 3,484.80	\$ -	\$ 1,036.80	\$ -	\$ 3,744.00	\$ 26,941.60
Ralph's Grocery Total		\$ 32,888.08	\$ 36,172.80	\$ 3,484.80	\$ -	\$ 1,036.80	\$ -	\$ 3,744.00	\$ 27,987.20

05-31-98

CUSTOMER		SALES PRODU		TOTAL		CURRENT	1-30 DAYS	31-60 DAYS	61-90 DAYS	91 & OVER
NAME	NUMBER	ACCRUAL								
Ray's	RAY0011		\$	(8.96)	\$	(8.96)	\$	\$	\$	\$
Ray's	RAY0013		\$	(8.96)	\$	(8.96)	\$	\$	\$	\$
Ray's Total			\$	(17.92)	\$	(17.92)	\$	\$	\$	\$
Ryan's, Inc	RYAD001		\$	185.39	\$	-	\$	\$	\$	\$
Ryan's, Inc Total			\$	185.39	\$	-	\$	\$	\$	\$
Safeway	SAF0001		\$	4,767.60	\$	-	\$	\$	\$	185.39
Safeway	SAF0002		\$	32,019.40	\$	1,201.50	\$	\$	2,346.40	2,421.20
Safeway	SAF0003		\$	(1,235.00)	\$	(1,235.00)	\$	\$	3,232.24	3,457.58
Safeway	SAF0005		\$	4,129.79	\$	777.59	\$	\$	-	\$
Safeway Total		\$	38,681.79	\$	744.09	\$	\$	\$	5,678.64	3,352.20
SaverMart	SAV0001		\$	10,727.38	\$	-	\$	\$	24,128.08	9,230.38
SaverMart Total		\$	10,727.38	\$	-	\$	\$	\$	-	10,727.38
Shops	SHD0001		\$	3,940.80	\$	-	\$	\$	1,348.80	2,592.00
Shops	SHD0002		\$	643.20	\$	-	\$	\$	240.00	403.20
Shops	SHD0003		\$	2,064.00	\$	-	\$	\$	2,004.00	\$
Shops	SHD0004		\$	7,944.00	\$	-	\$	\$	7,944.00	\$
Shops Total		\$	14,592.00	\$	-	\$	\$	\$	10,539.20	\$
Smith's Food & Drug	SMD001		\$	12,535.85	\$	12,456.00	\$	\$	2.16	1.73
Smith's Food & Drug Total		\$	12,535.85	\$	12,456.00	\$	\$	\$	2.16	1.73
Star Bros.	STB0001		\$	945.06	\$	945.06	\$	\$	\$	75.96
Star Bros. Total		\$	945.06	\$	945.06	\$	\$	\$	\$	75.96
Super Valu Corporation	SUV0001		\$	3,581.60	\$	3,581.60	\$	\$	\$	\$
Super Valu Corporation	SUV0002		\$	11,617.09	\$	11,616.00	\$	\$	\$	\$
Super Valu Corporation	SUV0003		\$	1,615.97	\$	950.40	\$	\$	240.50	1.08
Super Valu Corporation	SUV0005		\$	620.49	\$	612.00	\$	\$	8.49	55.09

25/07/2008 11:20:11 AM LIT-12 34461436

05-31-08 728

CUSTOMER		SALES PROMO		TOTAL		CURRENT		1 - 30 DAYS		31 - 60 DAYS		61 - 90 DAYS		91 & OVER	
NAME	NUMBER	ACCRUAL													
Super Valu Corporation	SUV0006		\$ 2,750.40	\$ 2,750.40	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Super Valu Corporation Total		\$ 674.06	\$ 20,165.55	\$ 19,490.40	\$ -	\$ 249.39	\$ 369.58	\$ 56.18							
Target	TAR0001		\$ 7,492.80	\$ 7,492.80	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Target	TAR0002		\$ 5,001.60	\$ 5,001.60	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Target	TAR0003		\$ 12,873.98	\$ 12,370.64	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Target	TAR0004		\$ 11,614.84	\$ 11,006.40	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Target	TAR0005		\$ 11,487.95	\$ 10,006.60	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Target	TAR0006		\$ 8,836.80	\$ 8,836.80	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Target	TAR0007		\$ 9,448.01	\$ 8,971.20	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Target	TAR0008		\$ 6,416.55	\$ 5,051.20	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Target	TAR0009		\$ 12,276.80	\$ 13,276.80	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Target	TAR0010		\$ 5,092.80	\$ 5,092.80	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Target Total		\$ 2,686.29	\$ 81,492.13	\$ 89,805.04	\$ -	\$ 1,644.73	\$ 476.81	\$ 565.35							
UL TAC	UL T0001		\$ 7,171.20	\$ 2,836.80	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
UL TAC Total		\$ 4,334.40	\$ 7,171.20	\$ 2,836.80	\$ -	\$ 273.60	\$ 1,742.40	\$ 2,318.40							
United Grocers	UNIG001		\$ 4,819.70	\$ 4,233.68	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
United Grocers Total			\$ 4,819.70	\$ 4,233.68	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
URMA Stores	URMA001		\$ 4,103.50	\$ 4,103.50	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
URMA Stores Total			\$ 4,103.50	\$ 4,103.50	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Vons Grocery	VON0001		\$ 4,608.00	\$ -	\$ 4,608.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Vons Grocery Total			\$ 4,608.00	\$ -	\$ 4,608.00	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Walgreens	WAL0001		\$ 17,539.31	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Walgreens	WAL0002		\$ 14,184.48	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Walgreens	WAL0003		\$ 10,192.32	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Walgreens	WAL0004		\$ 10,951.07	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Walgreens	WAL0005		\$ 18,023.04	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Walgreens	WAL0006		\$ 9,265.68	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -

06/25/2008 11:11:55 AM ULTRA-TRACE 2124461463

NO. 600 NP. 15/23 029

05-31-08

CUSTOMER		SALES PROMO		CURRENT		1-30 DAYS	31-60 DAYS	61-90 DAYS	91 & OVER
NAME	NUMBER	ACCRUAL	TOTAL						
Walgreens	WAL0007	\$	\$ 16,035.79	\$	\$	\$	\$ 8,789.84	\$ 7,017.12	\$ 218.83
Walgreens Total		\$ 54,294.61	\$ 96,201.69	\$	\$	\$	\$ 57,614.64	\$ 36,732.32	\$ 7,854.73
Walmart	WAM0001		\$ 3,186.80	\$ (132.48)	\$	\$	\$ 940.67	\$ 198.72	\$ 2,171.09
Walmart	WAM0002		\$ 2,057.05	\$	\$	\$	\$	\$ 443.70	\$ 1,613.35
Walmart	WAM0003		\$ 264.96	\$ (198.72)	\$	\$	\$ 264.96	\$	\$
Walmart	WAM0005		\$ 66.24	\$	\$	\$	\$	\$	\$
Walmart	WAM0010		\$ 66.24	\$	\$	\$ 108.72	\$	\$	\$
Walmart	WAM0011		\$ 45.26	\$	\$	\$	\$ 66.24	\$	\$
Walmart	WAM0012		\$ 66.24	\$	\$	\$	\$ 66.24	\$ 45.26	\$
Walmart	WAM0015		\$ 66.24	\$	\$	\$	\$ 66.24	\$	\$
Walmart	WAM0018		\$ 66.24	\$	\$	\$	\$ 66.24	\$	\$
Walmart	WAM0024		\$ 331.20	\$ (331.20)	\$	\$	\$ 331.20	\$	\$
Walmart Total		\$ 152.70	\$ 6,150.23	\$ (331.20)	\$	\$ 188.72	\$ 1,409.79	\$ 687.68	\$ 3,785.24
Grand Total		\$ 339,208.32	\$ 914,863.45	\$ 237,392.86	\$	\$ 4,806.721	\$ 129,045.90	\$ 152,309.45	\$ 397,309.32

1 581,655

Trade Receivables  
Before Reserve for Doubtful  
Accounts, Sales Discounts and  
Cash Discounts

JUL 11 9 19 2008 5:53 AM ULTRAFLEX

P. 16/23

c:\accounting\way\inv.xls

## Raw Mtl Inventory

Inventory Analysis - On Site Inventory		For the period ending May 31, 1998					
Part No.	Description	Vendor	Unit of Measure	Qty on Hand	Standard Price	Standard Value	Total Value
RAW MATERIAL INVENTORY							
UCCAD001	Compacted Case 24/6	Bolte Cascade	ca	69	0.1798	12.41	12.41
UCCAD001A	Compacted Case 24/6	Bolte Cascade	ca	8,087	0.2170	1,753.75	1,753.75
UCCAD004	Compacted Case 18/14	Bolte Cascade	ca	8,668	0.2100	1,818.60	1,818.60
UCCAD005	Compacted Case 17/20	Bolte Cascade	ca	2,108	0.2750	577.50	577.50
UCCAD006	Compacted Case 17/24	Bolte Cascade	ca	6,607	1.2100	7,996.87	7,996.87
UCRW002	Helix Wrap Film 8.75	Clippy	lb	15,518	3.9700	61,606.46	61,606.46
UCRW007	Resin Film	Liberty Tool	ca	4,861,500	0.0394	205,019.60	205,019.60
UCRW001	Shrink Wrap Film - 17"	Oxyvac	lb	151,500	100.0400	15,150,000	15,150,000
UCRW002	Shrink Wrap Film - 17"	Oxyvac	lb	72	190.0600	13,684.32	13,684.32
UCRW003	Shrink Wrap Film - 18"	Oxyvac	lb	47	116.7100	5,471.37	5,471.37
UCRW004	Shrink Wrap Film - 14"	Oxyvac	lb	93,065	0.0619	5,762.72	5,762.72
UCAD001	Carton 6 ct	Jefferson Smurfit	ca	129,994	0.0856	11,127.49	11,127.49
UCAD001F	Carton 6 ct French	Jefferson Smurfit	ca	31,515	0.0756	2,699.46	2,699.46
UCAD004	Carton 14 ct	Jefferson Smurfit	ca	190,417	0.1315	25,039.84	25,039.84
UCAD004F	Carton 14 ct French	Jefferson Smurfit	ca	19,306	0.1115	2,153.74	2,153.74
UCAD005	Carton 20 ct	Jefferson Smurfit	ca	14,000	0.1264	1,769.60	1,769.60
UCAD005F	Carton 20 ct French	Jefferson Smurfit	ca	489,445	0.0408	19,977.40	19,977.40
UJAD002	Insert 3 color 7 Panel	Artcraft	ca	13,643	0.0489	664.34	664.34
UJAD003	Insert 3 color 7 Panel	Artcraft	ca	78,818	0.0258	2,011.50	2,011.50
UJAD003F	Insert 3 color 7 Panel French	Artcraft	ca	104,117	0.0535	5,574.40	5,574.40
UJAD004	Insert 3 color 8 Panel	Thomas Printing	ca	68,775	0.0104	716.43	716.43
UJAD004F	Insert 3 color 8 Panel French	Thomas Printing	ca	409,139.10	0.0104	4,251.95	4,251.95
UJAD005	Insert 1 Panel \$1.00 Off	Thomas Printing	ca				
TOTAL				68,775	0.0104	716.43	716.43
GRAND TOTAL						409,139.10	409,139.10

6/19/98

NO. 127

LL TRAFLEX + 12124461488

11:15

06/09/98

## Onfile Raw Mill Inventory

Inventory Analysis - On-Site Inventory for the period ending May 31, 1998							
Part No.	Description	Vendor	Unit of Measure	May Qty on Hand	Standard Price Per BOM	5/1/98 Total Value @ Standard	5/1/98 Total Value @ Standard
<b>RAW MATERIAL</b>							
GR6532	Raw Compound	Liberty Tool & Mfg. Inc.	lb	7,650	2,290	17,538.19	
1-VON Lat #23589(2) Liberty Tool	Raw Compound	Liberty Tool & Mfg. Inc.	lb	217	2,290	541.12	
1-VON Lat #23589(2) VON Robbin	Raw Compound	Liberty Tool & Mfg. Inc.	lb		2,290		
1-VON Lat #23589 Compound Form	Raw Compound	Liberty Tool & Mfg. Inc.	lb		2,290		
1-VON Lat #23590(2) VON Robbin	Raw Compound	Liberty Tool & Mfg. Inc.	lb		2,290		
1-VON Lat #23590(2) Liberty Tool	Raw Compound	Liberty Tool & Mfg. Inc.	lb		2,290		
1-VON Lat #23590 Compound Form	Raw Compound	Liberty Tool & Mfg. Inc.	lb		2,290		
GR6531	Raw Compound	J.K. Maf	lb	31,753	2,290	72,714.76	
GR6531	Raw Compound	Bedwell Tubace	lb	1,834	2,290	4,199.86	
GR6531	Raw Compound	Brecker Plastics	lb	300	2,210	663.00	
GR6531	Raw Compound	Dorfield Underhill, Inc.	lb	4,100	2,210	9,061.00	
GR6531	Raw Compound	Spartan Plastics	lb		2,210		
ULCA001	Raw Compound	Choppy	lb	10,459	2,210	23,114.39	
ULCA004	Raw Compound	Jefferson Souffit	ca		0.0619		
ULCA005	Raw Compound	Jefferson Souffit	ca	234,000	0.0656	15,351.60	
ULCA006	Raw Compound	Jefferson Souffit	ca	105,000	0.1315	13,807.50	
ULCA007	Raw Compound	Jefferson Souffit	ca	110,500	0.1361	15,044.05	
ULCA008	Raw Compound	Atlanta Plastics	ca		0.0409		
ULCA009	Raw Compound	Atlanta Plastics	ca		0.075		
<b>Total</b>							
<b>Grand Total</b>							

c:\accounting\onfile\INV.XLS

6/8/98

NO.12: D14

6/8/98 11:15 ULTRAFLEX + 12124461489

## Non Conforming MCI

Ultrascan, Inc.				5/1/98	5/1/98
Inventory Analysis - Non-Conforming Inventory				Standard	Total
for the period ending May 31, 1998				Price	Value @
Part No.	Description	Vendor	Unit of Measure	May Qty on Hand	Per UOM Standard
NON-CONFORMING MATERIAL					
UCW002	Indimate Wrap Film 8.75	Diamond Plastics	lb	5.073	1.21
UCRF002	Reactive Film	Deerfield	lb		
ULCA001	Run	Liberty Tool	ca	1,200	0.0504 60.48
ULCA004F	Carton 14 ea French	Jefferson Smurfit	ca	2,380	0.0619 147.32
ULCA005F	Carton 20 ea French	Jefferson Smurfit	ca	8,002	0.0856 684.97
ULD003	Insert 3 color 8 Panel	Arvink	ca	125	0.1315 42.74
00160-14	14 Count Case	Ultrascan, Inc.	ca	99,474	0.025 2,261.85
00290	20 Count Case	Ultrascan, Inc.	ca		48.3103
00240	24 Count Case	Ultrascan, Inc.	ca		46.0945
TOTAL				54.8335	
QUARANTINED MATERIAL				23,335.19	
00240	24 Count Case	Ultrascan, Inc.	ca		54.8335
UCR001	Run	Liberty Tool	ca		
UCRF002	Reactive Film	Deerfield	lb		0.0504
UCW002	Indimate Wrap Film 8.75	Diamond Plastics	lb		1.21
ULD003	Insert 1 Panel \$1.00 Off	Turner Printing	ca		0.0104
TOTAL				0.0104	
SPECIAL HANDLING					
UCRF002	Reactive Film	Deerfield	lb		3.97
ULCA001	Run	Liberty Tool	ca		0.0504
TOTAL				3.97	
GRAND TOTAL				23,335.19	

c:\accounting\mci\_inv.xls

6/2/98

N.121 D12

ULTRAFEM + 12124461489

11:15

06/09/98



NO. 11:15 06/09/98

11:15 06/09/98

CHAMBERS/STANLEY, NW 283

WIP

Inventory Analysis - Work in Process for the period ending May 31, 1998				5/1/98 Standard Price	5/1/98 Total Value
Part No.	Description	Unit of Measure	May Qty on Hand	Per UOM	Standard
WIP					
UCAS04	Completed Case 1220	ea		0.227	-
UCRW03	Electronic Wiring Frame 8.75	lb		1.21	-
UCRF002	Resistor Wire Fibers	lb		3.97	-
UCR001	Pin	ea		0.0584	-
UCSW03	Shield Wrap Fibre-15"	cl		150.06	-
UCAS04	Custom 20 cl	cl		0.0556	-
UASW02	Insert 3 each 7 Pin	ea		0.0409	-
UASW04	Insert 1 panel Price Video	ea			-
			Value in WIP for work order		-
			<b>Grand Total</b>		-

013

NO. 121

L.L. TRFEM + 12124461469

11:15

06/09/98



## Printed Goods

Inventory Analysis - Finished Goods for the period ending May 31, 1998									
Part No.	Description	Unit of Measure	Qty on Hand	Standard Price Per UOM	Value @ Standard	Units Per UOM	Total Number of Units		
00002	50Kcup in Infinate Wrap	ea	30	0.1806	5.418	1	30		
00005	Infinate Even Pack	ea		0.3821	12.85	1	807		
00060	6 Count Case	case	20,094	28.605	574,786.17	2	2,895,536		
00060A	6 Count Case-Schleier	case	942	28.605	27,001.12	144	135,936		
00060F	6 Count Case-French	case	816	28.348	23,104.99	144	128,144		
00061	6 Count Carton	ch	12,607	1.1843	14,923.76	8	75,604		
00063	6 Count 3 Pack	ch	38	3.5756	135.87	18	684		
00126	Display 12 PC/6 CT	case	582	14.2116	7,986.92	72	40,464		
00160	16 Count Case	case		52.4415		288			
00160-14	14 Count Case	case	877	48.5105	42,118.02	252	289,404		
00160-14F	14 Count Case-French	case	874	48.6554	42,193.78	252	169,928		
00161	16 Count Cartons	ch		2.9007		161			
00161-14	14 Count Cartons	ch	82,510	2.6825	221,477.51	14	1,155,980		
00163	16 Count 3 Pack	ch	4	8.085	32.34	42	168		
00280	20 Count Case	case	2,107	46.0845	97,121.11	246	505,880		
00280F	20 Count Case-French	case	140	46.1942	6,466.77	240	33,600		
00281	20 Count Carton	ch	884	3.8237	3,418.19	20	17,880		
00281 IRC	20 Count Carton IRC	ch	767	3.8237	3,009.25	20	15,740		
00283	20 Count 3 Pack	ch		11.5236		90			
00284	24 Count Case IRC	case	5,890	34.8535	205,116.42	288	1,638,720		
00284F	24 Count Case-French	case		54.8535		288			
00285	24 Count Carton	ch	10	4.5711	45.71	24	240		
00285 9	Display 24 PC/6 CT	case	2	13.7133	27.43	72	144		
00285F	Display 24 PC/6 CT (F)	case		28.4232		144			
00286	Display 24 PC/6 CT (IRC)	case	302	28.4232	8,585.81	144	43,488		
00286V	Display 24 PC/6 CT (V)	case	319	28.4232	9,107.23	144	54,576		
00287	Display 24 PC/6 CT-Schleier	case	175	28.4232	4,974.06	144	25,200		
003661	Display 38 PC/6 CT (IRC)	case		19.3608		102			
003661F	Display 38 PC/6 CT (F)	case	28	42.6348	1,193.77	216	8,048		
01220	Display 12 PC/20 CT (IRC)	case	532	45.8644	24,410.50	240	127,680		
01246	Display 24 PC/6 CT (IRC)	case	67	28.4232	1,904.35	144	9,648		

26 JUN 2008 15:27:54M LTL TRAFFIC 24461488

NO. 500 P. 21/23 003

## Finished Goods

Inventory Analysis - Finished Goods for the period ending May 31, 1998									
Part No.	Description	Unit of Measure	Qty on Hand	Std Price	Value @ Std Price	Units Per UOM	Total Number of Units		
01368	Display 36 PC/6 CT (HRC)	case	283	37.5522	10,627.27	196	55,488		
01414T	Display 14 PC/14 CT (HRC)	case	18	40.8098	730.96	224	4,037		
01418	Display 14 PC/18 CT (HRC)	case	50	40.8098	2,040.49	224	11,200		
01418T	Display 14 PC/18 CT (C)	case	110	28.4232	3,126.55	144	15,340		
02246	Display 24 PC/6 CT (HRC)	case	678	21.3174	14,459.03	218	148,884		
02246A	Display 24 PC/6 CT (HRC)	case	198	42.6348	8,441.69	218	47,788		
02356	Display 36 PC/6 CT (HRC)	case	328	42.6348	13,984.21	218	78,848		
02356A	Display 36 PC/6 CT (HRC)	case	112	37.5522	4,205.85	196	21,967		
05356	Display 36 PC/6 CT (HRC)	case	1,968	37.5522	73,902.73	196	385,728		
21414	Display 14 PC/14 CT (HRC)	case							
OFF SITE - Mongia & Sampson - Ontario, CA									
00850	Instead 6 CT	case	13,768	28.605	396,670.64	144	1,039,102		
00850A	Instead 6 CT-Walgreen	case		28.605					
00126	Display Counter-Malgreens	case	1,534	52.4415	80,689.41	228	478,592		
00180	Instead 18 CT	case	19,908	48.5103	965,646.03	252	5,018,312		
00200	Instead 20 CT	case	4,008	46.0845	184,792.85	240	862,160		
00240HRC	Instead 24 CT HRC	case	1,856	54.8535	102,136.83	288	537,408		
00246	6 CT Promo Displays	case		28.4232		144			
00246T	6 CT Promo Displays	case		28.4232		144			
00246T	6 CT Promo Displays	case		28.4232		144			
00246T	6 CT Promo Displays	case		28.4232		144			
00260A	Instead Distribution PK	case	29	18.7056	542.46	36	2,764		
00360T	6 CT Promo Displays	case		42.6348		218			
01220	Display 12 PC/20 CT (HRC)	case	1	42.6348	42.63	240	240		
01356	6 CT Promo Displays	case		42.6348		218			
01414T	14 CT Promo Displays	case		37.5522		196			
01418	18 CT Promo Displays	case		40.8098		224			

c:\Account\closing\may\_mv.xls

05/JUN/98 15:55:56M ULTRAFEM  
 05/06/98 15:55:56M ULTRAFEM  
 121,446,148B

NO. 490 NO. 55/53 024

Finished Goods

Quantity, Inc. Inventory Analysis - Finished Goods for the period ending May 31, 1998									
Part No.	Description	Unit of Measure	May Qty on Hand	Standard Price	Total Value @ Standard	Units per U.S.	Total Number of U.S.		
OFF SITE - Morgan & Simpson - Hawaii									
01416-5	16 CT Primo Displays	case	-	40.8038	-	224	-		
01416-7	16 CT Primo Displays	case	-	42.6348	-	216	-		
03368	6 CT Primo Displays	case	-	42.6348	-	216	-		
03368	6 CT Primo Displays	case	-	42.6348	-	216	-		
11414	14 CT Primo Displays	case	-	37.5522	-	186	-		
21414	14 CT Primo Displays	case	-	37.5522	-	186	-		
TOTAL					\$ 1,715,740.18		2,085,564		
OFF SITE - Morgan & Simpson - Hawaii									
00060	16 CT Primo Displays	case	82	28.605	2,345.61	144	11,280		
00160-14	16 CT Primo Displays	case	85	48.5103	4,123.31	252	21,420		
00200	16 CT Primo Displays	case	48	48.0845	2,312.54	240	11,520		
00368	6 CT Primo Displays	case	-	42.6348	-	216	-		
00368	6 CT Primo Displays	case	10	42.6348	426.35	216	4,304		
11414	14 CT Primo Displays	case	30	37.5522	1,126.57	186	5,280		
TOTAL					\$ 10,818.75		84,732		
OFF SITE - Morgan & Simpson - Portland, OR									
00060	16 CT Primo Displays	case	59	28.605	1,687.70	144	8,280		
00160-14	16 CT Primo Displays	case	101	48.5103	4,899.54	252	25,452		
00200	16 CT Primo Displays	case	85	48.0845	4,087.18	240	20,400		
00240	16 CT Primo Displays	case	64	54.8535	3,510.62	288	18,432		
01248	6 CT Primo Displays	case	17	28.4232	483.19	144	2,448		
01368	6 CT Primo Displays	case	-	42.6348	-	216	-		
01414	14 CT Primo Displays	case	106	37.5522	3,980.53	186	20,716		
02248	6 CT Primo Displays	case	80	28.4232	2,273.86	144	11,520		
02368	6 CT Primo Displays	case	93	42.6348	3,963.04	216	20,088		
11414	14 CT Primo Displays	case	-	37.5522	-	186	-		
21414	14 CT Primo Displays	case	140	37.5522	5,257.31	186	21,440		
TOTAL					\$ 28,976.97		185,052		
OFF SITE - Morgan & Simpson, New Jersey									
00060	16 CT Primo Displays	case	2,007	28.605	57,410.24	144	288,000		
00060A	16 CT Primo Displays	case	360	28.605	10,297.80	144	51,840		
00160	16 CT Primo Displays	case	81	52.4415	4,247.76	288	24,336		
00160-14	16 CT Primo Displays	case	1,177	48.5103	57,094.62	252	286,800		
00700	16 CT Primo Displays	case	101	48.0845	4,791.83	240	24,000		

JUN 9 2008 5:57AM ULTRAFLEX 12124461488

NO. 30 P. 23/21 635

c:\account\closing\NAV\_INV.ELS

Page 4 of 4

6/9/08

## Planned Goods

Ultraflex, Inc. Inventory Analysis - Planned Goods for the period ending May 31, 1998									
Part No.	Description	Unit of Measure	Key Qty on Hand	Standard Price Per UOM	Value @ Standard	Units Per UOM	Total Number of Units		
00240	INSTAL 24 CT	Case	700	54.8535	38379.57	288	228,572		
00240RRC	INSTAL 24 CT RRC	Case	-	54.8535	-	288	-		
01206	5 CT Photo Displays	Case	-	42.6348	-	216	-		
02245	5 CT Photo Displays	Case	160	28.4232	4,547.71	144	23,040		
02306	5 CT Photo Displays	Case	485	42.8346	20,677.38	216	104,760		
TOTAL					\$ 104,212				
GRAND TOTAL @ STANDARD					\$ 3,523,946.58	36,377,853			
Lower of Cost or Market Adjustment					\$ 18,595.58				
GRAND TOTAL					\$ 3,505,350.99	36,377,853			

① Unadjusted for Absolute Inventory  
Reduce of \$129,816

RAW. 7.1998 2:32PM ULTRAFEM

NO. 158 P. 2/4

**Ultrafem**  
INC

374 Riverside Avenue  
Westport, CT 06880

Tel. (203) 341-3461  
Fax (203) 341-7463

Dear HBA Buyer:

Ultrafem, Incorporated, makers of INSTEAD, announced April 1, 1998 that it has filed a Chapter 11 bankruptcy petition. This action has been taken in an attempt to rebuild the Company and its brand INSTEAD.

The Company is currently seeking additional financing or will possibly sell the Company and its assets to a qualified buyer. As the Company comes out of Chapter 11, it will be necessary to establish new terms and conditions concerning cash discounts, trade funding and shipping status. The new policies will be in effect until new financing has been secured or a buyer for the Company is identified.

Your support of the INSTEAD brand has been greatly appreciated and we would like to continue our relationship with you. We are revising our policies to provide incentives to our retail partners who choose to keep INSTEAD in distribution. The following changes demonstrate our commitment to re-establish the business and to reward your efforts in moving the business forward.

Our plans to relaunch the brand will be communicated to you once we emerge from Chapter 11. For now, the following policy changes will be put in place in an effort to simplify our relationship during the transition.

***Cash Discounts***

The current policy is 2% 30 net 31. As of April 1, 1998 the new terms will be 12% 30 net 31. To qualify for these terms all past deductions and receivables must be current (i.e., no receivables over 30 days and all outstanding deductions must be validated and cleared).

***Trade Funding***

As of April 1, 1998 no additional funds will be applied toward trade programs. Any promotions executed by Ultrafem's trade partners will be funded through the additional cash discount funds. Any deductions, other than damaged goods, taken by the trade after April 1, 1998 will not be honored by Ultrafem. As with the cash discount policy, this policy will be in effect until further financing has been secured or a buyer has been found for the company.

June 12, 1998 (9:47am)

**SCHEDULE 3.10**  
**CONTRACTS AND LEASES**

APR. 7. 1998 2:19PM ULTRAFEM

NO. 158 P. 3/4

**Ultrafem**  
INC

274 Riverside Avenue  
Westport, CT 06880


Tel (203) 341-3461  
Fax (203) 341-7463

***Shipping Status***

Purchase orders in-house or future purchase orders from customers with receivables balances over 30 days old will not be honored. Those orders will be filled once all receivable balances have been paid.

Ultrafem is looking for your support as it attempts to re-establish the Company and **INSTEAD**. Any questions concerning these or other company policies should be directed to your local representative.

Sincerely,



Jeffrey C. Nardoci  
Senior Vice President, Sales

In re - Ultrafem, Inc.

Case No. 98 B 42280 (PCB)

## SCHEDULE G — EXECUTORY CONTRACTS AND UNEXPIRED LEASES

Describe all executory contracts of any nature and all unexpired leases of real or personal property. Include any timeshare interests. State nature of debtor's interest in contract, i.e., "Purchase," "Agent," etc. State whether debtor is the lessor or lessee of a lease. Provide the names and complete mailing addresses of all other parties to each lease or contract described.

NOTE: A party listed on this schedule will not receive notice of the filing of this case unless the party is also scheduled in the appropriate schedule of creditors.

Name & Mailing address including zip code of other parties to lease or contract	Description of contract or lease
Alpha One 1600 Moberly Lane Bentonville Arkansas 72701	Retail Broker Agreement
American Properties as an agent for Lavoisier Properties Corp 130 W. 42nd street NY, NY 10036	Nonresidential Real Property lease for 130 W. 42nd street suite 1103
American Stock Transfer & Trust company 40 Wall Street, 46th Floor New York, NY 10005 Contact: Ann Carfunkle	Transfer Agent and Registrar Agreement
Ascom 19 Forest Parkway PO Box 838 Shelton, CT 06484-0903 Contact: Kathie Ruggiero	Rental agreement for Postage Meter
AT&T Capital Leasing Services The Corporate Center PO Box 9104 Framingham, MA 01701	Lease for 4 fax machines



Name & Mailing address including zip code of other parties to lease or contract	Description of contract or lease
Audrey Contente 211 E. 70th Street, apt 16C New York, NY 10022	Employment Agreement, Name, Likeness and Voice Release Termination Benefits Agreement Indemnity Agreement Option Certificate and Agreement
Belk Mignogna Associates 373 Park Avenue South New York, NY 10016 Contact: Wendy Blattner	Annual Report Agency
Bozell Worldwide 40 West 23rd Street New York, NY 10010 Contact: Joanne Davis	Contract for advertising, public relations, direct
BRI Medical Device Group 15825 Shady Grove Road, Suite 70 Rockville, MD 20850 Contact: David West	Consulting Agreement for Medical Data
CED 521 Burlington Missoula, MT 59801 Attn: Jim	Light bulb Agreement
Clopax Plastics 312 Walnut Street, Suite 1600 Cincinnati, OH 45202-4036	Reservoir Film Manufacturer
CMR 700 W. Lincoln, Suite 200 Charleston, IL 61920 Contact: Wendy Greeson	Agreement regarding management of post office box for collection of consumer letters
Colin Kagel 94 Long Hill Road Deep River, CT 06417	Advisory and Consulting Agreement for Human Resources
Dana Saad N 3803 Sullivan, Building 105 Spokane, WA 99216 Attn: Patrick Saad	Contract for Rim Manufacturer

Name & Mailing address including zip code of other parties to lease or contract	Description of contract or lease
Deloitte & Touche, LLP 2 World Financial Center NY, NY 10281 Contact Steve Gallucci	Accounting Agreement
Dixon Marketing 301 Darby Road PO Box 1618 Kinston, NC 28503	Military Sales Broker Agreement
Dori Reap 160 E. 38th Street Apt 15H NY, NY 10016	Employment Agreement Option Certificate (two) and Agreement Amendment to Employment Agreement Letter of Agreement for Expense Allowance
Elliott Company Roger Elliott 5 Burlington Woods Drive, Suite 203 Burlington, MA 01803-4542	Strategic Partner Finder
Epimedix Inc 2030 S. Ocean Drive #1627 Hallandale, FL 33009 Contact: Dr. Jeffrey Perlman	Consulting Agreement on regulatory issues
GE Capital Modular Space PO Box 641595 Missoula, MT 59806	Plant/Warehouse located at 1600 North Avenue Missoula, MT 59801
Gelco 10700 Prairie Lakes Drive Eden Prairie, MN 55344 Contact: Valerie Bunnis	Contract to provide rapid draft system for trade promotions
Gruntal (Hampshire) 717 5th Ave New York, NY 10022 Contact: Jeff Berman	Investment banking agreement

Name & Mailing address including zip code of other parties to lease or contract	Description of contract or lease
Hockfield & Associates 887 East Wilmette Avenue, Suite J Palatine, IL 60067 Contact: Ed Hockfield	Sales Broker Agreement
Hynes Sales 6525 Morrison Blvd Charlotte, NC 243211 Contact: John Greene	Sales Broker Agreement
IJ White 20 Executive Blvd Farmingdale, NY 11735 Attn: Tom Wedell	Contract to build System Accumulator Spare Parts
INAC Corp a CIGNA Company 401 Whitehorse Road, PO Box 9050 Voorhees, NJ 08043	Commercial Premium Finance Agreement (one for D&O insurance and one for product liability)
Jefferson Smurfit 1319 Dexter Avenue North #106 Seattle, WA 98109 Attn: Pete Burquist	Purchase Order for cartons not yet released
Jefferson Smurfit 1050 N. Kent Street St. Paul, MN 55117	Letter agreement for storage of cartons
Jefferson Smurfit 601 Monster Road SW Renton, WA 98056 Attn: Dana Pyle	Purchase Order for cartons not yet released
John Jeffery Corporation PO Box 697 Bellmawr, NJ 21227	Public warehouse located at 50 Heller Road, Belmar NJ 21227, which stores inventory (no formal agreement)
John Andersen c/o Lillie Goodrich 7-A Patricia Lane Cos Cob, CT 06807	Employment Agreement; Option Certificate and Agreement; Amendment to Employment Agreement
Landau & Landau 36 Seymour Street London W1H 5WD	Residential Real Property Lease Ultrafem UK apartment 13 Healhcroft Hampstead Way London NW11 7HH

Name & Mailing address including zip code of other parties to lease or contract	Description of contract or lease
Lehman Brothers 200 Vessy Street 3 World Financial Center New York, NY 10285	Investment Banking Agreement
M&K Associates 89 Main Suite 209 Medway, MA 02053 Contact Mark Moroney	Sales Broker Agreement
Market Growth Resources 372 Danbury Road Wilton, CT 06897-2530 Contact: Mickey Jardon	Contract for consumer promotion services
Master Lease a division of Tokai Financial 1055 Westlakes Drive Berwyn, PA 19312 Contact: Mary An Macri	Rental agreement for Ascom Mail Machine and Ascom scale
Med Write Associates 31651 Auburn Drive Birmingham, MI 48025	Letter of Agreement for Technical Manuscript
Meridian Consulting 274 Riverside Avenue Westport, CT 06880 Contact: Jeff Hill	Consulting Agreement for outsourcing
Michele Blankford 2 Hudson Avenue Nyack, NY 10960	Loan Repayment Agreement
Mid States 3245 Holman Drive S. Chicago Heights, IL 60411-5599	Contract to build and install Shingling conveyor
Minolta One International Blvd., 10th Floor Mahwah, NJ 07430-0631 800 553 3067 ext 2283 for Lyle	Lease for 1 photocopier
Mobley Henson consulting 3494 Camini Tassajara Road Suite 430 Danville, CA 94506	Finders Agreement

Name & Mailing address including zip code of other parties to lease or contract	Description of contract or lease
Morgan & Sampson Pacific 10572 Calle Lee Suite 138 Los Alamitos, CA 90720 Contact: Chip Carter	Brokerage Agreement
Morgan and Sampson 1651 S. Carlos Avenue Ontario Ca 91761	Public warehouse located at 1651 S. Carlos Avenue, Ontario, CA 91761, which stores inventory
Morgan & Sampson, Honolulu 429C Walakamike Road Honolulu, HI 96817	Nonresidential Lease for public warehouse located at 429C Walakamilo Road, Honolulu Hawaii 96817, which stores inventory
Mr. & Mrs. Elof Johansson 1 East River Place, Apt. 12D/E New York, New York 10021	Residential Real Property Sublease 1 East River Place Apt. Lease
NCH 75 Tri- State International Suite 400 Lincolnshire, IL 60069	Agreement to manage coupon redemption in US
NCH Canada 160 McNabb Street Markham, Ontario L3R 4B8 Contact: Mike Feeley	Agreement to manage coupon redemption in Canada
Nielsen 299 Park Avenue New York, NY 10171 Contact: Carolyn Cacciola	Agreement to provide syndicated data
NPD Group 900 West Shore Road Port Washington, NY 11050-0402 Contact: Mark Truss	Consulting Agreement to manage diary panel for consumer research
Orchard Close LTD c/o The Capco Group Capco House 31-37 North Quay Douglas, Isle of Man, British Isles	Agreement for Consulting Services related to investor relations in Europe
Pitney Bowes PO Box 85460 Louisville, KY 40285-5460	Postage machine Agreement

Name & Mailing address including zip code of other parties to lease or contract	Description of contract or lease
PL Thomas Group Two North Riverside Plaza, Suite 1760 Chicago, IL 60606 Contact: Phil Thomas	Financial Investor Relations Services
Polygram Filmed Entertainment Distribution 9333 Wilshire Blvd Beverly Hills, CA 90210 Contact: Kelly Clough	Product Placement Agreement for Your Friends and Neighbors movie
Poppe Tyson 40 West 23rd Street New York, NY 10010	Internet Agency Agreement
ProActive International Huis Ter Lucht 8 3155 EB Maasland The Netherlands Contact: Ban Van der Kooij	Strategic Partner Finder
Proskauer Rose LLP 1585 Broadway New York, NY 10036 Contact: Michael Bellinger	Retention Agreement re: Contente v. Ultrafem and John W. Andersen
Quintiles PO Box 13979 Research Triangle Park, NC 27709 Durham, NC 27703 Contact Jim Mannion	Consulting Agreement
Remmele Engineering 10 Old Highway 8 S.W. New Brighton, MN 55112 Contact: William Iacoe	Contracts to Manufacture Equipment Spare Parts Purchase Order - Down Payment on A/P
ReProtect The Johns Hopkins University Dept Biophysics/Jenkins Hall 3400 N. Charles Street Baltimore, MD 21218 Contact Richard Cone	License, research and Product Development Agreement

Name & Mailing address including zip code of other parties to lease or contract	Description of contract or lease
Richlund and Associates 2050 Bluestone Drive Saint Charles, MO 63303	Lease for telephone equipment located at 1600 North Avenue, Missoula, MT 59801
Roger Levitt President & CEO Boxing International LLC 230 Park Avenue, Suite 1514 New York, NY 10169	Strategic Partner Finder Agreement
Rudie Wilhelm Warehouse Co. PO Box 22226 Milwaukee, Or 97222-0226	Pubic warehouse located at 2400 South East Mailwell Drive, Milwaukee, Or 97222, which stores inventory
Sales Force 135 S. LaSalle Street Dept. 1814 Chicago, IL 60674	Sales Broker Agreement
Scott Materials 707 Batcheller Lane Sioux Falls, SD 57105	Agents Fee Agreement
Shared Technologies Fairchild Telecom 300 West Service Road Chantilly, Va 22021	Agreement for 130 W. 42nd Street phone system
Sharon Hillier 945 Field Club Road Pittsburgh, PA 15238	Consulting Agreement (member of SAB)
Shell Company PO Box 2463 Houston, TX 77252-2463	Sales Contract for Raw Materials
Shelter West Inc. PO Box 4746 Missoula, MT 59806	Administrative Office located at 629 SW Higgins Avenue, Suite B Missoula, MT 59801
Solow Management Corp. 9 West 57th Street New York, NY 10019	Residential Real Property Lease for corporate apartment at 1 East River Place Apt 12 D/E.
Sprint PO Box 930331 Atlanta, GA 31193-0331	Sprint Frame Relay contract

Name & Mailing address including zip code of other parties to lease or contract	Description of contract or lease
Supermarkets On Line 500 W. Putman Ave Greenwich, CT 06830	Agreement for on line coupon service
Ted Cohen 316 Eisenhower Parkway Livingston, NJ 07039	Investigator agreement for rim compression study
Telespectrum 1100 East Hector Street Suite 416 Conshahoken, PA 19428	1-800 Instead Voice Mail Box
The Sage Group 245 Route 22 West, Suite 304 Bridgewater, NJ 08807 Contact Gordon Ramseier	Strategic Partner Finders Agreement
Tonya Hinch 25 W. 15 St 4th floor NY, NY 10011	Employment Agreement; Option Certificate and Agreement; Amendment to Employment Agreement
Wasserstein Perella & Company 31 West 52nd Street NY, NY 10019	Investment Banking Agreement
Western Trade Center PO Box 8182 Missoula, MT 59807	Plant/Warehouse located at 1600 North Avenue, Missoula, MT 59801
Gary Nordmann 14 Belmont Place Huntington, NY 11743	Employment Agreement; option and Certificate agreement.



June 12, 1998 (9:47am)

**EXHIBIT 6.2**

TOGUT, SEGAL & SEGAL  
Attorneys for Debtor-in-Possession  
One Penn Plaza  
New York, New York 10119  
(212) 594-5000  
Albert Togut (AT-9759)  
Neil Berger (NB-3599)

UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK

HEARING DATE: 6/ /98  
AT: \_\_\_\_ PM

In re:

ULTRAFEM, INC.,

Debtor.

Employer Tax Identification No. 33-0435037

Chapter 11 Case No.  
98 B 42280 [PCB]

**ORDER (i) SCHEDULING (a) HEARING TO APPROVE ASSET PURCHASE AGREEMENT BETWEEN THE DEBTOR AND AKCESS PACIFIC GROUP, LLC FOR THE SALE OF SUBSTANTIALLY ALL OF THE DEBTOR'S ASSETS FREE AND CLEAR OF ALL LIENS, CLAIMS AND ENCUMBRANCES AND TO CONSIDER OBJECTIONS, IF ANY; AND (b) A PRIOR BIDDING HEARING TO CONSIDER HIGHER AND BETTER OFFERS; (ii) APPROVING BREAK-UP FEE PAYABLE TO AKCESS PACIFIC GROUP, LLC PURSUANT TO ASSET PURCHASE AGREEMENT; (iii) ESTABLISHING BIDDING PROCEDURES FOR THE HEARINGS; (iv) APPROVING THE FORM AND METHOD OF SERVICE OF NOTICE OF THE PROPOSED SALE AND HEARINGS; AND (v) ESTABLISHING DEADLINE AND PROCEDURES FOR THE FILING AND SERVICE OF OBJECTIONS AND HIGHER OR BETTER OFFERS**

Upon the annexed application dated June \_\_, 1998 (the "Application") of Ultrafem, Inc., as Debtor-in-Possession (the "Debtor"), by its attorneys, Togut, Segal & Segal, seeking entry of an Order pursuant to §§363(b), (f), and (m) and 365(a) and (f) of Title 11, United States Code (the "Bankruptcy Code") and Rules 2002, 6004, 6006 and 9006 of the Federal Rules of Bankruptcy Procedure ("Bankruptcy Rules") and Rule 6004-1 of the Local Rules for the United States Bankruptcy Court for the Southern District of New York (the "Local Rules"): (i) scheduling (a) a hearing (the

*Hearing*

"Approval Hearing") to consider approval of the Asset Purchase Agreement (the "Sale Agreement"), by and between the Debtor and Akcess Pacific Group, LLC (the "Buyer"), annexed to the Application as Exhibit "1", for the sale of substantially all of the Debtor's assets including, without limitation: the Debtor's patent known as "Vaginal Discharge Collection Device and Intravaginal Drug Delivery System", U.S. Patent No. 5,295,984, and all of the Debtor's other patents, trademarks, servicemarks and other intellectual property; all the Debtor's personal property including its machinery, equipment and inventory; and certain unexpired lease agreements and account receivable claims (collectively, the "Assets"), free and clear of all liens, claims, interests, and encumbrances; and (b) scheduling a prior bidding hearing (the "Bidding Hearing") to consider higher or better offers, if any; (ii) establishing bidding procedures; (iii) approving a break-up fee (the "Break-Up Fee") payable to the Buyer pursuant to the terms of the Asset Purchase Agreement; (iv) approving the form and method of notice of the Approval Hearing and the Bidding Hearing; and (v) establishing a deadline and the procedures for the filing and service of objections or higher or better offers, if any;

AND the Official Committee of Unsecured Creditors (the "Committee") having no objection to the entry of this Order, as evidenced by the subjoined signature of its attorneys; and the relief sought appearing reasonable, proper and necessary; and good and sufficient cause appearing therefor, and no further notice being required, it is

ORDERED, that the Notice substantially in the form annexed to the Application as Exhibit "2" be, and it is hereby is, approved in all respects; and it is further

ORDERED, that higher or better offers (the "Competing Offer") for the purchase of the Assets must: (i) be on substantially the same terms as contained in the Sale Agreement except for the purchase price which must be higher, by not less than \$500,000 (the "Initial Overbid"); (ii) be accompanied by a cashier's or certified check equal to ten (10%) of the purchase price of such bid ("Deposit"), which shall be delivered to Togut, Segal & Segal, as attorneys for the Debtor, to be held in escrow pending the Court's determination of the Sale and which will be (a) applied toward the purchase price if the bid is approved by the Court whereupon the Deposit will automatically be deemed to be non-refundable; (b) retained by the Debtor if the Sale is approved by the Court, but the successful Bidder fails to timely close; or (c) refunded in full promptly after the Hearing if the bid is not approved; and (iv) provide for the closing (the "Closing") to occur not later than three (3) days after the date the Court signs an order authorizing and approving the Sale to the over-Bidder; and it is further

ORDERED, that all Competing Offers for purchasing the Assets must be made so as to be received by: (i) Togut, Segal & Segal, attorneys for the Debtor, One Penn Plaza, New York, New York 10119, facsimile number (212) 967-4258, Attn: Neil Berger, Esq.; and (ii) Kensington & Ressler, L.L.C., attorneys for the Committee, 400 Madison Avenue, New York, New York 10117-1901, Attn: Howard D. Ressler, Esq.,

facsimile number (212) 838-7060, by not later than June \_\_, 1998 at 5:00 PM (the "Submission Date"), unless the Debtor and the Committee in their mutual discretion, extend the Submission Date; and it is further

**ORDERED**, that any party submitting a Competing Offer shall provide with its offer, to the reasonable satisfaction of the Debtor and the Committee, written evidence that it has the financial capability to pay, at the Closing, the balance of the purchase price approved by the Court ; and it is further

**ORDERED**, that Competing Offers made in compliance with the provisions of this Order will be considered at the Bidding Hearing which will be conducted by the Debtor at the offices of Houlihan Lokey Howard & Zukin ("Houlihan Lokey"), investment advisor to the Committee, 31 West 52nd Street, 11th Floor, New York, New York 10119 on June \_\_, 1998 at 10:30 am, at which time and place (i) Competing Offers for the Assets will be entertained, with all bidding above the Initial Overbid being made in increments of at least \$100,000, and (ii) an announcement may be made concerning which of the offers, if any, constitutes the highest and best offer for the Assets and is otherwise acceptable to the Debtor (the "Accepted Offer"); and it is further

**ORDERED**, that the Approval Hearing shall be held before the Honorable Prudence Carter Beatty, Bankruptcy Judge, at the United States Bankruptcy Court for the Southern District of New York, Courtroom 617, One Bowling Green, New York, New York, on June \_\_, 1998 at \_\_ P.M., or soon as counsel

may be heard, to consider and approve the Sale Agreement or any Accepted Offer; and it is further

ORDERED, that the \$150,000 Break-Up Fee payable to the Buyer in accordance with the terms of the Sale Agreement be, and it hereby is, approved; and it is further

ORDERED, that for cause shown and pursuant to Bankruptcy Rules 2002(a)(2) and 9006(c), Notice of the Application, Sale Agreement, the Bidding Hearing and the Sale Hearing shall be good and sufficient, if (1) service of a copy of this Order, the Application and its Exhibits by Federal Express or similar overnight courier is made on or before June \_\_, 1998 upon: (a) Carolyn S. Schwartz, United States Trustee for this District, Attn: Pamela J. Lustrin, Esq.; (b) the Committee, c/o Kensington & Ressler, I.L.C., L.L.C., Attn: Howard D. Ressler, Esq.; (c) the Debtor's twenty largest creditors; (d) the Buyer, c/o Zevnik Horton Guibord McGovern Palmer & Fagnani, L.L.P., 333 South Grand Avenue, Los Angeles, California 90071, Attn: Thomas James Wingard, Esq.; (e) Houlihan Lokey, 31 West 52nd Street, 11th Floor, New York, New York 10119, Attn: Mr. Michael Stewart; (f) all parties to the Debtor's unexpired real property leases and executory contracts; (g) Audrey Contente ("Contente") c/o Skadden, Arps, Slate, Meagher & Flom LLP, 919 Third Avenue, New York, New York 10022-3897, Attn: Michael L. Cook, Esq.; (h) Richard C. Potter, Double Arrow Ranch, Seeley Lake, Montana 59868 and c/o Nurture, Inc., 5840 Expressway, Missoula, Montana 59802; (i) Bruce F. Rose, 215706 Yorba Linda Boulevard, No. 202, Yorba Linda, California 92687; (j) Wendell W. Guthrie, 445 Daly

Avenue, Missoula, Montana 59801; (k) Randy S. Wills, 5331 White Cloud, Florence, Montana 59833; and upon (l) all parties having filed a Notice of Appearance in this case; (2) service of the Notice by first class mail is made on or before June \_\_\_\_\_ 1998 to: (a) all of the Debtor's known creditors; and (b) any known party which has expressed an interest in acquiring the Assets; and (3) publication of the Notice once in the Wall Street Journal (National edition) and if feasible, once in a trade publication that the Debtor and the Committee may, in their joint discretion, determine is likely to reach prospective bidders, is made not later than June 19, 1998; and it is further

**ORDERED**, that (i) itemized statements of any and all pre-petition defaults alleged by any non-debtor party to the Debtor's unexpired executory contracts or unexpired leases to be assumed and assigned; and (ii) objections, if any, to the relief sought by the Application: must be made in writing, must set forth the name of the non-debtor party, the nature and amount of any claims or interest held or asserted against the Debtor's estate or its property, the basis for such default or objection and the specific grounds therefor, and conform to the requirements of: (a) the Bankruptcy Code; (b) the Bankruptcy Rules; and (c) the Local Bankruptcy Rules, and be filed with the Bankruptcy Court, with copies delivered directly to Bankruptcy Judge Beatty's Chambers and to: (i) the Debtor c/o Togut, Segal & Segal, One Penn Plaza, New York, New York 10119, Attn: Neil Berger, Esq.; (ii) the Buyer c/o Zevnik Horton Guibord McGovern Palmer & Fagnani, L.L.P., 333 South Grand Avenue, Los Angeles, California 92101, Attn: Thomas James Wingard, Esq.; (iii) the

Committee c/o Kensington & Ressler, L.L.C., 400 Madison Avenue, New York, New York 10017-1910, Attn: Howard D. Ressler, Esq.; (iv) Houlihan Lokey, 31 West 52nd Street, 11th Floor, New York, New York 10119; and (v) the United States Trustee, 80 Broad Street, New York, New York 10004, Attn: Pamela J. Lustrin, Esq., so as to be filed and received not later than June \_\_\_\_\_, 1998 at 5:00 p.m.; and it is further

**ORDERED**, that objections, if any, which are not timely filed and served in accordance with the foregoing shall be forever barred and waived; and it is further

**ORDERED**, that the requirement under Local Bankruptcy Rule 9013-1(b) for the filing of a separate Memorandum of Law be, and it hereby is, dispensed with and waived; and it is further

[Concluded on Following Page]



ORDERED, that the Approval Hearing may be adjourned from time to time without further notice other than announcement of such adjournment at the Approval Hearing.

DATED: New York, New York  
June , 1990

---

HONORABLE PRUDENCE CARTER BEATTY  
UNITED STATES BANKRUPTCY JUDGE

NO OBJECTION:

OFFICIAL COMMITTEE OF UNSECURED  
CREDITORS,

By its attorneys,  
KENSINGTON & RESSLER, L.L.C.,  
By:

---

HOWARD D. RESSLER, Esq. (HDR-3881)  
A Member of the Firm

Togut, Segal & Segal  
 Attorneys for Debtor  
 and Debtor-in-Possession  
 One Penn Plaza  
 New York, New York 10119  
 Albert Togut (AT-9759)  
 Neil Berger (NB-3599)

UNITED STATES BANKRUPTCY COURT  
 SOUTHERN DISTRICT OF NEW YORK

In re:	X	:	Chapter 11 Case No.
ULTRAFEM, INC.,	:	:	98 B 42280 [PCB]
Debtor.	:	:	
Employer Tax Identification No. 33-0435037	:	:	
	X		

**ORDER (i) APPROVING SALE AGREEMENT BY AND  
 BETWEEN THE DEBTOR AND AKCESS PACIFIC GROUP LLC; (ii)  
 AUTHORIZING, PURSUANT TO §363 OF THE  
 BANKRUPTCY CODE, THE SALE OF SUBSTANTIALLY  
 ALL OF THE DEBTOR'S ASSETS FREE AND CLEAR OF LIENS,  
 CLAIMS AND ENCUMBRANCES; AND (iii) AUTHORIZING,  
 PURSUANT TO §365 OF THE BANKRUPTCY CODE, THE  
 ASSUMPTION AND ASSIGNMENT BY THE DEBTOR OF  
CERTAIN UNEXPIRED LEASES AND EXECUTORY CONTRACTS**

UPON the application (the "Application") of Ultrafem, Inc. (the "Debtor"), dated June \_\_\_, 1998, for the entry of an Order pursuant to §§363(b), (f) and (m), and 365(a) and (f) of the Bankruptcy Code, authorizing the Sale Agreement among the Debtor and Akcess Pacific Group LLC (the "Buyer"), dated June \_\_\_, 1998 (the "Sale Agreement"), a copy of which is annexed hereto as Exhibit "1", pursuant to which the Debtor has agreed to sell, subject to approval by this Court, its patent known as "Vaginal Discharge Collection Device and Intravaginal Drug

Delivery System", U.S. Patent No. 5,295,984 (the "Patent") and all of the Debtor's other patents, copyrights, trademarks, service marks, tradenames and all applications therefore, and all of the assets identified in the Schedule annexed hereto as Exhibit "2" and identified in the Sale Agreement (the "Assets"); and pursuant to the June \_\_\_\_ 1998 (the "Scheduling Order") Order (a) fixing the date, time and place of the hearing to approve the Sale Agreement (the "Approval Hearing"), (b) approving form and manner of notice thereof, and (c) setting the procedures for the submission of competing offers; and good and sufficient notice of the Application, the Bidding Hearing, the Approval Hearing, and the Sale Agreement (all as defined in the Scheduling Order) and the opportunity to file and serve objections and higher and better offers, having been given, as evidenced by Affidavits of Service and Affidavits of Publication filed with the Clerk of this Court, and no further notice being necessary; and upon the record of the Approval Hearing; and all parties in interest having been heard or having had the opportunity to be heard regarding the Application and approval of the Sale Agreement; and the Court having considered any and all competing offers, and having determined that such competing offers are not higher and better offers for the Assets; and the Court having considered any responses and objections to the Application, and having overruled any such objections; and upon the consent of the Committee; and good and sufficient cause being shown therefor; it is

**HEREBY FOUND that:**

1. This Court has jurisdiction over this proceeding pursuant to 28 U.S.C. §§1334 and 157(a). The Application is a core proceeding pursuant to 28 U.S.C. §157(b).
2. Good and sufficient notice of the Application, the Sale Agreement, the Bidding Hearing, and the Approval Hearing has been given by the Debtor pursuant to the Scheduling Order.
3. All objections to the Application and the entry of this Order are overruled and the Application is granted.
4. The Debtor is the owner of the Assets and the interests subject to the Sale Agreement including, without limitation, the Patent, known as: "Vaginal Discharge Collection Device and Intravaginal Drug Delivery System", U.S. Patent No. 5,295,984, and all of the Debtor's other patents, trademarks and other intellectual properties to be conveyed pursuant to the Sale Agreement ("Patents") and the Debtor is able to convey title to the Assets and the Patents to the Buyer pursuant to the terms of the Sale Agreement.
5. The Debtor is authorized to sell the Assets and the Patents to Akcess Pacific Group, LLC (the "Buyer") pursuant to the Sale Agreement.
6. The purchase of the Assets and the Patents by the Buyer and the Sale thereof by the Debtor, pursuant to this Order and the Sale Agreement, was negotiated in good faith and represent an arms' length transaction.

7. The sale of the Assets pursuant to the Sale Agreement is in the best interests of this estate and its creditors.

8. The terms of the Sale Agreement reflect the Debtor's prudent business judgment under the relevant circumstances.

9. The claims asserted against the Patents by Audrey Contente are the subject of a *bona fide* dispute.

10. The Debtor has satisfied the requirements of §§363(f) and 365(a) and (b) of the Bankruptcy Code.

**IT IS HEREBY ORDERED that:**

A. Pursuant to §§363(b), (f) and 365 of the Bankruptcy Code, the Debtor is authorized to consummate the transactions contemplated under the Sale Agreement, and transfer the Assets and the Patents to the Buyer free and clear of all mortgages, security interests, charges, encumbrances, liens, assessments, covenants, claims, interests, title defects, pledges, and burdens of every kind whatsoever including, without limitation, any and all claims with respect to the Patents and any royalties therefrom asserted by Audrey Contente in the action pending in the United States District Court for the Southern District of New York, Case No. 98 Civ. 0912 or otherwise (collectively, "Liens").

B. Any Liens that encumber or purport to encumber the Assets shall be transferred to and attach to the proceeds of the Assets with the same

force, validity, priority and effect, if any, as they had against the Assets and subject to the further order of this Court.

C. In the event that any Person or Entity (as those terms are defined in the Bankruptcy Code) which has filed statements or other documents or agreements evidencing Liens on or interests in the Assets has not delivered to the Debtor prior to the Closing, in proper form for filing and executed by the appropriate parties, assignment statements, termination statements, instruments of satisfaction, releases of liens, and other documents for the purpose of documenting the release of all Liens, or other interests which such person or entity has with respect to the Assets, the Debtor is authorized and directed to execute and file such statements, instruments, releases, and other documents on behalf of the person or entity with respect to the Assets.

D. At the Closing, the Buyer is authorized and directed to assume and pay, or otherwise satisfy in full in accordance with their terms or such other terms agreed to by and between the Buyer and such other parties, the Assumed Liabilities (as defined in the Sale Agreement), and the Debtor is permanently relieved of any and all obligations on account of the Assumed Liabilities and all persons or entities who have asserted or may assert a claim on account of any of the Assumed Liabilities are permanently barred from asserting such claim against the Debtor.

E. Upon the Closing, the Buyer shall not be deemed to (i) be the successor of the Debtor, (ii) have, de facto or otherwise merged with or into the Debtor, or (iii) be a continuation or substantial continuation of the Debtor or the enterprise of the Debtor.

F. Except to the extent otherwise expressly provided in the Sale Agreement and this Order, at the Closing, the Buyer shall not assume any liability or obligation of the Debtor of any kind, character or description whether known or unknown, absolute or contingent, accrued or unaccrued, liquidated or unliquidated, secured or unsecured, joint or several, due or to become due, vested or unvested, executory, determined, determinable or otherwise, and whether or not the same is required to be accrued on the financing statements of the holder of the liability or obligation.

G. Upon the Closing, the Buyer will pay to the Debtor the Purchase Price in full (as defined in the Sale Agreement).

H. The Debtor is hereby granted a valid and perfected first priority lien and security interest in and against all of the Patents (the "Debtor Lien") in the amount of \$2,500,000, and the Debtor Lien be, and it hereby is, perfected and effective as of the date hereof, without the necessity of the filing or recordation of any document or other notice. Notwithstanding the foregoing, the Debtor may record a copy of this Order with any recording officer that it may deem necessary or

appropriate to evidence, perfect or give notice of the Debtor Lien, and the Buyer shall execute any and all documents which the Debtor reasonably requests with respect to the Debtor Lien, including, but not limited to, evidencing and/or recording the Debtor Lien.

I. This Court shall retain jurisdiction over the Debtor and the Buyer, including, without limitation, jurisdiction to resolve any disputes, claims, or actions which may arise in connection with the Sale Agreement and any other agreements or instruments executed in connection therewith, the transactions contemplated under the Sale Agreement and such other agreements and instruments and for the purpose of enforcing the terms and provisions of this Order.

J. The Debtor is authorized and directed to execute, acknowledge, and deliver such corporate name change certificates, deeds, assignments, conveyances, and other assurances, documents, and instruments of transfer and take such other action that may be reasonably necessary to perform the terms and provisions of the Sale Agreement and related agreements, and shall take any other action that may reasonably be requested by the Buyer for purposes of assigning, transferring, granting, conveying, and confirming to the Buyer, or reducing to possession, any or all of the Assets and the Patents and to execute such nonmaterial amendments to the Sale Agreement and related agreements as may be required to effectuate the Sale Agreement and the consummation of the purchase and sale.



K. For each of the Assets consisting of or related to leasehold interests in property owned by others, the conveyance, assignment, transfer, and delivery thereof to the Buyer shall be subject to all of the rights and interests of the owner of the leased property other than rights not enforceable under §365 of the Bankruptcy Code.

L. From and after entry of this Order, the Debtor shall not take or cause to be taken any action which would interfere with the transfer of the Assets to the Buyer or its assignees or designees in accordance with the terms of this Order.

M. All persons or entities who are presently, or at the Closing (as defined in the Sale Agreement), in possession of any of the Assets are hereby directed to surrender possession of such Assets to the Buyer or its assignees or designees at the Closing.

N. From and after the Closing, the Buyer shall have the right and authority, subject to the terms of the Sale Agreement, to collect for the account of the Buyer any sums which shall be due and payable on account of any of the Assets transferred or intended to be transferred to the Buyer at the Closing and to endorse with the name of the Debtor any checks or drafts relating to the Assets which may be payable to the order of the Debtor; provided, however, that the disposition of any such sums and any such checks shall be in accordance with the terms of the Sale Agreement.

O. At or prior to the Closing, the Seller shall pay or cause to be

paid any and all transfer, stamp or other similar taxes and any filing or recording fees payable as a result of the sale or transfer of the Assets and the assumption and assignment of the Assumed Liabilities (as defined in the Sale Agreement).

P. The Debtor may, at a time and in a manner satisfactory to the Buyer, in its sole discretion, execute and deliver whatever lawful agreements that are reasonably necessary and make whatever lawful arrangements that are reasonably required to assure the transfer of the Assets free and clear of any claims by any governmental unit for taxes incurred as a consequence of the sale of any of the Assets under the terms of the Sale Agreement or to relieve the Buyer from any claim for transferee liability with respect to such taxes.

Q. Pursuant to §365(f) of the Bankruptcy Code, conditioned upon the closing of the transactions contemplated by the Sale Agreement, all obligations under executory contracts and unexpired leases listed in schedules of the Sale Agreement shall be assumed by the Debtor and assigned to the Buyer, without the execution of any further documents or instruments. Unless the other parties to such unexpired leases or executory contracts shall have waived their rights to receive a cure of any pre-petition defaults, the Debtor shall cure all defaults under such executory contracts or unexpired leases within thirty (30) days after the Closing, and this Court shall retain jurisdiction to hear and determine any and all disputes in connection therewith. Upon the Closing, the Debtor shall have no further obligations under such executory contracts or expired leases pursuant to §365(k) of the Bankruptcy Code.

R. The provisions of this Order authorizing the Debtor to enter into the Sale Agreement and authorizing and directing the transactions contemplated by the Sale Agreement shall be self-executing and neither the Debtor nor the Buyer shall be required to execute or file any releases, termination statements, assignments, consents, or other instruments to effectuate consummation to implement the foregoing provisions hereof except as provided in the Sale Agreement and this Order. Notwithstanding the foregoing, the Debtor, Buyer and all other parties are authorized and directed to take any and all actions necessary and appropriate to effectuate, consummate, and implement fully the Sale Agreement.

S. The Buyer is a purchaser in good faith of the Assets and is entitled to the protection afforded by §363(m) of the Bankruptcy Code.

T. This Order is binding upon and inures to the benefit of any successors or assigns of the Debtor or the Buyer, including any trustee appointed in this case or any subsequent case of the Debtor under Chapter 7 of the Bankruptcy Code.

U. This Order is a final, appealable order.

DATED: New York, New York  
June , 1998

HONORABLE PRUDENCE CARTER BEATTY  
UNITED STATES BANKRUPTCY JUDGE

**EXHIBIT "2"**

**ULTRAPEM, INC.**  
**Debtor-in-Possession**  
**Chapter 11**  
**Case No. 98 B 42280 [PCB]**

**SCHEDULE OF ASSETS TO BE CONVEYED PURSUANT TO SALE AGREEMENT**

1. All patents, copyrights, trademarks, service marks, and trade names, and all applications therefor, whether U.S. or foreign, and franchises, goodwill and other intangible property including but not limited to, product formulas, research and development, trade secrets and know how, including, without limitation, the Debtor's patent known as "Vaginal Discharge Collection Device and Intravaginal Drug Delivery System", U.S. Patent No. 5,295,984;
2. All machinery, equipment, furniture, office equipment, other fixed assets, tools and molds, equipment and material tangible personal property owned by the Debtor and useful or used in the operation of its business wherever located including the Assets located at the Debtor's plant and warehouse in Missoula, Montana and its offices in New York City, and any assignable third party warranties;
3. All existing inventory, finished goods and work-in-progress, and related raw materials, boxes, packaging and other materials and supplies and any assignable third party warranties;
4. All fixtures and improvements, including work-in-progress, if any, owned by the Debtor and located in and on the real property leased by the Debtor and used or useful in the operation of its business and any assignable third party warranties;
5. All of the other fixed and other tangible property owned by the Debtor or useful in the operation of its business, and replacements thereof and improvements thereto;
6. All open trade accounts receivable, unbilled orders, and contract rights relating to the sale of the Product existing as of the Closing Date;
7. All records relating to regulatory filings, inspection reports and correspondence relating thereto, including but not limited to 510(k) application(s) sales, distribution, advertising and marketing, including all market research, artwork, advertising, marketing concepts, marketing materials and market measurement data associated with the Product, and the Debtor's files, logs and other records, including accounting records specifically relating to the operation of the Debtor's

business, as Buyer may reasonably require, but not including any corporate or accounting books or records of the Debtor;

8. To the extent assignable, the rights of the Debtor under or to the contracts, licenses, leases and agreements listed in Schedule 1.3 of the Sale Agreement in effect on the Closing Date relating to the operation of the Business and the Assets (other than agreements with employees) including confidentiality agreements, non-disclosure agreements and non-compete agreements, and any renewals or extensions thereof; and

9. All of the Debtor's right, title and interest in and to the name "Ultrafem" and the business now known as Ultrafem, Inc., which engages in the manufacture, distribution and sale of the Product.

## **EXHIBIT D**

Registration No. 33-97960

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## AMENDMENT NO. 4

TO  
FORM S-1

REGISTRATION STATEMENT  
UNDER  
THE SECURITIES ACT OF 1933

### ULTRAFEM, INC.

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation or organization)

3841  
(Primary standard industrial  
classification code number)

33-0435037  
(I.R.S. employer  
identification no.)

PROCESSED BY

207-156: P L10  
FEB 22 1996

500 Fifth Avenue, Suite 3620  
New York, New York 10110  
(212) 575-5740

(Address, including zip code, and telephone number,  
including area code, of registrant's principal executive offices)

John W. Andersen  
President and Chief Executive Officer  
Ultrafem, Inc.  
500 Fifth Avenue, Suite 3620  
New York, New York 10110  
(212) 575-5740

DISCLOSURE  
INCORPORATED

(Name, address, including zip code, and telephone number, including area code, of agent for service)

#### Copies to:

Gerald Adler, Esq.  
Shereff, Friedman, Hoffman &  
Goodman, LLP  
919 Third Avenue  
New York, New York 10022  
(212) 758-9500

Richard Marlin, Esq.  
Kramer, Levin, Naftalis, Nessen,  
Kamin & Frankel  
919 Third Avenue  
New York, New York 10022  
(212) 715-9100

Approximate date of commencement of proposed sale to the public:  
As soon as practicable after this Registration Statement becomes effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐


If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. ☐

#### CALCULATION OF REGISTRATION FEE

Amount and Title of Each Class of Securities to be Registered	Amount to be Registered	Proposed Maximum Offering Price Per Security (1)	Proposed Maximum Aggregate Offering Price	Amount of Registration Fee (2)
Common Stock, \$0.001 par value . . . . .	8,176,867(3)	\$10	\$81,768,670	\$28,196.09

- (1) Estimated solely for purposes of calculating the registration fee.  
(2) In Amendment No. 3 to the Registration Statement, the Company registered 7,686,867 shares of Common Stock. The registration fee being submitted with this Amendment No. 4 is for the additional 490,000 shares of Common Stock which are being registered hereby.  
(3) Includes 4,286,867 shares of Common Stock which may be sold by certain Selling Stockholders, and 510,000 shares of Common Stock issuable upon exercise of an option granted to the Underwriters to cover over-allotments.

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.



THERE ARE A TOTAL OF 207 PAGES CONTAINED IN THIS MANUALLY SIGNED ORIGINAL AND ANY EXEMPT OR AT-A-GLANCE HEREIN. WE EXHIBIT INDEX PAGE 44 CONTAINED ON PAGE 1544 OF THIS DOCUMENT

**EXHIBIT 10.55**



**LICENSE, RESEARCH AND PRODUCT DEVELOPMENT AGREEMENT**

THIS AGREEMENT by and between Ultrafem, Inc., a Delaware corporation ("Ultrafem"), and ReProtect, LLC, a Maryland limited liability company ("ReProtect"), is made as of this 8th day of February, 1996 (hereinafter referred to as the "Agreement").

**WITNESSETH:**

WHEREAS, Ultrafem is the owner of United States Patent Number 5,295,984 entitled "Vaginal Discharge Collection Device and Intravaginal Drug Delivery System" which may be used for reproductive health and related products using the feminine hygiene device (the "Feminine Cup") as a vaginal delivery mechanism for vaginal treatment and protection;

WHEREAS, ReProtect desires to conduct research and development of different applications and uses of the Feminine Cup as a vaginal delivery mechanism for vaginal treatment/protection, contraception, prevention of sexually transmitted diseases, and topical and systemic therapies during and not during menstruation;

WHEREAS, Ultrafem and ReProtect desire to enter into this Agreement to facilitate the research, development and marketing of the Feminine Cup for various applications;

WHEREAS, ReProtect is the owner of an invention (the "Acidic Buffer") covered by a patent application filed June 29, 1994 entitled "A Device and Method for Acidic Buffering," that discloses an "Absorbent Buffer" and a "Buffer Gel";

WHEREAS, Ultrafem desires to license the Acidic Buffer and certain other intellectual property owned by ReProtect for certain applications;

WHEREAS, the parties intend to develop a long-term mutually beneficial relationship;

NOW, THEREFORE, in consideration of the foregoing and of the respective covenants and agreements contained herein, and with the intention of being legally bound hereby, the parties agree as follows:

**I. OBLIGATIONS OF THE PARTIES**

**(a) ReProtect.**

(i) ReProtect shall devote a significant amount of its time and effort to the research and development of different applications and uses of the Feminine Cup, including, without limitation, long-range research. Such applications and uses shall include, without limitation, vaginal delivery mechanisms for vaginal treatment/protection, contraception,

prevention of sexually transmitted diseases, including AIDs ("STD"), and topical and systemic therapies, both during and not during menstruation. Without limiting the foregoing, ReProtect agrees to consult with Ultrafem and make such presentations as Ultrafem shall request to Ultrafem's potential customers, suppliers, investors, strategic partners and others, provided, that, Ultrafem shall give ReProtect reasonable advance notice of the date and time of such presentations and shall pay the reasonable actual costs of travel and lodging. ReProtect hereby grants Ultrafem the exclusive worldwide perpetual license to develop, use, market, sell, sub-license, sub-contract, manufacture, distribute and otherwise commercially exploit all of ReProtect's right, title and interest in and to all technology, know-how, inventions, discoveries, ideas, innovations, concepts, information, data, and/or products and/or applications thereof, whether or not patentable, to the extent that such items are physical components of or improvements which are applied in the manufacturing process to the Feminine Cup, and which arise out of or result from the research and development performed in accordance with the terms of this Agreement.

(ii) In addition to and without limiting the provisions of paragraph I(a)(i), ReProtect hereby grants Ultrafem the exclusive worldwide perpetual license to develop, use, market, sell, sub-license, sub-contract, manufacture, distribute and otherwise commercially exploit all of its right, title and interest in and to the Acidic Buffer to the extent it is applied in the manufacturing process to, or become physical components of or improvements which are applied in the manufacturing process to, the Feminine Cup, including, without limitation, the acidic buffer gel and/or absorptive acidic buffer claimed in the Acidic Buffer invention when included as a component of the Feminine Cup. At such time as it can do so under law, Ultrafem shall and/or shall cause its successors, assignees, subsidiaries or licensees to use reasonable best efforts to produce, manufacture, develop, bring to market, sell and/or commercially exploit the Feminine Cup with the Acidic Buffer. The license granted by this paragraph I(a)(ii) is sometimes referred to herein as the "Cup License."

(iii) In addition to and without limiting the provisions of paragraph I(a)(i) and (ii), ReProtect hereby grants Ultrafem the worldwide perpetual license to develop, use, market, sell, sub-license, sub-contract, manufacture, distribute and otherwise commercially exploit all of its right, title and interest in and to that portion of the Acidic Buffer which is not a vaginal device (the "Gel") (without the Feminine Cup or other vaginal device) solely for vaginal applications or uses. The license granted by the prior sentence shall be a non-exclusive license in the countries listed on Schedule I(a)(iii) hereto and exclusive in all other countries, territories and jurisdictions. In countries where the license is non-exclusive, each of ReProtect and Ultrafem shall have the right to market the Gel. The parties agree that they shall keep each other informed with respect to their plans to market and their marketing the Gel in such non-exclusive countries and to cooperate with each other in the countries where the license is non-exclusive to allow ReProtect to achieve the goal of making the Gel available to women worldwide, especially in the non-exclusive countries where clinical trials have been conducted, and to allow Ultrafem to achieve the maximum profit from commercially exploiting the Gel. The parties agree that they shall in good faith consider any request to remove a country from the non-exclusive license and either add such country to the exclusive license or remove such

country from the non-exclusive license granted Ultrafem in view of their respective goals set forth in the prior sentence. Either party can make a request to remove a country from the non-exclusive license as provided in the preceding sentence. In the event that within 90 days after any such written request, the parties cannot agree on the status of the non-exclusive license in such country, then the dispute shall be submitted to arbitration (x) in accordance with the procedures set forth in paragraph V(c); and (y) in which arbitration, the arbitrators shall consider the respective goals of the parties set forth in this paragraph. At such time as it can do so under law, subject to the last sentence of paragraph IV(e)(2), Ultrafem shall and/or shall cause its successors, assignees, subsidiaries or licensees to use reasonable best efforts to produce, manufacture, develop, bring to market, sell and/or commercially exploit the Gel. The license granted by this paragraph I(a)(iii) is sometimes referred to herein as the "Gel License."

(b) Ultrafem.

(i) In consideration of ReProtect's research and development activities contemplated by paragraph I(a)(i) above and the license granted by such paragraph I(a), Ultrafem shall pay ReProtect, such payments to accrue commencing with the date that the Ultrafem Board of Directors approves this Agreement and the first such payment to be made on the third business day after consummation of Ultrafem's initial public offering (the "First Payment Date") and thereafter such payments shall be made on the first business day of each month thereafter until the end of the Term (as defined below) \$40,000, provided, however, that the monthly amount payable pursuant to this paragraph I(b)(i) shall increase to \$83,300 (or more in Ultrafem's sole discretion) commencing with the first business day of the month immediately following any month in which Ultrafem consummates one or more debt or equity financings, the gross proceeds of which, when added to the gross proceeds of all other debt and equity financings consummated by Ultrafem after the date hereof, results in aggregate gross proceeds of at least \$25 million.

(ii) In consideration of the license granted to it in paragraph I(a)(ii) above, Ultrafem (1) shall pay ReProtect by check payable to its order on the First Payment Date \$100,000, (2) grants ReProtect the options set forth in this paragraph I(b)(ii) and (3) shall pay ReProtect the royalties set forth in this paragraph I(b)(ii). Ultrafem hereby grants ReProtect options to purchase the number of shares of Common Stock, par value \$.001 per share, of Ultrafem set forth below, exercisable commencing with the events described below and which shall have the additional terms and conditions set forth below and in Annex I(b)(ii) hereto:

<u>Number of Shares</u>	<u>Date or Event On or After Which Shares May be Purchased Pursuant to the Option</u>
50,000	On or after the date hereof. (Initial Exercise Price - \$8 per share, provided however that such exercise price shall be reduced to \$6 per share upon consummation of Ultrafem's initial public offering)
50,000	On or after the date of the issuance to ReProtect of a patent for the Acidic Buffer (Initial Exercise Price - \$8 per share, provided however that such exercise price shall be reduced to \$6 per share upon consummation of Ultrafem's initial public offering)

50,000

Options for the number of shares set forth opposite such milestone shall be exercisable on or after the date each of the following milestones is met with respect to a product to be submitted for regulatory approval as a contraceptive product (the "Contraceptive Cup") utilizing the Acidic Buffer (with or without Nonoxynol-9 ("N-9")) combined with the Feminine Cup (initial exercise price - \$8 per share):

- a. 10,000 shares - Initiation of U.S. safety (Phase I) trial approved by the U.S. Food and Drug Administration (the "FDA") of the Contraceptive Cup in humans;
- b. 10,000 shares - Completion of U.S. efficacy (Phase II) trials approved by the FDA in humans of the Contraceptive Cup;
- c. 10,000 shares - Obtaining United States regulatory approval for marketing the Contraceptive Cup;
- d. 10,000 shares - Market introduction of the Contraceptive Cup;
- e. 10,000 shares - Finalizing a strategic alliance with a third party for the Contraceptive Cup.

50,000

Options for the number of shares set forth opposite such milestone shall be exercisable on or after the date each of the following milestones is met with respect to a product to be submitted for regulatory approval as a prophylactic product for protection against STDs (including AIDs) ("STD Cup") that uses an Acidic Buffer combined with the Feminine Cup (with or without N-9) that may or may not be identical with the Contraceptive Cup (initial exercise price - \$8 per share):

- a. 10,000 shares - Initiation of U.S. safety (Phase I) trial approved by the FDA of the STD Cup in humans;
- b. 10,000 shares - Completion of U.S. efficacy (Phase II) trials approved by the FDA in humans of the STD Cup;
- c. 10,000 shares - Obtaining United States regulatory approval for marketing the STD Cup;
- d. 10,000 shares - Market introduction of the STD Cup;
- e. 10,000 shares - Finalizing a strategic alliance with a third party for the STD Cup.

25,000

Options for the number of shares set forth opposite such milestone shall be exercisable on or after the date each of the following milestones is met with respect to a product to be submitted for regulatory approval as a therapeutic product for treating and/or preventing vaginal yeast infections or bacterial vaginosis (the "Therapy Cup") that uses an Acidic Buffer with or without pharmaceutical agents combined with the Feminine Cup and that may or may not be identical with the Contraceptive Cup or STD Cup (initial exercise price - \$8 per share):

- a. 5,000 shares - Initiation of U.S. safety (Phase I) trial approved by the FDA of the Therapy Cup in humans;
- b. 5,000 shares - Completion of U.S. efficacy (Phase II) trials approved by the FDA in humans of the Therapy Cup;
- c. 5,000 shares - Obtaining United States regulatory approval for marketing the Therapy Cup;
- d. 5,000 shares - Market introduction of the Therapy Cup;
- e. 5,000 shares - Finalizing a strategic alliance with a third party for the Therapy Cup.

If any of the milestones are deleted by Ultrafem, in its sole discretion, the options subject to such milestone shall vest proportionately with and at such times as the other milestones in such

category are met. In the event the milestone relating to obtaining United States regulatory approval for marketing a product is achieved, all other milestones in such category, other than one-half of the options relating to a strategic alliance (options for 5,000 shares or 2,500 shares, as the case may be) and all of the options relating to market introduction (options for 10,000 shares or 5,000 shares, as the case may be), shall vest. The parties may at any time or from time to time alter the milestones by mutual agreement. All of the above options shall become exercisable, regardless of whether any of the events set forth above have occurred, upon a Change of Control (as such term is defined in Annex I(b)(ii) hereto) of Ultrafem. All options that are not exercisable upon expiration of the Term shall become exercisable upon the expiration of the Term. All of these options shall finally expire ten years and six months after the First Payment Date. Except as expressly set forth above, the initial exercise price ("Exercise Price") of the options shall be \$8 per share, subject to adjustment as provided in Annex I(b)(ii) hereto.

Ultrafem shall pay ReProtect royalties in an amount equal to \$.01 (one cent) for each unit of the Feminine Cup, which includes the Acidic Buffer as a component or improvement, sold by Ultrafem, its successors, assigns, subsidiaries, or licensees (which licensees are manufacturing the Feminine Cup with Acidic Buffer). The terms of paragraph I(c) shall apply to the royalties provided for in this paragraph as if fully set forth herein.

(iii) In consideration of the license granted to it in paragraph I(a)(iii) above, Ultrafem (1) shall pay ReProtect by check payable to its order on the First Payment Date \$100,000, (2) grants ReProtect the options set forth in this paragraph I(b)(iii) and (3) shall pay ReProtect the royalties set forth in this paragraph I(b)(iii). Ultrafem hereby grants ReProtect options to purchase the number of shares of Common Stock, par value \$.001 per share, of Ultrafem set forth below, exercisable commencing with the events described below and which shall have the additional terms and conditions set forth below and in Annex I(b)(ii) hereto:

<u>Number of Shares</u>	<u>Date or Event or After Which Shares May be Purchased Pursuant to the Option</u>
50,000	On or after the date hereof.
50,000	Options for the number of shares set forth opposite such milestone shall be exercisable on or after the date each of the following milestones is met with respect to the use of the Gel (without a vaginal device other than an applicator) as a contraceptive product (the "Contraceptive Gel"):
	a. 10,000 shares - Initiation of U.S. safety (Phase I) trial approved by the FDA of the Contraceptive Gel in humans;
	b. 10,000 shares - Completion of U.S. efficacy (Phase II) trials approved by the FDA in humans of the Contraceptive Gel;
	c. 10,000 shares - Obtaining United States regulatory approval for marketing the Contraceptive Gel;
	d. 10,000 shares - Market introduction of the Contraceptive Gel;
	e. 10,000 shares - Finalizing a strategic alliance with a third party for the Contraceptive Gel.



50,000

Options for the number of shares set forth opposite such milestone shall be exercisable on or after the date each of the following milestones is met with respect to the use of the Gel (without a vaginal device other than an applicator) as a prophylactic product for protection against STDs (including AIDS) ("STD Gel") that may or may not be identical with the Contraceptive Gel:

- a. 10,000 shares - Initiation of U.S. safety (Phase I) trial approved by the FDA of the STD Gel in humans;
- b. 10,000 shares - Completion of U.S. efficacy (Phase II) trials approved by the FDA in humans of the STD Gel;
- c. 10,000 shares - Obtaining United States regulatory approval for marketing the STD Gel;
- d. 10,000 shares - Market introduction of the STD Gel;
- e. 10,000 shares - Finalizing a strategic alliance with a third party for the STD Gel.

25,000

Options for the number of shares set forth opposite such milestone shall be exercisable on or after the date each of the following milestones is met with respect to the use of the Gel (without a vaginal device other than an applicator) as a therapeutic product for treating and/or preventing vaginal yeast infections or bacterial vaginosis (the "Therapy Gel" (that may or may not be identical with the Contraceptive Gel));

- a. 5,000 shares - Initiation of U.S. safety (Phase I) trial approved by the FDA of the Therapy Gel in humans;
- b. 5,000 shares - Completion of U.S. efficacy (Phase II) trials approved by the FDA in humans of the Therapy Gel;
- c. 5,000 shares - Obtaining United States regulatory approval for marketing the Therapy Gel;
- d. 5,000 shares - Market introduction of the Therapy Gel;
- e. 5,000 shares - Finalizing a strategic alliance with a third party for the Therapy Gel.

If any of the milestones are deleted by Ultraferm, in its sole discretion, the options subject to such milestone shall vest proportionately with and at such times as the other milestones in such category are met. All of the above options shall become exercisable, regardless of whether any of the events set forth above have occurred, upon a Change of Control (as such term is defined in Annex I(b)(ii) hereto) of Ultraferm. All options that are not exercisable upon expiration of the Term shall become exercisable upon the expiration of the Term. All options shall finally expire ten years and six months after the First Payment Date. The initial exercise price of the options shall be \$8 per share, subject to adjustment as provided in Annex I(b)(ii) hereto. In the event the milestone relating to obtaining United States regulatory approval for marketing a product is achieved, all other milestones in such category, other than one half of the options relating to a strategic alliance (options for 5,000 shares or 2,500, as the case may be) and all of the options relating to market introduction (options for 10,000 shares or 5,000, as the case may be), shall vest. The parties may at any time or from time to time alter the milestones by mutual agreement.

Ultrafem shall pay ReProtect royalties equal to 5% of Net Sales derived from the sale of the Gel without the Feminine Cup or other vaginal device (other than an applicator) with respect to which patents have been issued and 3% of Net Sales derived from such product with respect to which patents have not been issued. "Net Sales" as used herein, shall mean the total invoiced amount of all sales by Ultrafem or its licensee (which is either the primary manufacturer or primary distributor of the product) or assignee (which is either the primary manufacturer or primary distributor of the product) of the Gel without the Feminine Cup or other vaginal device (other than an applicator), less cash and trade discounts, returns, allowances, free goods, and replacements, taxes applicable to such sales, and governmental charges assumed and delivery charges borne by Ultrafem or such licensee or assignee. If the Gel is marketed in the same package as the Feminine Cup or other device but not as an integral part of the Feminine Cup or other device then Net Sales shall be based on that portion of Net Sales attributable to the Gel alone. The terms of paragraph I(c) shall apply to such royalties as if fully set forth herein.

(c) All royalties provided for in paragraph I(b) shall be due and payable during the Term or any time thereafter, it being expressly understood that upon termination of this Agreement, Ultrafem may in its sole discretion continue any or all of the licenses granted hereunder to the extent set forth in Paragraph IV(d) below by paying the Royalties due hereunder. Royalties shall be paid within 30 days after the end of each calendar quarter, which payment shall be accompanied by a statement setting forth the number of units sold during such calendar quarter and a calculation of the Royalties due to ReProtect in respect thereof. Ultrafem shall keep complete and accurate books of account and records covering all sales of units of the Feminine Cup with Acidic Buffer and/or units of the Acidic Buffer without the Feminine Cup. ReProtect and its duly authorized representatives shall have the right, during normal business hours and upon reasonable advance notice and without interrupting Ultrafem's business, at any time during the Term and thereafter, to examine and copy such books of account and records and all other materials as may be reasonably necessary or appropriate to verify the information contained in the royalty statements submitted to ReProtect pursuant to this Agreement. In the case of any deviation of Royalties versus reported Royalties, Ultrafem shall pay any Royalties due within ten days, with interest thereon from the date such Royalties were due through and including the date of payment, at and changing with the rate announced from time to time by, Citibank N.A. at its principal office in New York City as its "prime rate," plus 2%, and, if such deviation exceeds 5%, Ultrafem shall pay the reasonable costs of such examination. All books of account and records relating to a particular calendar year shall be kept available for inspection as provided herein for at least two years after the end of such year.

(d) In the event Ultrafem determines, as a consequence of consumer research, regulatory requirements, the manufacturing process or otherwise, to market the Acidic Buffer as part of the same package as a Feminine Cup, and as a result royalties would be due under both paragraphs I(b)(ii) and I(b)(iii), then ReProtect shall, within 30 days after it receives notice from Ultrafem, decide whether royalties on such product are payable under paragraph I(b)(ii) or I(b)(iii); it being the parties agreement that Ultrafem shall be responsible for paying royalties for a product pursuant to paragraph I(b)(ii) or I(b)(iii) but not both.

(e) Ultrafem shall use its best efforts, subject to its fiduciary duties, to nominate and recommend for election a person designated by ReProtect who shall be a principal of ReProtect to serve on Ultrafem's Board of Directors (the "Board") for each year during the Term, except that Ultrafem shall not be required to so nominate a designee if such representative's term is not then up for reelection. ReProtect's initial designee is Dr. Richard Cone.

(f) Ultrafem agrees that it will pursue the development and marketing of a Contraceptive Cup prior to pursuing the development and marketing of either the STD Cup or Therapy Cup.

(g) Ultrafem confirms that it intends to market the Gel worldwide through one or more of the following distribution channels: private distribution, commercial distribution and/or governmental distribution. Such marketing and distribution may be accomplished with or without one or more strategic partners, depending on the territory. Ultrafem will act reasonably in considering any request by ReProtect to delete one or more specific countries from the worldwide license granted hereby. However, Ultrafem shall not be obligated to do so.

(h) Ultrafem and ReProtect have a mutual interest in developing a method (possibly through one or more charitable foundations) of allocating a portion of profits derived from the sale of products which use the licenses granted under this Agreement in developed markets for the benefit of women in underdeveloped commercial markets. The parties agree to consider developing such a mutually agreeable method which would require the financial participation of each of them on a mutually agreeable basis to be determined as well as a mutually agreeable definition of those who will benefit from such allocation.

## II. OWNERSHIP OF INTELLECTUAL PROPERTY

Each of ReProtect and Ultrafem shall own an undivided one-half interest in any and all products, processes, technologies and inventions, including, without limitation, new contributions, improvements, discoveries and applications conceived, developed, invented, made or found by ReProtect which are related in any way or arise out of ReProtect's activities (i) pursuant to paragraph I(a) of this Agreement, whether or not patentable, that are physical components of or improvements which are applied in the manufacturing process to the Feminine Cup; or (ii) which are included on a Budget (as defined in paragraph VI(a) of this Agreement) and with respect to which some funds have been expended. ReProtect shall own any and all products, inventions and/or technology used without the Feminine Cup made solely by a ReProtect employee subject to any interest of JHU (as defined herein) and subject to Ultrafem's rights pursuant to paragraphs I and V of this Agreement. Ultrafem shall own any and all products, inventions and/or technology made solely by Ultrafem employees, whether or not related to the Feminine Cup, which shall not be subject to this Agreement.



### III. JHU AGREEMENT

(a) ReProtect shall maintain an agreement (which agreement shall be reasonably acceptable to Ultrafem) with Johns Hopkins University ("JHU") throughout the Term of this Agreement. ReProtect's agreement with JHU shall include the following terms:

(1) ReProtect shall be granted access and use of a laboratory and office facilities at JHU which shall be adequate in the reasonable opinion of ReProtect and Ultrafem for the performance of ReProtect's obligations pursuant to paragraph I(a) of this Agreement.

(2) Rights to and ownership of intellectual property shall be treated as provided under the caption "Intellectual Property" in the Research Agreement referred to in paragraph III(c) below.

(b) ReProtect's interest in any items jointly owned by it and JHU or licensed by it from JHU or with respect to which it has a right of first negotiation, to the extent such items if they had existed as of the date hereof would have been subject to the licenses granted under paragraph I(a) of this Agreement, shall become subject to the licenses granted by ReProtect pursuant to paragraph I(a) of this Agreement.

(c) Ultrafem acknowledges that the Agreement between JHU and ReProtect dated September 12, 1995, a copy of which is annexed as Exhibit III hereto, is acceptable to Ultrafem.

### IV. TERM

(a) This Agreement shall commence as of the date hereof and shall terminate on the tenth anniversary of the First Payment Date (the "Term") unless terminated sooner in accordance with the provisions of this paragraph IV.

(b) This Agreement shall terminate prior to the tenth anniversary of the First Payment Date at any time upon ninety (90) days prior written notice given by Ultrafem to ReProtect.

(c) This Agreement shall terminate prior to the tenth anniversary of the First Payment Date upon ninety (90) days prior written notice given by ReProtect to Ultrafem, provided however that ReProtect shall have the right to give such notice only within thirty (30) days after the occurrence of one of the following events:

(1) Ultrafem does not consummate an initial public offering or raise aggregate gross proceeds of \$20 million or more in equity and debt financings after the date hereof and on or before June 30, 1996, provided, however that the \$100,000 due pursuant to paragraph I(b)(ii), the \$100,000 due pursuant to paragraph I(b)(iii) and all amounts accrued pursuant to paragraph I(b)(i) which have not been paid shall be payable to ReProtect on the date of termination;

(2) Ultrafem does not commence the initial marketing of the Feminine Cup as a feminine protection product in the United States or Europe on or before June 30, 1997; or

(3) Ultrafem fails to make the payments due under paragraph I(b)(i) hereof and such failure continues for a period of 90 days after written notice has been received by Ultrafem from ReProtect.

(d) The monthly payments provided for in paragraph I(b)(i) of this Agreement shall continue after the date of termination of the Term as a result of termination by Ultrafem for a period of six months. In addition, upon termination of this Agreement for any reason, Ultrafem shall have the right, in its sole discretion, to continue the licenses granted by ReProtect pursuant to paragraph I(a) hereof with respect to any or all inventions, products, uses or applications which at the date of such termination are licensed by ReProtect to Ultrafem hereunder and either (i) with respect to which an application has been submitted to the FDA regarding Phase II clinical trials or (ii) which are being marketed by Ultrafem anywhere in the world, in consideration of the payment by Ultrafem to ReProtect of the royalties provided in this Agreement with respect to such product.

(e) ReProtect shall have the right to terminate the license of a particular product granted by this Agreement upon ninety days prior written notice given by ReProtect to Ultrafem, provided however that ReProtect shall have the right to give such notice only within thirty (30) days after the occurrence of one of the following events with respect to such product:

(1) with respect to a product covered by the Gel License, if Ultrafem has not provided the amount of funding set forth below (which shall be in addition to the funding to be provided under paragraph I(b) of this Agreement) with respect to clinical trials approved by the FDA within the time period set forth below and such funding has not been provided by other sources:

AMOUNT OF FUNDING

Up to and including \$500,000

Greater than \$500,000 and less than \$3 million

\$3,000,000 or more

TIME PERIOD COMMENCING WITH DATE  
AFTER JUNE 30, 1996 ULTRAFEM IS  
NOTIFIED IN WRITING OF FDA  
APPROVAL TO PROCEED WITH TRIAL

Ninety Days

One Year

Two Years

(2) with respect to the first product covered by the Gel License, subject to the last sentence of this paragraph, (i) if a contraceptive product using the Acidic Buffer (without a vaginal device other than an applicator) (the "Contraceptive Gel") is not introduced

into the market within one year (or six months if Ultrafem has not then commenced marketing the Contraceptive Cup in the United States and ReProtect does not reasonably believe that marketing of the Contraceptive Cup will commence in such one year period) after the FDA has granted final approval to commence marketing the Contraceptive Gel in the United States; or (ii) if, once marketing of the Contraceptive Gel has commenced, Ultrafem refuses to market the Contraceptive Gel in a multiple application tube (as spermicide). The obligation of Ultrafem to market the Contraceptive Gel shall be excused during each period of delay caused by matters which are beyond the control of Ultrafem, including, without limitation, legal or other regulatory impediments, strikes, shortages of raw materials, government orders or acts of God.

(f) The parties agree that on or after the seventh anniversary of the First Payment Date, ReProtect may give written notice to Ultrafem that it would like certain modifications in the Agreement. The modifications could apply to the balance of the Term of the Agreement and/or to an extension of the Term. The notice must state, in detail, ReProtect's requested modifications. If in ReProtect's opinion the requested modifications so warrant, ReProtect may state in such written notice that if the modifications are not made, ReProtect would demand an early termination of the provisions of the Agreement set forth in this paragraph IV(f).

If ReProtect demands an early termination, the parties will have a three month period to negotiate in good faith with a view to resolving the issues raised by ReProtect. If at the end of such three month period, the issues have not been resolved to ReProtect's satisfaction, ReProtect may give Ultrafem written notice that it is terminating the provisions of the Agreement set forth below effective on the 90th day following the date of this second written notice. If ReProtect gives the notice referred to in the preceding sentence, the following provisions of the Agreement shall, from and after the 90th day following the date of such notice, no longer be applicable (except as set forth below): paragraphs I(a)(i); I(b)(i); I(e); I(h); II; III; V; VI(a); VI(b); VI(c); VI(d); VI(i); and VII(h). In addition, if ReProtect gives such second written notice, notwithstanding anything to the contrary contained herein, (i) any Options granted pursuant to paragraphs I(b) and I(c) hereof which are not exercisable on the date of such notice shall expire and be canceled and (ii) the "Non Competition Period" for all products and activities other than Competitive Products (as defined below) shall end at the later to occur of (x) two years after the ninetieth day after such second written notice and (y) the tenth anniversary of the First Payment Date. The Non Competition Period for Competitive Products shall be as provided in paragraph VI(e) below.

If the provisions of the Agreement set forth above are terminated pursuant to this paragraph IV(f): (i) ReProtect shall continue to comply after the date of termination with paragraph VI(d) with respect to all intellectual property that is co-owned by ReProtect and Ultrafem or licensed to Ultrafem hereunder; (ii) ReProtect shall supply Ultrafem with all data that was produced or developed by ReProtect or that ReProtect has the right to use in respect of projects included in the Budget and with respect to which some funds have been expended which exists at the date of termination; (iii) paragraph VI(b) shall continue to apply for a period of six months following the date of termination; and (iv) the parties shall cooperate toward achieving a smooth transition.

(g) Upon termination of this Agreement whether at the end of the Term or otherwise, each of Ultrafem and ReProtect shall have the right to develop and exploit, commercially or otherwise, all intellectual property in which they own an undivided one-half interest without any obligation to compensate the other for such development and/or exploitation, provided, however, that nothing in this sentence is intended to or shall diminish the parties' obligations pursuant to this Agreement which by their terms survive such termination, including without limitation, the licenses granted hereunder and the non-competition agreements contained herein.

#### **V. RIGHTS OF FIRST NEGOTIATION**

(a) In the event that during the Term, ReProtect desires to pursue commercial development of a product, invention or technology intended for vaginal use and which ReProtect in good faith believes is capable of commercial development, ReProtect shall notify Ultrafem of ReProtect's intention to seek to commercially develop such product, invention or technology. Ultrafem shall have the exclusive right for six (6) months from the date of receipt of such notice (accompanied by appropriate reports and documentation) to decide whether or not to pursue commercial development of such product, invention or technology. If during such six (6) month period Ultrafem determines not to seek commercialization of such product, invention or technology, it shall notify ReProtect of its determination. If during such six (6) month period Ultrafem determines to seek commercialization of such product, invention or technology, it shall notify ReProtect of its determination and the parties shall in good faith negotiate an exclusive license (or with respect to certain underdeveloped countries, a non-exclusive license) for such product. Such negotiation shall relate to a license which reflects the commercial value of the concept being considered as well as the structural terms, including, without limitation, the granting of an equity interest and payment of a royalty which the parties have historically found mutually acceptable, such as the Gel License and Cup License granted hereby. If, after six (6) months, the parties cannot agree on the terms of such license, then the terms of such license shall be determined by arbitration in accordance with the procedures set forth in paragraph V(c) below. Such arbitration shall be binding on the parties hereto except that Ultrafem may determine not to enter into a license agreement if the terms of such agreement as determined by the arbitrators are not satisfactory to Ultrafem. If Ultrafem determines not to seek commercialization of such product, invention or technology either during the initial six (6) month period or after the arbitration, ReProtect will be free to pursue commercial development of such product, invention or technology through alternate means, except as provided in paragraph VI(e) hereof, and except that for a six (6) month period following the later of the end of the six (6) month period during which Ultrafem has the right to determine whether or not to seek commercialization of such product, invention or technology, or the end of the arbitration, ReProtect shall not enter into any agreement with respect to such product whose material economic terms are not more favorable to ReProtect than the terms offered by Ultrafem. If ReProtect is entitled to pursue commercial development of a project, invention or technology after complying with, and in accordance with, this paragraph V(A), then Ultrafem shall be deemed to have assigned to ReProtect all of its right, title and interest in such product, invention or technology and shall execute such documents as may be reasonably requested by ReProtect

to evidence ReProtect's exclusive right to pursue such commercial development, in each case without any compensation to Ultrafem.

(b) In the event that during the Term, Ultrafem desires to pursue a research and development activity not covered by this Agreement, Ultrafem shall notify ReProtect of Ultrafem's intention to pursue such activity. ReProtect shall have the exclusive right for ninety (90) days from the date of receipt of such notice (accompanied by appropriate reports and documentation) to decide whether or not to pursue such research and development. If during such ninety (90) day period ReProtect determines to pursue such research and development, it shall notify Ultrafem of its determination and the parties shall in good faith negotiate an exclusive research and development agreement. If, after ninety (90) days, the parties cannot agree on the terms of such agreement, then Ultrafem will be free to pursue such research and development through alternate means, provided that for a ninety (90) day period following the end of the ninety day (90) period referred to earlier in this sentence, Ultrafem shall not enter into any agreement with respect to such research and development whose material economic terms are not more favorable to Ultrafem than the terms offered by ReProtect.

(c) The following terms shall apply to any arbitration hereunder. A party shall provide written notice of the dispute to the other party and such notice shall contain the appointment of an individual to serve as an arbitrator of the dispute. Within thirty (30) days of its receipt of such notice, the other party shall provide written notice to the first party which notice shall contain the appointment of another individual to serve as an arbitrator of such dispute. Within thirty (30) days of the period described above, the two individuals previously appointed shall mutually select a third individual to serve as an arbitrator of the dispute. In the event that the two (2) designated arbitrators are unable to agree on the third arbitrator, the third arbitrator shall be selected by the senior officer of the American Arbitration Association in New York, New York. The three arbitrators shall then deliver a notice to each of the parties designating the time and place in the United States of the arbitration hearing with respect to the dispute. The decision or order by the arbitrators shall be binding upon the parties hereto and shall be non-appealable in any manner and may be entered into any court of competent jurisdiction. The decision of the arbitrators shall be based on the substantive law of the State of New York without giving effect to the procedural laws or rules or to the principles of conflicts of laws thereof. The arbitrators selected for the purposes of this paragraph shall be independent and unrelated third parties, who have experience in commercial and contractual relations.

## VI. COVENANTS

(a) **Budget.** In connection with the performance of its obligations hereunder, commencing with the first month following the date of this Agreement, and no later than December 1 and June 1 during each year of the Term, ReProtect shall deliver to Ultrafem a budget and operating plan for the use and expenditure of the funds payable under paragraph 1(b)(i) of this Agreement for the twelve (12) month period commencing with the immediately succeeding January 1 and July 1. In addition, in connection with the performance of its



obligations hereunder, each such budget shall contain a five year business plan for ReProtect for the use and expenditure of funds payable under paragraph I(b)(i) of the Agreement for the five year period beginning with the date referred to in the prior sentence, or for such shorter period as may remain in the Term. Ultrafem shall have thirty (30) days to review and approve the budget. ReProtect shall operate and expend funds in accordance with the budget approved by Ultrafem. To the extent the budget is not approved by the Chief Executive Officer of Ultrafem, ReProtect shall continue to operate and expend funds received under this Agreement in accordance with the last budget which has been so approved. For purposes of this Agreement, the term "Budget" shall mean a budget approved by the Chief Executive Officer of Ultrafem.

The Managing Director of ReProtect shall report to the Chief Executive Officer of Ultrafem. The Managing Director of ReProtect shall meet with the Chief Executive Officer of Ultrafem at least once every three (3) months during the term. Such meetings shall be scheduled on the first business day of each of January, April, July and October, respectively, for a meeting to convene within ten (10) days thereafter. ReProtect shall furnish to Ultrafem at least once every three months a detailed report of the actual uses of the funds provided to ReProtect under this Agreement, provided that not more than 15% of such funds may be used by ReProtect as a "non-accountable" allowance. Such report shall contain the following four columns: "Actual expenditures for the prior three months (shown on a month by month basis);" "Projected expenditures for the prior three months (shown on a month by month basis) as reflected in the budget;" "Actual expenditures for the twelve months ended on the last day of the prior month;" and "Projected expenditures for the preceding twelve months ended on the last day of the prior month as reflected in the budget." ReProtect shall provide Ultrafem with such additional information and documentation as Ultrafem shall reasonably request, including, without limitation, such additional financial information as the Chief Financial Officer of Ultrafem shall request, consistent with Ultrafem's obligations as a public company (or a company seeking to become a public company).

(b) Access and Audit. Ultrafem, through its employees, consultants or other representatives, shall have the right during normal business hours to inspect and audit ReProtect's operations to determine whether or not ReProtect is complying in all respects with its obligations hereunder. Ultrafem warrants that all such inspections and audits shall be carried out in a manner calculated not to unreasonably interfere with ReProtect's conduct of business and to ensure the continued confidentiality of ReProtect's business and technical information. Further, Ultrafem agrees to comply with all of ReProtect's safety and security requirements during any visits. Appropriate employees or representatives of Ultrafem shall have the right periodically and upon reasonable advance notice to audit the books and records of ReProtect that relate in any fashion to the provision by ReProtect of services hereunder. ReProtect will provide copies of all relevant documentation and appropriate ReProtect personnel will be made available to answer questions and provide information in connection with any such audit.

(c) Research and Development. ReProtect hereby covenants and agrees to take all necessary steps to ensure that it has the equipment, instrumentation, resources and trained personnel to conduct research and development in accordance with the terms hereof. ReProtect

shall be responsible for all processes, cleaning and methods of validation, stability studies toxicity and biocompatibility tests or other tests and procedures in developing products and applications in accordance with the terms hereof. ReProtect shall ensure that all procedures and testing performed which may be used to obtain regulatory approval comply with applicable good laboratory practice regulations. ReProtect shall maintain complete and accurate documentation of all validation data, stability testing data, quality control and toxicity and biocompatibility testing and any other data required for the research and development of the Feminine Cup and Acidic Buffer. ReProtect shall promptly disclose to Ultrafem all new inventions or product applications which arise out of ReProtect's activities pursuant to paragraph I(a) of this Agreement or which may be used with the Feminine Cup or Acidic Buffer, and shall provide Ultrafem, at Ultrafem's request, accurate and complete copies of all notes, data, and other information relating to such developments, inventions or product applications. ReProtect acknowledges that Ultrafem intends to file applications with domestic and foreign authorities, including, without limitation, the Food and Drug Administration, and that all notes, reports, data and other information provided by ReProtect may be used in such applications. ReProtect shall provide Ultrafem with all notes, reports, data and other information reasonably requested by Ultrafem in connection with any such application. ReProtect may utilize subcontractors in performing certain trials, tests and procedures with respect to one or more products provided that it shall be the responsibility of ReProtect to ensure that such subcontractors comply with the requirements of this Agreement.

(d) Patent Filings. ReProtect agrees that it will file and maintain (or cause JHU to file and maintain) all United States or foreign patents for all products, processes, technologies and inventions licensed to Ultrafem under this Agreement. ReProtect shall bear all expenses of such filings and maintenance provided however that Ultrafem shall pay one-half of such expenses if Ultrafem is the one-half owner of such patent. ReProtect shall notify Ultrafem at least thirty (30) days prior to the making of any filing with respect to any patent covering a product licensed to Ultrafem under this Agreement and shall give Ultrafem a period of at least 20 days to review and comment on any such filing before such filing is made. ReProtect shall provide Ultrafem promptly with all correspondence, notices, office actions and applications with the United States Patent and Trademark Office and any foreign patent office relating to any intellectual property licensed by Ultrafem hereunder or co-owned by ReProtect and Ultrafem. The foregoing sentence shall apply to, without limitation, any application for the Acidic Buffer.

(e) Non-Competition. Each of ReProtect and the employees who are signatories hereto (the "Employees") agree that during the Non-Competition Period (as defined below), it, he or she shall not, except with respect to and to the extent provided under Permitted Exceptions (as defined below), directly or indirectly (whether as an officer, director, executive, employee, representative, agent, licensor or consultant, or through the acquisition of an equity interest or by making a loan or advance to any entity or otherwise) assist, participate or engage in the marketing of any vaginal product which is competitive with, (i) any vaginal product which Ultrafem is then marketing or (ii) any vaginal product which Ultrafem has the right (or an option to obtain the right) to market and with respect to which an application for Phase I clinical trials has been submitted to the FDA (or an equivalent submission has been made or clinical trials

have begun in any other jurisdiction), in any geographic area in which any of Ultrafem's products are then being marketed. The parties confirm their belief that the provisions of this paragraph are reasonable and necessary to protect the competitive position of the parties in view of the nature of this Agreement.

The term "Non-Competition Period" means the period beginning with the date hereof and ending (i) upon the complete termination of this Agreement pursuant to paragraph IV(b) or (c) hereof, if such termination occurs prior to the first anniversary of the date hereof; (ii) one year after termination of this Agreement pursuant to paragraph IV(b) or (c) hereof if such termination occurs on or after the first anniversary of the date hereof but prior to the second anniversary of the date hereof; and (iii) two years after the earlier of the end of the Term or after termination of this Agreement pursuant to paragraph IV(b) or (c) hereof, if such termination occurs on or after the second anniversary of the date hereof; provided, however, that, with respect to a Competitive Product (as defined below) the Non-Competition Period shall end on the latest to occur of (i) the dates set forth in the foregoing sentence; and (ii) the date Ultrafem does not have any obligation to pay any royalties pursuant to either paragraph I(b) or paragraph I(c). The term "Competitive Product" means any vaginal product which utilizes the Acidic Buffer or any component thereof, including, without limitation, the Gel (with or without a device), whose purpose is contraception, protection or prevention of STDs (including AIDS), or as therapy for treating and/or preventing vaginal yeast or bacterial vaginosis, provided, however, that the term "Competitive Product" shall not include a product which is marketed primarily to a male market even though such product can also be applied externally to the vaginal area.

The following are Permitted Exceptions:

(1) If ReProtect terminates the license of a particular product granted by this Agreement pursuant to paragraph IV(e)(1) hereof, then the marketing of the Gel (without a vaginal device other than an applicator) to be used for the same application as was contemplated by the trial which Ultrafem failed to fund shall not be prohibited by this paragraph VI.

(2) If ReProtect terminates the license of a particular product granted by this Agreement pursuant to paragraph IV(e)(2) hereof, then the marketing of the Gel without a vaginal device, other than an applicator, for the same application as is contemplated by said paragraph IV(e)(2) shall not be prohibited by this paragraph VI.

(3) The marketing of a product (other than a Competitive Product) which is subject to paragraph V(a) of this Agreement and with respect to which ReProtect complied with the terms of said paragraph V(a) but Ultrafem determined not to seek commercialization or with respect to which Ultrafem determined not to enter into a license agreement after receiving the determination of the arbitrators in accordance with said paragraph V(a).



(4) The marketing of a Competitive Product which is subject to paragraph V(a) of this Agreement and with respect to which ReProtect complied with the terms of said paragraph V(a) but Ultrafem determined not to enter into a license agreement after receiving the final determination of the arbitrators regarding the terms of the license agreement as contemplated by paragraph V(a).

(5) The marketing of the Gel (without the Feminine Cup or other vaginal device) in countries where the license granted by paragraph I(a)(iii) is non-exclusive.

If ReProtect or an Employee breaches, or threatens to commit a breach of, this paragraph VI(e) (the "Restrictive Covenants"), Ultrafem shall have the following rights and remedies, each of which rights and remedies shall be independent of the others and severally enforceable, and each of which is in addition to, and not in lieu of, any other rights and remedies available to Ultrafem under law or in equity: (A) the right and remedy to have the Restrictive Covenants specifically enforced by any court of competent jurisdiction, it being agreed that any breach or threatened breach of the Restrictive Covenants would cause irreparable injury to Ultrafem and that money damages would not provide an adequate remedy to Ultrafem and (b) the right and remedy to require the person that violates the Restrictive Covenant to account for and pay over to Ultrafem all compensation, profits, monies, accruals, increments or other benefits derived or received by such person as the result of any action constituting a breach of the Restrictive Covenants.

Each of ReProtect and the Employees acknowledges and agrees that the Restrictive Covenants are reasonable and valid in geographical and temporal scope and in all other respects. If any court determines that any of the Restrictive Covenants, or any part thereof, are invalid or unenforceable, the remainder of the Restrictive Covenants shall not thereby be affected and shall be given full effect without regard to the invalid portions. If any court determines that any of the Restrictive Covenants, or any part thereof, is unenforceable because of the duration or geographical scope of such provision, such court shall have the power to reduce the duration or scope of such provision, as the case may be, and, in its reduced form, such provision shall then be enforceable. Ultrafem, ReProtect and each Employee intend to and hereby confer jurisdiction to enforce the Restrictive Covenants upon the courts of any jurisdiction within the geographical scope of such Restrictive Covenants. If the courts of any one or more of such jurisdictions hold the Restrictive Covenants unenforceable by reason of the breadth of such scope or otherwise, it is the intention of such parties that such determination not bar or in any way affect the right of Ultrafem or any successor thereto to the relief provided above in the courts of any other jurisdiction within the geographical scope of such Restrictive Covenants, as to breaches of such Restrictive Covenants in such other respective jurisdictions, such Restrictive Covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants.

(f) Confidentiality. Each of ReProtect, the Employees and Ultrafem shall maintain in confidence and not use or disclose to any third party, except for scientific publication as contemplated by the Research Agreement annexed as Exhibit III hereto, and except as is specifically contemplated herein or is otherwise necessary to perform their respective obligations under this Agreement, and then only on a confidential basis, any information, including without limitation business and technical information, experience or data regarding any facility,

programs, laboratories, processes, products, costs, equipment operation or customers, relating to the services performed pursuant to or in connection with this Agreement. Nothing herein shall prevent any party from disclosing any information required to be disclosed by law or from disclosing information which (i) has been published or has become part of the public domain other than by acts, omissions or fault of such party, (ii) was lawfully received by such party from a third party free of any obligation of confidentiality to such third party, or (iii) which such party can demonstrate was already in its possession prior to receipt thereof, directly or indirectly, from the other party.

(g) Insurance. Ultrafem shall at all times during the term hereof maintain general liability insurance, including products liability for all products marketed by Ultrafem. From and after the date that Ultrafem commences marketing of a product which is covered by a license granted hereunder, such insurance shall have coverage applying anywhere in the world that Ultrafem markets such product regardless of where a claim is filed, and shall name ReProtect as an additional insured. Ultrafem shall furnish certificates of insurance evidencing the foregoing coverage as and when reasonably requested by ReProtect.

(h) Sufficient Number of Shares. Ultrafem further covenants and agrees that it shall at all times have authorized and reserved, free from pre-emptive rights, a sufficient number of shares of its Common Stock to provide for the exercise of the options granted pursuant to this Agreement.

(i) Clinical Trials. Without limiting the parties obligations hereunder, except as otherwise provided below, the parties agree that ReProtect shall be responsible for preparing the protocols and dealing with the FDA with respect to trials of applications of the Acidic Buffer without the Feminine Cup or other vaginal device (except an applicator). ReProtect shall keep Ultrafem fully informed with respect to, and Ultrafem shall have the right to review and comment on, all such submissions and dealings. Notwithstanding the foregoing, Ultrafem shall have the right to choose the manufacturers, packaging, suppliers and make all other decisions regarding the marketing of any such product, subject to applicable laws and regulations, and ReProtect shall not in any way obligate Ultrafem with respect to such marketing except as expressly provided herein with respect to the marketing of the Gel in a multiple application tube. Without limiting the parties obligations hereunder, the parties agree that they shall be jointly responsible for preparing the protocols and dealing with the FDA with respect to trials of applications of the Feminine Cup (and/or trials of applications of the Gel without the Feminine Cup or other vaginal device (except an applicator) which are being funded in whole or in part by Ultrafem), provided however that Ultrafem shall have the right to choose the manufacturers, packaging, suppliers and make all other decisions regarding marketing of any such product, subject to applicable laws and regulations.

## VII. REPRESENTATIONS AND WARRANTIES OF REPROTECT

ReProtect hereby represents and warrants to Ultrafem:

(a) Organization; Authority; Enforceability. ReProtect is a limited liability company duly organized, validly existing and in good standing under the laws of the State of Maryland and has all requisite and authority to enter into this Agreement and to consummate the transactions contemplated hereby. This Agreement has been duly executed and delivered by ReProtect, has been duly authorized by all necessary action, and when this Agreement becomes the legal and valid obligation of Ultrafem in accordance with paragraph VIII(a), it will constitute the legal, valid and binding obligation of ReProtect enforceable in accordance with its terms.

(b) No Conflict or Breach. The execution and delivery of this Agreement, the consummation of the transactions contemplated hereby, and the fulfillment of the terms hereof, will not (i) constitute, with or without the giving of notice or passage of time, or both, a breach of any of the terms or provisions of, or a default under any agreement, indenture or other instrument to which ReProtect is a party or by which it or any of its property is bound, (ii) cause, or give any person grounds to cause, with or without the giving of notice or passage of time, or both, the maturity of any material liability or obligation of ReProtect to be accelerated, increased or otherwise affected, or (iii) conflict with ReProtect's Articles of Organization or Operating Agreement, or equivalent organizational documents, or any judgment, decree, order or award of any court, governmental body or arbitrator binding upon ReProtect, or any law, rule, or regulation applicable to it.

(c) Approvals. No consent, action, approval or authorization prescribed by any law, rule or regulation, or by any agreement to which ReProtect is a party, is required in order to permit the consummation of the transactions contemplated by this Agreement.

(d) No Legal Bar. ReProtect is not prohibited by any order, writ, injunction or decree from consummating the transactions contemplated by this Agreement, and no action or proceeding is pending or, to the best of ReProtect's knowledge, threatened against ReProtect which questions the validity of this Agreement or any of the actions which the parties hereto have taken in connection herewith or which it is contemplated they shall take in connection herewith.

(e) Finder. ReProtect has taken no action and has not dealt with any person in any manner which will result in any liability to ReProtect to pay any brokerage fees or commissions or finder's fees with respect to this Agreement or the transactions contemplated hereby.

(f) Exercise of Options; Registration Statement. ReProtect is purchasing the options granted herein for its own account, for investment purposes only, and not for the account of any other entity, and not with a view to distribution, assignment or resale to others or to fractionalization. ReProtect shall not sell, assign, hypothecate or otherwise transfer the options, other than pursuant to an exemption from the registration requirements of the Securities Act of

1933, as amended. Ultrafem may request, as a condition to any such transfer, a written opinion of counsel, satisfactory to Ultrafem and its counsel, to the effect that the proposed disposition is exempt from such registration requirements. ReProtect has carefully considered and has, to the extent it believes such discussion necessary, discussed with its legal, tax and financial advisers the suitability of an investment in Ultrafem for its particular tax and financial situation, and ReProtect has determined that the receipt of the options is a suitable investment.

ReProtect hereby agrees that for a period of 18 months after the effective date of a registration statement relating to Ultrafem's initial public offering, ReProtect will not offer, sell, contract to sell, grant any option for the sale of, or otherwise dispose of, directly or indirectly, any shares of Common Stock of Ultrafem, or securities convertible into or exercisable or exchangeable for shares of Common Stock or other securities of Ultrafem, held by ReProtect as of such effective date without Ultrafem's prior written consent; provided, however, that ReProtect may (a) offer, sell, contract to sell, grant an option for the sale of, or otherwise dispose of all or any part of its shares of Common Stock or other such security or instrument of Ultrafem during such period if such transaction is private in nature and the transferee of such shares of Common Stock or other securities or instruments agrees, prior to such transaction, to be bound by all of the provisions of paragraph VII(f) of this Agreement; and (b) sell or otherwise dispose of any shares of Ultrafem Common Stock purchased in the open market subsequent to the commencement of Ultrafem's initial public offering.

Ultrafem shall use its best efforts to file with the Securities and Exchange Commission and have declared effective a Registration Statement on Form S-8 (or similar form) covering the issuance of Ultrafem shares of Common Stock which do not contain a "restricted securities" legend upon the exercise of the options granted pursuant to paragraphs I(b)(ii) and I(b)(iii) of this Agreement (the "Registrable Securities") or, alternatively a Registration Statement on a Form S-3 (or other applicable form) covering the resale by the holders thereof of the shares of Common Stock issued upon exercise of such options. ReProtect shall notify Ultrafem in writing no later than the first anniversary of the First Payment Date of whether it desires that Ultrafem file a Registration Statement on Form S-8 or on Form S-3. In the event ReProtect does not duly give such notice, Ultrafem shall choose the applicable form of registration statement but if ReProtect gives such notice in a timely fashion Ultrafem shall file the form chosen by ReProtect. Such filing shall be made no later than 18 months after the effective date of a registration statement with respect to Ultrafem's initial public offering of Common Stock. Ultrafem shall use its best efforts to maintain the effectiveness of such Registration Statement until the first anniversary of the expiration of the Term.

After the completion by Ultrafem of an initial public offering, and so long as there is no effective registration statement covering the issuance or resale of the Registrable Securities, if Ultrafem proposes to register any of its securities under the Securities Act of 1933, as amended (the "Securities Act") (other than by a registration on Form S-4 or S-8 or any successor or similar forms) it will, each such time, give prompt written notice (at least 20 business days before the proposed registration) to all holders ("Holders") of Registrable Securities of its intention to do so. Upon the written request of any such Holder, made within 15 business days



after the receipt of any such notice (which request shall specify the Registrable Securities intended to be disposed of by such Holder and the intended method of disposition thereof), Ultrafem will use its best efforts to effect the registration under the Securities Act of all such Registrable Securities, to the extent required to permit the disposition (in accordance with the intended methods thereof) of the Registrable Securities so to be registered; provided, however, that if at any time after giving written notice of its intention to register securities and before the effective date of the related registration statement Ultrafem determines for any reason not to register or to delay registration of such securities, Ultrafem may, at its election, give written notice of such determination to each Holder and, (x) in the case of a determination not to register, shall be relieved of its obligation to register any Registrable Securities in connection with such registration, and (y) in the case of a determination to delay registering, shall be permitted to delay registering any Registrable Securities, for the same period as the delay in registering such other securities. Ultrafem will pay all registration expenses in connection with each registration of Registrable Securities requested pursuant to the terms hereof, excluding any fees or disbursements of counsel to the Holders and excluding underwriting discounts and commissions in respect of the sale of the Registrable Securities, if any.

Notwithstanding anything in this Agreement to the contrary, Ultrafem shall be entitled to postpone for a reasonable period of time (but not exceeding 180 days) the filing or effectiveness of any registration statement otherwise required to be prepared and filed by it pursuant to this paragraph (f) if Ultrafem determines, in its sole discretion, that (x) Ultrafem is in possession of material information that has not yet been disclosed to the public and Ultrafem deems it to be advisable not to disclose such information at such time in a registration statement, (y) such registration and offering would adversely affect any financing, acquisition, corporate reorganization, acquisition by Ultrafem of any of its securities (under Rule 10b-6 or otherwise) or other material transaction involving Ultrafem or any of its Affiliates (as defined in the rules and regulation adopted under the Securities Exchange Act of 1934, as amended), or (z) Ultrafem is subject to an underwriter's lock-up and, in any such case Ultrafem gives the Holders written notice of any such determination and an approximation of the anticipated delay.

If a requested registration pursuant to this paragraph VII(f) above, involves an underwritten offering (on a firm commitment basis), and the managing underwriter(s) advises Ultrafem in writing (with a copy provided to each holder of Registrable Securities requesting registration) that, in its opinion, the number of Registrable Securities and other securities requested to be included in such registration including shares of Common Stock of holders who have incidental registration rights pursuant to other agreements with Ultrafem ("Other Shares") exceeds the number which can be sold in such offering (within a price range acceptable to Ultrafem), then Ultrafem will include in such registration, to the extent of the number which Ultrafem is so advised can be sold in such offering, first, all securities proposed by Ultrafem to be sold for its own account, second, any securities which, as of the date of the execution of this Agreement, have, by their terms, a priority with respect to incidental registration rights, third, the Registrable Securities and Other Shares of holders who are entitled to registration at the same time as the Registrable Securities, pro rata among all holders requesting registration on the basis of the total number of shares beneficially owned by such holders and fourth, other

securities requested to be included in such registration *pro rata* among all such holders of Common Stock requesting registration on the basis of the total number of shares owned by such holders of Common Stock.

Ultrafem may require each seller of Registrable Securities as to which any registration is being effected to furnish Ultrafem such information regarding such seller and the distribution of such securities as Ultrafem may from time to time reasonably request in writing.

Ultrafem will, as soon as practicable notify each seller of Registrable Securities covered by such registration statement, when a prospectus relating thereto is required to be delivered under the Securities Act, upon discovery that, or upon the happening of any event as a result of which, the prospectus includes an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances under which they were made, and, at the request of any such seller, promptly prepare and file with the Commission and furnish to such seller a reasonable number of copies of any supplement or amendment as may be necessary so that, as thereafter delivered to the purchasers of such securities, such prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances under which they are made. Each Holder agrees by acquisition of such Registrable Securities that, upon receipt of any notice from Ultrafem of the happening of any event of the kind described in this subparagraph, such Holder will forthwith discontinue such Holder's disposition of Registrable Securities pursuant to the registration statement relating to such Registrable Securities until such Holder's receipt of the copies of the supplemented or amended prospectus contemplated hereby and, if so directed by Ultrafem, will deliver to Ultrafem (at Ultrafem's expense) all copies, other than permanent file copies, then in such Holder's possession of the prospectus relating to such Registrable Securities current at the time of receipt of such notice.

The indemnification and contribution provisions annexed as Exhibit VII(f) hereto are hereby incorporated by reference herein.

(g) Patent Disclosure. Prior to the date hereof, ReProtect has furnished to Ultrafem true, complete and correct copies of the patent application of the Acidic Buffer entitled "A Device and Method for Acid Buffering;" and all correspondence of any nature whatsoever (including without limitation patent office actions) between the United States Patent Office and ReProtect or any third party relating to such patent application.

(h) Rights in Intellectual Property. ReProtect hereby represents and warrants that ReProtect has exclusive ownership of the patent application for the Acidic Buffer. Each of ReProtect and the Employees hereby represent and warrant that ReProtect has previously supplied to Ultrafem a true correct and complete copy of ReProtect's operating agreement dated as of December 4, 1995, as amended on February 6, 1996, which is and shall remain throughout the Term in full force and effect and is and shall remain throughout the Term the valid and binding obligation of each of the signatories thereto, provided, however, that the signatories

thereto may amend such agreement without Ultrafem's consent unless such amendment relates to Section 10.4 or the paragraphs, sentences or sections referred to in such Section 10.4 of which Ultrafem is a third party beneficiary, in which event Ultrafem's prior written consent to the amendment shall be required. In addition, ReProtect and the Employees agree that a change of control of ReProtect by way of merger, sale of substantially all of its assets or otherwise shall require the prior written consent of Ultrafem which consent shall not be unreasonably withheld. To the best of ReProtect's knowledge, there are no claims, demands, or proceedings alleging any infringement in any patents or other intellectual property rights of third parties, or otherwise challenging ReProtect's right to own, use or license the Acidic Buffer. To the best of ReProtect's knowledge, the patent application for the Acidic Buffer has been duly filed in or issued in the United States Patent and Trademark Office and the foreign patent offices listed in Schedule VII(b) hereto in accordance with all applicable provisions of law and administrative regulations applicable in the United States and such jurisdictions, respectively.

#### VIII. REPRESENTATIONS AND WARRANTIES OF ULTRAFEM

Ultrafem hereby represents and warrants to ReProtect:

(a) Organization: Authority: Enforceability. Ultrafem is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to enter into this Agreement and to consummate the transactions contemplated hereby. At the time Ultrafem obtains the approval of its Board of Directors (which shall be prior to February 29, 1996), this Agreement (including without limitation the options granted hereby) will have been duly executed and delivered by Ultrafem, will have been duly authorized by all necessary corporate action, and will constitute the legal, valid and binding obligation of Ultrafem enforceable in accordance with its terms. In the event Ultrafem does not obtain the approval of its Board of Directors prior to the First Payment Date, this Agreement (including without limitation the options) shall be null and void.

(b) No Conflict or Breach. The execution and delivery of this Agreement, the consummation of the transactions contemplated hereby, and the fulfillment of the terms hereof, will not (i) constitute, with or without the giving of notice or passage of time, or both, a breach of any of the terms or provisions of, or a default under any agreement, indenture or other instrument to which Ultrafem is a party or by which it or any of its property is bound, (ii) cause, or give any person grounds to cause, with or without the giving of notice or passage of time, or both, the maturity of any material liability or obligation of Ultrafem to be accelerated, increased or otherwise affected, or (iii) conflict with Ultrafem's Certificate of Incorporation, or By-Laws, or any judgment, decree, order or award of any court, governmental body or arbitrator binding upon Ultrafem, or any law, rule, or regulation applicable to it.

(c) Approvals. No consent, action, approval or authorization prescribed by any law, rule or regulation, or by any agreement to which Ultrafem is a party, is required in order to permit the consummation of the transactions contemplated by this Agreement.

(d) No Legal Bar. Ultrafem is not prohibited by any order, writ, injunction or decree from consummating the transactions contemplated by this Agreement, and no action or proceeding is pending or, to the best of Ultrafem's knowledge, threatened against Ultrafem with questions the validity of this Agreement or any of the actions which the parties hereto have taken in connection herewith or which it is contemplated they shall take in connection herewith.

(e) Finder. Ultrafem has taken no action and has not dealt with any person in any manner which will result in any liability to Ultrafem to pay any or finder's fees with respect to this Agreement or the transactions contemplated hereby.

(f) Shares of Common Stock. Ultrafem represents and warrants to ReProtect that all shares of Common Stock issuable upon due exercise of the options granted hereunder will, upon issuance in accordance with the terms of the options, be validly issued, fully paid and nonassessable, with no personal liability attaching to the ownership thereof, and free from all taxes, liens and charges with respect to the issue thereof.

(g) Rights in Intellectual Property. Ultrafem has exclusive ownership of the Feminine Cup, subject to the rights of the holders of certain secured debt of Ultrafem. To the best of Ultrafem's knowledge, there are no claims, demands, or proceedings alleging any infringement in any patents or other intellectual property rights of third parties, or otherwise challenging Ultrafem's right to own, use or license the Feminine Cup. To the best of Ultrafem's knowledge, the patent application for the Feminine Cup has been duly filed in or issued in the United States Patent and Trademark Office and the foreign patent offices listed in Schedule VIII(g) hereto in accordance with all applicable provisions of law and administrative regulations applicable in the United States and such jurisdictions, respectively.

(h) Employee Leaving. Ultrafem acknowledges that it shall not be deemed a breach of this Agreement by ReProtect if one of the Employees leaves the employ of ReProtect during the Term.

#### **IX. INDEMNIFICATION**

(a) By ReProtect. ReProtect hereby agrees to indemnify, defend and hold harmless Ultrafem and its officers, directors, employees and affiliates from and against any and all demands, claims, actions, causes of action, assessments, losses, damages, injuries, liabilities, costs and expenses, including without limitation, interest, penalties and reasonable attorneys' fees and expenses (collectively "Damages") asserted against, imposed upon or incurred by Ultrafem or its officers, directors, employees and affiliates, directly or indirectly related to, arising out of or resulting from:



- (i) any breach of any of the representations and warranties of ReProtect contained herein;
- (ii) any breach or failure by or on behalf of ReProtect to perform any obligation of ReProtect contained herein; and
- (iii) any failure of ReProtect, or anyone acting on behalf of ReProtect, to observe or comply with any applicable laws, rules or regulations related in any fashion to ReProtect's performance of its obligations hereunder.

(b) By Ultrafem. Ultrafem hereby agrees to indemnify, defend and hold harmless ReProtect and its officers, directors, employees and affiliates from and against any and all Damages asserted against, resulting to, imposed upon or incurred by ReProtect or its officers, directors, employees and affiliates, directly or indirectly related to, arising out of or resulting from:

- (i) any breach of any of the representations and warranties of Ultrafem contained herein;
- (ii) any breach or failure by or on behalf of Ultrafem to perform any obligation of Ultrafem contained herein; and
- (iii) any failure of Ultrafem, or anyone acting on behalf of Ultrafem, to observe or comply with any applicable laws, rules or regulations related in any fashion to Ultrafem's performance of its obligations hereunder;

(c) Ultrafem shall indemnify and hold ReProtect harmless from and against all losses, liability and expenses incurred as a result of any claims, suits or causes of action, arising out of death or injury to persons under strict liability relating to a product sold by Ultrafem pursuant to a license granted by this Agreement, from any person, firm or corporation (except that ReProtect shall be solely liable, without indemnity by Ultrafem and shall indemnify Ultrafem, for all losses, liability and expenses incurred as a result of any claim, suit or cause of action to the extent such loss, liability or expense arises from ReProtect's negligence or willful misconduct).

(d) A party entitled to indemnification hereunder ("Indemnified Party") will promptly give notice to the other party ("Indemnifying Party") of any claim of a third party which may reasonably be expected to result in a claim for indemnification ("Third Party Claim") by the Indemnified Party. An Indemnifying Party shall have the right to direct the defense, compromise or settlement of a Third Party Claim with counsel selected by it, provided the Indemnifying Party gives written notice to the Indemnified Party of its election to do so within twenty (20) days after receipt of notice in accordance with the preceding sentence. If the Indemnifying Party fails to so notify the Indemnified Party of its election to defend a Third Party Claim, the Indemnified Party will (upon further notice to the Indemnifying Party) have the right

to undertake the defense, compromise or settlement thereof on behalf of and for the account and expense of the Indemnifying Party, subject to the right of the Indemnifying Party to assume the defense of such Third Party Claim at any time prior to settlement, compromise or final determination thereof if and only if, in the reasonable judgment of the Indemnified Party, such assumption would not prejudice the defense thereof or the rights of the Indemnified Party. In the event an Indemnifying Party has assumed the defense of any Third Party Claim, the Indemnified Party shall nonetheless have the right to select its own counsel and participate in the defense thereof at and for its own expense and account. Counsel for the Indemnified Party in such circumstances shall consult and cooperate with counsel for the Indemnifying Party in defending against any such Third Party Claim.

(e) An Indemnifying Party shall not under any circumstances, without the written consent of the Indemnified Party, settle or compromise any Third Party Claim or consent to the entry of any judgment or decree which does not include as an unconditional term thereof the giving by the third party claimant to the Indemnified Party release from all liability in respect of such Third Party Claim.

(f) All claims for indemnification hereunder shall be made in a written notice setting forth the nature of the claim for indemnification and the type and amount (if known) of relief sought. Both parties agree that no claims for indemnification shall be made hereunder unless the party requesting indemnification shall have a good faith belief that it is entitled to indemnification hereunder. In the event that more than one party is an Indemnified Party in any claim or action, then the Indemnifying Party shall be responsible for the costs and expenses of only one counsel for all Indemnified Parties.

(g) In the event of acts by a third party which ReProtect or Ultrafem believes constitute an infringement of any patent relating to a product which is co-owned by Ultrafem and ReProtect and which is not licensed by Ultrafem hereunder, Ultrafem or ReProtect may elect to prosecute a suit for infringement after notice to the other of that intention. Each party shall pay one-half of the legal fees and costs of prosecution subject to being reimbursed therefor from any recovery in said suit. Such recovery shall be shared equally by the parties. Notwithstanding anything to the contrary contained in this paragraph, in the event of acts by a third party which ReProtect or Ultrafem believes constitute an infringement of any patent relating to a product which is licensed to Ultrafem hereunder, Ultrafem may in its sole discretion elect to prosecute a suit for infringement. Ultrafem shall be solely responsible for the legal fees and costs of prosecution in any such suit and shall be entitled to any recovery in any such suit. The parties shall fully cooperate with each other in connection with the prosecution of any such litigation, including participating therein as plaintiff if so requested by the other party. The parties shall agree on legal counsel, or if they cannot agree, the party electing to prosecute such suit may select legal counsel.

**X. MISCELLANEOUS**

(a) Entire Agreement; Amendments. This Agreement along with the annexes and exhibits hereto constitute the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements and understandings, whether oral or written, except that the Confidentiality Agreement dated as of December 5, 1995, between the parties shall continue in full force and effect with respect to ReProtect's patent application and operating agreement. No modification, amendment or waiver of any provision of this Agreement shall be effective unless in writing and signed by the party or parties against whom enforcement thereof is sought, and any such waiver or consent shall be effective only in the specific instance and for the purpose for which given.

(b) Specific Performance; Jurisdiction. ReProtect, the Employees and Ultrafem each acknowledge that the license granted hereunder to Ultrafem is unique and that Ultrafem may have no adequate remedy at law for the failure by ReProtect or the Employees to perform their respective obligations hereunder including, without limitation, the non-competition and confidentiality clauses contained in paragraphs VI(c) and (d) hereof. Accordingly, each of the parties agrees that in the event of any such failure, Ultrafem shall have the right, in addition to any other rights which it may have at law, in equity or otherwise, to specific performance of any and all of such other party's obligations under this Agreement. The parties agree that any action for equitable relief to enforce this Agreement or any provision hereof may be brought in any court of competent jurisdiction in the State of New York, and each party hereby consents to personal jurisdiction in any such action and waives any right to contest such jurisdiction on the grounds of forum non conveniens.

(c) Severability. The invalidity of all or part of any paragraph of this Agreement shall not render invalid the remainder of such paragraph or of this Agreement. If any provision of this Agreement including, without limitation, the non-competition and confidentiality clauses contained in Paragraphs VI(c) and (d) hereof, is so broad as to be unenforceable, such provision shall be interpreted to be only so broad as is enforceable.

(d) Notices. Except as otherwise specified herein, all notices, requests, demands, consents and other communications required or permitted to be given or made hereunder, including notice of change of address, shall be in writing and shall be deemed to have been duly given or made when received, and shall be either hand delivered, telexed, faxed or mailed, federal express courier, registered or certified first class mail, postage prepaid, return receipt requested, to the party to whom the same is so given or made as follows:

(i) if to Ultrafem, to:

Ultrafem, Inc.  
500 Fifth Avenue, Suite 3620  
New York, New York 10110  
Attention: John Andersen, President

and Chief Executive Officer

(ii) if to ReProtect, to:

ReProtect, LLC  
703 Stags Head Road  
Baltimore, Maryland 21286  
Attention: Richard A. Cone, Managing Director

(iii) if to the Employees, to each of their addresses set forth on the signature pages hereto.

(e) Binding Effect; Benefits; Assignment. This Agreement shall be binding upon and shall inure to the benefit of and be enforceable by the parties hereto and their respective successors, permitted assigns, heirs and legal representatives. ReProtect may not assign this Agreement without the prior written consent of Ultrafem, which consent shall not be unreasonably withheld. Ultrafem may not assign this Agreement unless (i) Ultrafem has received the prior written consent of ReProtect, which consent shall not be unreasonably withheld; or (ii) such assignment is to a pharmaceutical or consumer product company with annual gross revenues of \$100 million.

(f) Headings. The headings of this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.

(g) Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original and all of which taken together shall be deemed to constitute a single instrument.

(h) Governing Law. This Agreement shall be governed by, and construed and interpreted in all respects in accordance with the laws of the State of New York, without giving effect to the principles of conflict of laws thereof.

(i) Further Assurances. The parties hereto hereby agree to execute and deliver any further instruments, certificates and documents as may be reasonably requested from it by another party hereto in order to carry out the terms and conditions of this Agreement.

IN WITNESS WHEREOF, the parties hereto have executed and delivered, or have caused this Agreement to be executed and delivered, by their duly authorized representative as of the date above written.

ULTRAFEM, INC.

By \_\_\_\_\_  
Name:  
Title:

REPROTECT, LLC

By \_\_\_\_\_  
Name:  
Title:

The following employees are signing this Agreement with respect to paragraphs VI(e) and VI(f) and the second and third sentences of paragraph VII(h) only:

---

Dr. Richard Cone  
c/o ReProtect LLC  
703 Stags Head Road  
Baltimore, Maryland 21286

---

Dr. Kevin Whaley  
c/o ReProtect LLC  
703 Stags Head Road  
Baltimore, Maryland 21286

---

Dr. Thomas Moench  
c/o ReProtect LLC  
703 Stags Head Road  
Baltimore, Maryland 21286

**ANNEX I(b)(ii) TO RESEARCH AND PRODUCT DEVELOPMENT  
AGREEMENT BETWEEN REPROTECT, L.C. AND ULTRAFEM, INC.  
DATED AS OF FEBRUARY 8, 1996 (THE "AGREEMENT")**

This Annex forms a part of the Agreement. All capitalized terms not herein defined shall have the same meaning as is ascribed to such term in the Agreement.

The Options shall become exercisable upon the date of the occurrence of certain events as set forth in, and shall expire to the time set forth in, Paragraph I(b)(ii) of the Agreement. The Options may be exercised only by delivery by registered or certified mail to Ultrafem at its principal office of (i) written notice signed by the Option Holder of such exercise in form and substance identical to Exhibit I attached hereto stating the number of shares of common stock of Ultrafem ("Options Shares") then being purchased; (ii) payment of the aggregate Exercise Price, which payment shall be in the form of (a) a certified (unless such certification is waived by Ultrafem) check payable to the order of Ultrafem, Inc. or cash in the amount of the Exercise Price for such Option Shares, (b) certificates duly endorsed for transfer (with all transfer taxes paid or provided for) evidencing a number of shares of Common Stock of Ultrafem of which the aggregate Fair Market Value (as defined herein) on the date of exercise is equal to the aggregate Option Exercise Price of the Option Shares being purchased or (c) a combination of these methods of payment; and (iii) an executed investment letter in form and substance identical to Exhibit II attached hereto. Delivery of said notice and such documentation shall constitute an irrevocable election of the Option Holder to purchase the Option Shares specified in said notice, and the date on which Ultrafem receives said notice and documentation shall be the date as of which the Option Shares so purchased shall be deemed to have been issued. Ultrafem shall issue and deliver to the Option Holder a stock certificate or certificates evidencing the Option Shares so purchased. The term "Fair Market Value" shall mean (i) if the shares of Common Stock are listed on a registered securities exchange or quoted on the NASDAQ-National Market System, the closing price per share of Common Stock on such date (or, if there was no trading reported on such date, on the next preceding day on which there was trading reported); (ii) if the shares of Common Stock are not listed on a registered securities exchange and not quoted on the NASDAQ-National Market System, but the bid and asked prices per share of Common Stock are provided by NASDAQ, the National Quotation Bureau Incorporated or any similar organization, the average of the closing bid and asked price per share of Common Stock on such date (or, if there was no trading in the shares of Common Stock on such date, on the next preceding day on which there was trading) as provided by such organization; and (iii) if the shares of Common Stock are not traded on a registered securities exchange and not quoted on the NASDAQ-National Market System and the bid and asked price per share of the shares of Common Stock are not provided by NASDAQ, the National Quotation Bureau Incorporated or any similar organization, as determined by the Board or a committee thereof in good faith. Any such determination shall be final and binding on the Option Holder and Ultrafem.

The Option Holder agrees not sell, transfer, assign, pledge, hypothecate or otherwise dispose of any of the Option Shares unless and until all of the following have occurred: (i) the Option



Shares are disposed of pursuant to and in conformity with an effective registration statement filed with the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (the "Act"), or the Option Holder delivers to Ultrafem a written opinion of counsel, satisfactory to Ultrafem and its counsel, to the effect that the proposed disposition is exempt from the registration and prospectus delivery requirements of the Act; and (ii) the Option Holder delivers to Ultrafem a written opinion of counsel, satisfactory in form and substance to Ultrafem and its counsel, to the effect that the proposed disposition will not result in a violation of the securities laws of any state in the United States applicable to the transaction. Any attempted transfer and breach of this paragraph shall be null and void, and of no force or effect whatsoever.

Subject to any required action by the stockholders of Ultrafem:

- (i) if outstanding shares of Ultrafem's Common Stock (the "Outstanding Shares") shall be divided into a greater number of Outstanding Shares or a dividend in shares of Common Stock shall be paid in respect of shares of Common Stock, the Exercise Price in effect immediately prior to such subdivision or at the record date of such dividend shall, simultaneously with the effectiveness of such subdivision or immediately after the record date of such dividend, be proportionately reduced, and conversely if the Outstanding Shares shall be combined into a smaller number of Outstanding Shares, the Exercise Price in effect immediately prior to such combination shall, simultaneously with the effectiveness of such combination, be proportionately increased;
- (ii) when any adjustment is required to be made in the Exercise Price, the number of Option Shares purchasable upon the exercise of the Option shall be changed and the number determined by dividing (A) an amount equal to the number of Option Shares purchasable on the exercise of the Option immediately prior to such adjustment multiplied by the Exercise Price in effect immediately prior to such adjustment, by (B) the Exercise Price in effect immediately after such adjustment;
- (iii) in case of any capital reorganization, any reclassification of the shares of Common Stock (other than a change in par value or as a result of a stock dividend, subdivision, split up or combination of shares of Common Stock), or a consolidation or merger of Ultrafem with another person where Ultrafem is the surviving corporation (collectively referred to as "Reorganizations"), the Option Holder shall thereafter be entitled to purchase the kind and number of shares of stock or other securities or property of Ultrafem receivable upon such Reorganization by a stockholder holding the number of Option Shares which the Option entitles the Option Holder to purchase from Ultrafem immediately prior to such Reorganization; and in any case appropriate adjustment shall be made in the application of the provisions of this Annex to the end that the provisions set forth herein (including the specified changes and other adjustments to the Exercise



Price) shall thereafter apply to any Option Shares or other property thereafter purchasable upon exercise of the Option;

- (iv) a dissolution or liquidation of Ultrafem, or a merger or consolidation in which Ultrafem is not the surviving corporation, shall cause the Option to terminate. The Option Holder may, in such event, exercise at any time during a ten-day period ending on the fifth day prior to such dissolution or liquidation, or merger or consolidation in which Ultrafem is not the surviving corporation, the Option in whole or in part; provided, however, that if such merger or consolidation is to be consummated in whole or in part by the tender of shares of Common Stock to the surviving corporation, the Option Holder agrees to tender the Option Shares received upon exercise of the Option to the surviving corporation on the same terms and subject to the same conditions as are applicable to other stockholders of Ultrafem who are tendering their shares of Common Stock;
- (v) to the extent that the foregoing adjustments relate to stock or securities of Ultrafem, such adjustments shall be made by the Board of Directors of Ultrafem and its determination shall be final, binding and conclusive;
- (vi) the adjustments described in the foregoing paragraphs (i) through (v) shall constitute the sole and exclusive adjustments to be made to the Option, or the number of or Exercise Price of the Option Shares, with respect to any of the events described in those paragraphs; and
- (vii) the grant of the Option shall not affect in any way the right or power of Ultrafem to make adjustments, reclassification, reorganizations or changes in its capital or business structure, or to merge or consolidate or to dissolve, liquidate or sell or transfer all or any part of its business or assets.
- (viii) For purposes of this Annex, a "Change in Control" of Ultrafem occurs if: (a) any "person" (defined as such term is used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is or becomes the beneficial owner, directly or indirectly, of securities of the Company representing a majority or more of the combined voting power of Ultrafem's Outstanding Shares then entitled to vote for the election of directors; or (b) during any period of two consecutive years, individuals who at the beginning of such period constitute the Board of Directors of Ultrafem cease for any reason to constitute at least a majority thereof; or (c) Ultrafem shall sell all or substantially all of the assets of Ultrafem or merge with and into another person, where Ultrafem is not the surviving corporation.

In the event of a Change in Control of Ultrafem, the Options shall be immediately exercisable.

The Option Holder represents and agrees by signing the Agreement that if it exercises the Option in whole or in part, it will acquire the Option Shares upon such exercise for the purpose of investment and not with a view to the resale or distribution of the Option Shares, except as permitted by applicable securities laws, and that upon each exercise of the Option it will furnish to Ultrafem a written statement to such effect. The Option Holder agrees that Ultrafem may place on each certificate representing the Option Shares an appropriate legend or legends required by applicable federal and state securities laws.

The Option Holder shall have no rights as a stockholder with respect to the Option Shares until the date of the issuance of a stock certificate or stock certificates evidencing the Option Shares to the Option Holder. Except as set forth in (i) above, no adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property) or distributions or other rights for which the record date is prior to the date such stock certificate is issued.

Anything in the Agreement to the contrary notwithstanding, in no event may the Option be exercisable if Ultrafem shall, at any time and in its sole discretion, determine that (i) the listing, registration or qualification of any shares otherwise deliverable upon such exercise, upon any securities exchange or under any state or federal law, or (ii) the consent or approval of any regulatory body or the satisfaction of withholding tax or other withholding liabilities, is necessary or desirable in connection with such exercise. In such event, such exercise shall be held in abeyance and shall not be effective unless and until such withholding, listing, registration, qualification or approval shall have been effected or obtained free of any conditions not acceptable to Ultrafem in its sole discretion, notwithstanding any termination of any Option or any portion of any Option during the period when exercisability has been suspended.

**EXHIBIT I**

**Notice of Exercise**  
**(to be signed only upon exercise of the Option)**

**TO: Ultrafem, Inc.**

The undersigned, the holder of the within Option, hereby irrevocably elects to exercise the purchase right represented by such Option for, and to purchase thereunder, \_\_\_\_\_ shares of the Common Stock of Ultrafem, Inc. and herewith makes payment in cash of \$\_\_\_\_\_ therefor or surrenders the enclosed certificates of Common Stock duly endorsed for transfer to Ultrafem, Inc.

Dated: \_\_\_\_\_

\_\_\_\_\_  
(Signature must conform in all respects to  
name of holder as specified on the face of  
the Option)

\_\_\_\_\_  
Address  
\_\_\_\_\_

**EXHIBIT II**

**TO: Ultrafem, Inc.  
500 Fifth Avenue Suite 3620  
New York, NY 10110**

**Ladies and Gentlemen:**

The undersigned understands that the shares of Common Stock ("Shares") of UltraFem, Inc., a Delaware corporation (the "Company"), that it has today purchased, have not been registered under the Securities Act of 1933, as amended (the "Securities Act").

The undersigned agrees not to sell, transfer, assign, pledge, hypothecate, or otherwise dispose of any or all of the Shares otherwise than in accordance with the terms and provisions of that certain Research and Product Development Agreement dated \_\_\_\_\_, 1995 between ReProtect, LLC and the Company, the provisions of which are incorporated by reference herein. The undersigned agrees that the Company may issue stop transfer instructions to its transfer agent with respect to the Shares to the effect that there are restrictions on transfer as described above.

The undersigned understands that there is no market for the Shares and there may never be a market for the Shares, and that even if a market develops for the Shares, as a result of the foregoing restrictions on transfer and the undersigned's representations and warranties hereunder and under the aforementioned Agreement, the undersigned may never be able to sell or dispose of the Shares and may thus have to bear the risk of its investment in the Shares for a substantial period of time, or forever.

The undersigned further agrees to indemnify and hold the Company harmless at all times from and against any and all claims, actions, demands, liabilities, losses, damages, costs and expenses incurred by the Company as a result of the sale, transfer, assignment, pledge, hypothecation or other disposition by the undersigned of any or all of the Shares in violation of this letter, the aforementioned Agreement, the Securities Act, or any other applicable law.

Very truly yours,

---

## Exhibit VII(f)

(a) Subject to the conditions set forth below, Ultrafem agrees to indemnify and hold harmless each Holder of Registrable Securities (a "Eligible Holder"), its officers, directors, partners, employees and agents, and each person, if any, who controls any such person within the meaning of Section 15 of the Act or Section 20(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), from and against any and all loss, liability, charge, claim, damage, and expense whatsoever (which shall include, for all purposes of this Section 10, without limitation, attorneys' fees and any and all expense whatsoever incurred in investigating, preparing, or defending against any litigation, commenced or threatened, or any claim whatsoever, and any and all amounts paid in settlement of any claim or litigation), as and when incurred, arising out of, based upon, or in connection with, (i) any untrue statement or alleged untrue statement of a material fact contained in (A) any registration statement, preliminary prospectus, or final prospectus (as from time to time amended and supplemented), or any amendment or supplement thereto, relating to the offer and sale of any of the Registrable Securities, or (B) any application or other document or communication (in this Section 10, referred to collectively as an "application") executed by, or on behalf of, Ultrafem or based upon written information furnished by, or on behalf of, Ultrafem filed in any jurisdiction in order to register or qualify any of the Registrable Securities under the securities or "blue sky" laws thereof or filed with the Commission or any securities exchange; or any omission alleged omission to a state a material fact required to be stated therein or necessary to make the statements therein not misleading, unless such statement or omission was made in reliance upon, and in conformity with, written information furnished to Ultrafem with respect to such Eligible Holder by, or on behalf of, such person expressly for inclusion in any registration statement, preliminary prospectus or final prospectus, or any amendment or supplement thereto, or in any application, as the case may be, or (ii) any breach of any representation, warranty, covenant, or agreement of Ultrafem contained in this Exhibit or paragraph VII(f) of the Agreement. The foregoing agreement to indemnify shall be in addition to any liability Ultrafem may otherwise have, including liabilities arising under this Exhibit or paragraph VII(f) of the Agreement.

If any action is brought against any Eligible Holder or any of its officers, directors, partners, employees or agents, or any controlling persons of such person (an "indemnified party") in respect of which indemnity may be sought against Ultrafem pursuant to the foregoing paragraph, such indemnified party or parties shall promptly notify Ultrafem in writing of the institution of such action (but the failure so to notify shall not relieve Ultrafem from any liability other than pursuant to this paragraph (a) and Ultrafem shall promptly assume the defense of such action, including, without limitation, the employment of counsel reasonably satisfactory to such indemnified party or parties, and payment of expenses. Such indemnified party or parties shall have the right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of such indemnified party or parties unless the employment of such counsel shall have been authorized in writing by Ultrafem in connection with the defense of such action or shall not have promptly employed counsel reasonably satisfactory to such indemnified party or parties to have charge of the defense of such action or the named parties

to such action including both the indemnified and the indemnifying parties and such indemnified party or parties shall have reasonably concluded that there may be one or more legal defenses available to it or them or to other indemnified parties which are different from, or in addition to, those available to Ultrafem, in any of which events such fees and expenses shall be borne by Ultrafem and Ultrafem shall not have the right to direct the defense of such action on behalf of the indemnified party or parties. Anything in this paragraph (a) to the contrary notwithstanding, Ultrafem shall not be liable for any settlement of any such claim or action effected without its written consent. Ultrafem shall not, without the prior written consent of each indemnified party that is not released as described in this sentence, settle or compromise any action, or permit a default or consent to the entry of judgment in, or otherwise seek to terminate, any pending or threatened action, in respect of which indemnity may be sought hereunder (whether or not any indemnified party is a party thereto), unless such settlement, compromise, consent, or termination includes an unconditional release of each indemnified party from all liability in respect of such action. Ultrafem agrees promptly to notify the Eligible Holders of the commencement of any litigation or proceedings against Ultrafem or any of its officers or directors in connection with the sale of any Registrable Securities or any preliminary prospectus, prospectus, registration statement, or amendment or supplement thereto, or any application relating to any sale of any Registrable Securities.

(b) Each Eligible Holder severally agrees to indemnify and hold harmless Ultrafem, each director of Ultrafem, each officer of Ultrafem who shall have signed any registration statement covering Registrable Securities held by such Eligible Holder and each other person, if any, who controls Ultrafem within the meaning of Section 15 of the Act or Section 20(a) of the Exchange Act, to the same extent as the foregoing indemnity from Ultrafem to the Eligible Holders in paragraph (a), but only with respect to statements or omissions, if any, made in any registration statement, preliminary prospectus, or final prospectus (as from time to time amended and supplemented), or any amendment or supplement thereto, or in any application, in reliance upon, and in conformity with, written information furnished to Ultrafem with respect to any Eligible Holder by, or on behalf of, such Eligible Holder expressly for inclusion in any such registration statement, preliminary prospectus, or final prospectus, or any amendment or supplement thereto, or in any application, as the case may be. If any action shall be brought against Ultrafem or any other person so indemnified based on any such registration statement, preliminary prospectus, or final prospectus, or any amendment or supplement thereto, or any application, and in respect of which indemnity may be sought against any Eligible Holder pursuant to this paragraph (b), such Eligible Holder shall have the rights and duties given to Ultrafem, and Ultrafem and each other person so indemnified shall have the rights and duties given to the indemnified parties, by the provisions of paragraph (a).

(c) To provide for just and equitable contribution, if (i) an indemnified party makes a claim for indemnification pursuant to paragraph (a) or (b) (subject to the limitations thereof), but it is found in a final judicial determination, not subject to further appeal, that such indemnification may not be enforced in such case, or (ii) any indemnified or indemnifying party seeks contribution under the Act, the Exchange Act, or otherwise, then Ultrafem (including for this purpose any contribution made by, or on behalf of, any director of Ultrafem, any officer



of Ultrafem who signed any such registration statement, and any controlling person of Ultrafem), as one entity, and the Eligible Holders of the Registrable Securities included in such registration in the aggregate (including for this purpose any contribution by, or on behalf of, an indemnified party), as a second entity, shall contribute to the losses, liabilities, claims, damages, and expenses whatsoever to which any of them may be subject, on the basis of relevant equitable considerations such as the relative fault of Ultrafem and such Eligible Holder in connection with the facts which resulted in such losses, liabilities, claims, damages, and expenses. The relative fault, in the case of an untrue statement, alleged untrue statement, omission, or alleged omission, shall be determined by, among other things, whether such statement, alleged statement, omission, or alleged omission relates to information supplied by Ultrafem or by such Eligible Holders, and the parties' relative intent, knowledge, access to information, and opportunity to correct or prevent such statement, alleged statement, omission, or alleged omission. Ultrafem and the Eligible Holders agree that it would be unjust and inequitable if the respective obligations of Ultrafem and the Eligible Holders for contribution were determined by pro rata or per capita allocation of the aggregate losses, liabilities, claims, damages, and expenses (even if the Eligible Holders and the other indemnified parties were treated as one entity for such purpose) or by any other method of allocation that does not reflect the equitable considerations referred to in this paragraph (c). In no case shall any Eligible Holder be responsible for a portion of the contribution obligation imposed on all Eligible Holders in excess of its pro rata share based on the number of shares of Common Stock owned (or which would be owned upon exercise of all Registrable Securities) by it and included in such registration as compared to the number of shares of Common Stock owned (or which would be owned upon exercise of all Registrable Securities) by all Eligible Holders and included in such registration. No person guilty of a fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to contribution from any person who is not guilty of such fraudulent misrepresentation. For purposes of this paragraph (c), each person, if any, who controls any Eligible Holder within the meaning of Section 15 of the Act or Section 20(a) of the Exchange Act and each officer, director, partner, employee and agent of each such Eligible Holder or control person shall have the same rights to contribution as such Eligible Holder or control person and each person, if any, who controls Ultrafem within the meaning of Section 15 of the Act or Section 20(a) of the Exchange Act, each officer of Ultrafem who shall have signed any such registration statement and each director of Ultrafem shall have the same rights to contribution as Ultrafem, subject in each case to the provisions of this paragraph (c). Anything in this paragraph (c) to the contrary notwithstanding, no party shall be liable for contribution with respect to the settlement of any claim or action effected without its written consent. This paragraph (c) is intended to supersede any right to contribution under the Act, the Exchange Act, or otherwise.

## Schedule 1(a)(iii)

Burundi	The Gambia	Micronesia, Fed. Sts.
Comoros	Ghana	Mongolia
Ethiopia	Guinea	Papua New Guinea
Kenya	Guinea-Bissau	Phillipines
Lesotho	Liberia	Thailand
Madagascar	Mali	Tonga
Malawi	Mauritania	Vanuatu
Mozambique	Niger	Western Samoa
Rwanda	Nigeria	Afghanistan
Somalia	São Tomé and Príncipe	Bangladesh
Sudan	Sierra Leone	Bhutan
Tanzania	Togo	India
Uganda	Cameroon	Maldives
Zaire	Cape Verde	Nepal
Zambia	Congo	Pakistan
Zimbabwe	Côte d'Ivoire	Sri Lanka
Angola	Senegal	Yemen
Djibouti	Cambodia	Egypt, Arab Rep.
Mauritius	Indonesia	Guyana
Namibia	Lao PDR	Haiti
Swaziland	Myanmar	Honduras
Benin	Solomon Islands	Nicaragua
Burkina Faso	Fiji	
Central African Rep.	Kiribati	
Chad	Marshall Islands	
Equatorial Guinea		



Schedule VII(h)

U.S. AND FOREIGN PATENT APPLICATIONS

United States:

<u>Serial No.</u>	<u>Title</u>	<u>Filing Date</u>
08/266,777	A Device and a Method for Acidic Buffering	June 29, 1994

Foreign:

<u>App. No.</u>	<u>Title</u>	<u>Filing Date</u>
95/07865	A Device and a Method for Acidic Buffering	June 28, 1995

Filed under Patent Cooperation Treaty for

Australia  
Canada  
Europe  
Japan  
Mexico

JAN 25 '96 15:08 FR

TO 7091#213500-000# P.82

SCHEDULE VIII (g)U.S. Patent


<u>Country</u>	<u>Patent No.</u>	<u>Issue Date</u>
United States	5,295,984	March 22, 1994

Patent Applications

<u>Country</u>	<u>Patent Application No.</u>	<u>Filing Date</u>
Canada	2070426	December 7, 1990
Europe (designating: -Austria -France -Belgium -United Kingdom -Switzerland -Italy -Germany -Luxembourg -Denmark -Netherlands -Spain -Sweden)	91901923.2	December 7, 1990
Australia	46547/93	June 28, 1993
Brazil	PI 9306596-5	December 22, 1994
Canada	2138668	June 28, 1993
Europe	93916826.6	June 28, 1993
United States	08/215,062	March 21, 1994

## **EXHIBIT E**






---

Robert S. Weisbein (0080)  
**FOLEY & LARDNER LLP**  
90 Park Avenue  
New York, NY 10016-1314  
Phone: (212) 682-7474  
Fax (212) 687-2329

*Of Counsel:*

Victor A. Vilaplana, Esq.  
**FOLEY & LARDNER LLP**  
402 West Broadway  
Suite 2100  
San Diego, CA 92101-3542  
Phone: (619) 234-6655  
Fax: (619) 234-3510

*Attorneys for Plaintiff Instead Sciences, Inc.*



---

Eric J. Lobenfeld (EL-4560)  
Dillon Kim (DK-4121)  
**HOGAN & HARTSON LLP**  
875 Third Avenue  
New York, NY 10022  
Phone: (212) 918-3000  
Fax: (212) 918-3100

*Attorneys for Defendants  
ReProtect, Inc., Dr. Richard Cone,  
and Dr. Thomas Moench*

**SO ORDERED**, this \_\_\_\_ day of \_\_\_\_\_, 2008.

---

Honorable Denise Cote  
United States District Court Judge

**Kim, Dillon**

---

**From:** NYSD\_ECF\_Pool@nysd.uscourts.gov  
**Sent:** Tuesday, June 24, 2008 12:35 PM  
**To:** deadmail@nysd.uscourts.gov  
**Subject:** Activity in Case 1:08-cv-05236-DLC Instead Science, Inc. v. ReProtect, Inc. et al Stipulation and Order

This is an automatic e-mail message generated by the CM/ECF system. Please **DO NOT RESPOND** to this e-mail because the mail box is unattended.

**\*\*\*NOTE TO PUBLIC ACCESS USERS\*\*\*** Judicial Conference of the United States policy permits attorneys of record and parties in a case (including pro se litigants) to receive one free electronic copy of all documents filed electronically, if receipt is required by law or directed by the filer. PACER access fees apply to all other users. To avoid later charges, download a copy each document during this first viewing. However, if the referenced document is a transcript, the free copy and 30 page limit do not apply.

**U.S. District Court**

**United States District Court for the Southern District of New York**

**Notice of Electronic Filing**

The following transaction was entered on 6/24/2008 at 12:34 PM EDT and filed on 6/24/2008

**Case Name:** Instead Science, Inc. v. ReProtect, Inc. et al

**Case Number:** 1:08-cv-5236

**Filer:**

**Document Number:** 8

**Docket Text:**

**STIPULATION AND ORDER**, the time for all Stipulating Defendants to answer the complaint is extended to and including 7/31/08. ReProtect, Inc. answer due 7/31/2008; Richard Cone answer due 7/31/2008; Thomas Moench answer due 7/31/2008. (Signed by Judge Denise L. Cote on 6/23/08) (cd)

**1:08-cv-5236 Notice has been electronically mailed to:**

Eric J. Lobenfeld ejlobenfeld@hhlaw.com, mferrara@hhlaw.com

Robert S. Weisbein rweisbein@foley.com

Dillon Kim dkim@hhlaw.com

**1:08-cv-5236 Notice has been delivered by other means to:**

The following document(s) are associated with this transaction:

7/31/2008

**Document description:**Main Document

**Original filename:**n/a

**Electronic document Stamp:**

[STAMP dcecfStamp\_ID=1008691343 [Date=6/24/2008] [FileNumber=4734858-0  
] [7bfbf60b090a00684eeca4009122127038594e99ee532fbfb2e22a835c8d1e4ddd4  
366403e4a06b8134b377e750955bddd18ff81eb732a462df792670e7a8af8]]

## **EXHIBIT F**





February 25, 2003

Thomas Moench, M.D.  
ReProtect Inc.  
703 Stags Head Road  
Baltimore, MD 21286

Re: License, Research and Product Development Agreement between Ultrafem, Inc. and  
ReProtect, LLC February 8, 1996

Dear Dr. Moench

Instead, Inc. acquired all the scheduled assets of the bankrupt estate of Ultrafem, Inc. One such asset was a License, Research and Product Development Agreement with ReProtect, LLC. In review of this agreement, we notice that Ultrafem granted ReProtect a first right of negotiation with regard to its research and development needs. We are currently planning certain R&D efforts.


We would, therefore, request certain information from you:

1. Is it your understanding that this agreement is still in full force and effect?
2. If so, do you have the facilities to undertake R&D from Instead and is it your desire to undertake such efforts?
3. If not, when was it terminated and is there any agreement regarding such termination? Please provide us with the details of any discussions regarding termination.

It is our desire to work with companies such as ReProtect. We would, therefore, request that you provide us with as much information as possible.

I appreciate your cooperation in this matter.

Very truly yours,  
Instead, Inc.

by   
Mary B. Frost, President

## **EXHIBIT G**

## ReProtect, Inc.

703 Stags Head Road  
Baltimore, MD 21286  
Tel: 410-337-8377  
Fax: 410 337-3838

March 11, 2003

*PRIVILEGED AND CONFIDENTIAL*


Ms. Mary B. Frost  
President  
Instead, Inc.  
2081 Rutton Drive  
Suite 307  
Carrollton, Texas 75006

**Re: License, Research and Product Development Agreement  
Between Ultrafem, Inc. and ReProtect LLC dated  
February 8, 1996**

Dear Ms. Frost:

This letter is in response to your letter dated February 25, 2003 concerning the 1996 License Agreement between Ultrafem, Inc. and ReProtect LLC. Please be advised that the 1996 License Agreement was terminated in connection with the Ultrafem bankruptcy. As an executory contract, which was not expressly assigned and assumed in the connection with the bankruptcy, it was rejected in accordance with the bankruptcy plan and terminated.

Sincerely,

  
Thomas R. Moench, M.D.

CC: A. Lynne Puckett, Hogan & Hartson L.L.P.

## **EXHIBIT H**

**FAX**

From: Richard A. Cone

Professor, Department of Biophysics,  
Johns Hopkins University  
3400 North Charles, Baltimore, MD 21218  
Phone: 410-516-7259 Fax: 410-516-6597

Managing Director,  
ReProtect, LLC

703 Stags Head Road, Baltimore MD 21286  
Phone: 410-337-8377 Fax: 410-523-0676

To: Dori Reap,  
Office of the Chief Executive  
Ultrafem, Inc.

Fax: 212-921-2067

Date: 10 March 1998

Total number of pages: 1


Dear Dori,

Here is a typed fax that corrects the date on the hand-written notice I gave you. I guess my regret in writing the notice got in the way of getting the date right!

I hereby notify Ultrafem, Inc. that ReProtect, LLC, has not received the monthly payment of \$83,300 for March, 1998, the minimum payment specified by the License, Research and Product Development Agreement ("Agreement") between Ultrafem and ReProtect.

The terms of this Agreement [IVterm, (c)(3), on page 10] include that the Agreement terminates upon 90 days written notice by ReProtect to Ultrafem in Ultrafem fails to make the payments due under paragraph I(b)(i) and such failure continues for a period of 90 days after written notice has been received by Ultrafem from ReProtect.

I regret, deeply, that Ultrafem is unable to continue these payments at this time, and hope that some of the efforts now underway to "save" Ultrafem, and "Instead" are successful.



Richard A. Cone  
Managing Director,  
ReProtect, LLC.

# **EXHIBIT I**

*Ultrafem*  
INC.

TO: Ultrafem Board of Directors  
(Distribution Below)

FROM: Dori M. Reap *Dori*

DATE: March 13, 1998

RE: ReProtect Contract

---

Attached is the notice received from ReProtect regarding Ultrafem's nonpayment of the minimum payment due in March. As the notice states, Ultrafem has 90 days to rectify the situation prior to contract termination.

Please call with any questions.

Distribution:

Joy V. Jones (Chair)  
John W. Andersen  
Richard A. Cone  
Martin Nussbaum

Copies:

Gerald Adler  
Allan Hyman  
Tonya Hinch